Using Novel Data Types for Big Data Research in Epilepsy: Patient Records, Clinic Letters and Genetic Mutation by ,
  Swansea University E-Theses                                     
_________________________________________________________________________
   
Using Novel Data Types for Big Data Research in Epilepsy: Patient
Records, Clinic Letters and Genetic Mutation
   
Lacey, Arron S.
   
 
 
 
 How to cite:                                     
_________________________________________________________________________
  
Lacey, Arron S. (2019)  Using Novel Data Types for Big Data Research in Epilepsy: Patient Records, Clinic Letters
and Genetic Mutation. Doctoral thesis, Swansea University.
http://cronfa.swan.ac.uk/Record/cronfa48905
 
 
 
 Use policy:                                     
_________________________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence: copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder. Permission for multiple reproductions should be obtained from
the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
Please link to the metadata record in the Swansea University repository, Cronfa (link given in the citation reference
above.)
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/
 Using Novel Data Types for Big
Data Research in Epilepsy:
Patient Records, Clinic Letters
and Genetic Mutation
Submitted to Swansea University in fulfilment of the requirements for
the Degree of Doctor of Philosophy
Arron Lacey
BSc MSc MRes
Data Science
Swansea Neurology Research Group Swansea University Medical
School
Swansea University
February 2019
Declaration
I, Arron Lacey, confirm this thesis has not been submitted towards a previous degree
or other qualification, and is intended for submission of a Doctor of Philosophy,
awarded by Swansea University.
Signed: (candidate) Date:
I, Arron Lacey, confirm that all of the work presented in this thesis is my own
unless otherwise indicated. I have provided footnotes in the text where I have
received assistance and have indicated permissions for presenting work which is not
my own.
Signed: (candidate) Date:
I hereby give consent for my thesis, if accepted, to be available for photocopying
and for inter-library loans after expiry of a bar on access approved by the Swansea
University.
Signed: (candidate) Date:
1
Abstract
Introduction: The aims of this thesis was to explore novel data types in healthcare
that could enhance epidemiology studies in epilepsy and to develop novel methods of
analysing routinely collected linked healthcare data, unstructured free text in hospital
clinic letters and genetic variation.
Method: The SAIL Databank was used to source linked healthcare data for people
with epilepsy across Wales to study the effects of epilepsy and social deprivation,
coding of epilepsy in GP records and the educational attainment of children born to
mothers with epilepsy. Hospital clinic letters from Morriston Hospital in Swansea
were analysed using Natural Language Processing techniques to extract rich clinic
data not typically recorded as part of routinely collected data. An automated pipeline
was developed to predict the pathogenicity of Single Nucleotide Polymorphisms to
prioritize potential disease-causing genetic variation in epilepsy for further in-vitro
analysis.
Results: Incidence and prevalence of epilepsy was found to be strongly correlated
with increased social deprivation, however a 10 year retrospective follow-up study
found that there was no increase in deprivation following a diagnosis of epilepsy,
pointing to deprivation contributing to social causation of epilepsy rather than epilepsy
causing social drift. An algorithm was developed to accurately source epilepsy patients
from GP records. Sodium Valproate was found to reduce educational attainment
in 7 year olds by 12%. A Natural Language Processing pipeline was developed
to extract rich epilepsy information from clinic letters. A pipeline was created to
predict pathogencity of epilepsy SNPs that performed better than commonly used
software.
Conclusion: This thesis presents novel studies in epilepsy using population level
healthcare data, unstructured clinic letters and genetic variation. New methods were
developed that have the potential to be applied to other disease areas and used to
link different data types into routinely collected healthcare records to enhance further
research.
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Chapter 1
Introduction
1.1 Summary of Thesis Themes
This thesis documents research in epilepsy across 3 themes: epidemiology and big data,
natural language processing of clinic letters and predicting pathogenicity of single
nucleotide polymorphisms. The main aim was to describe how different methods and
data types across these themes can be brought together to enhance the opportunity
for epilepsy based research. This chapter introduces relevant studies related to the
three themes of research to support the motivations for this thesis, and chapter two
describes a comprehensive overview of the methods used to carry the work in this
thesis.
Chapter 3 documents the results for 3 longitudinal epidemiological studies in epilepsy
using the SAIL Databank. The SAIL Databank is a research platform for conducting
population level healthcare studies in Wales and specialises in anonymous linked ”Big
Data” across various healthcare services across Wales. The three studies in chapter
3 explore the effects of epilepsy on social deprivation, a validation of GP recorded
epilepsy diagnoses and the effects of exposure to antiepileptic drugs in the womb and
the impact it has on educational attainment in 7 year old children.
Chapter 4 aims to explore how data in unstructured clinic letters can be included
in epidemiology studies by using Natural Language Processing techniques. Only a
proportion of unstructured data such as that in clinic letters, discharge reports or
radiology and examination reports get entered into structure databases and audited
for research purposes, with many rich patient data often missing and not available for
research. Chapter 4 presents a study using NLP techniques to extract rich patient
information from 200 clinic letters from the Morriston hospital epilepsy clinic.
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Chapter 5 explores various techniques to predict pathogencity of a particular type of
genetic mutation called singe nucleotide polymorphisms, or SNPs. There are many
SNPs that have been documented as the cause of various types of epilepsy, but with
over 3 million variants in a person’s genome it is difficult to predict the impact of these
mutations in terms of likelihood of developing a disease. Bioinformatics pipelines
aim to reduce the search space within the human genome to focus on a very small
set of variants for further study. Part of these pipelines involves functional analysis
and there are many programs that specialize in predicting pathogenicity of SNPs, in
which the accuracy of these programs can differ in different disease areas. Chapter
5 aims to incorporate the knowledge from existing systems to build a pipeline that
accurately predict the pathogenicity of epilepsy SNPs.
1.2 Epilepsy
Epilepsy is a disease characterized by unprovoked seizures that can be distinctly
different from other types of seizures such as febrile seizures that occur mainly in
children during a fever and dissociative seizures that occur for psychological reasons.
It effects 1% of the population (600,000 individuals in the UK) [6] [7] and it has been
estimated that over 50 million people worldwide have epilepsy [8]. The International
League Against Epilepsy (ILAE) define epilepsy as any one of the following [9]:
1. Two unprovoked seizures occurring more than 24 hours apart
2. One unprovoked (or reflex) seizure and a probability of further seizures similar
to the general recurrence risk (at least 60%) after two unprovoked seizures,
occurring over the next 10 years
3. A diagnosis of an epilepsy syndrome
Epileptic seizures are treated with anti-epileptic drugs (AEDs) in which patients may
require a combination of AEDs to help control their seizures, and some may not
respond to AEDs at all, known as refractory epilepsy.
1.2.1 Epilepsy types
There are various epilepsy types that can be defined in various ways:
 Type of seizure
 Age at which seizure began
 Causes of seizure
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 The part of the brain involved during a seizure
 Severity and duration of seizures
 EEG electroencephalogram patterns
 Brain imaging
 Mode of inheritance
 Other disorders in additions to seizures
 Patterns of seizures during the day (at day or night)
While there are many syndromes within epilepsy such as Juvenile Myclonic Epilepsy,
Dravet Syndrome and Lennox-Gaut syndrome, epilepsy seizures are also used as a
diagnostic tool in clinical practice and combined with various other factors seizure
type will underpin an epilepsy syndrome. The use of seizures as a diagnostic tool is
useful in terms of choosing AED treatment, where different seizure types have well
defined AED regimes. Seizure categories in epilepsy are broadly defined by two types,
that being generalized or focal seizures.
1.2.2 Generalized seizures
Generalized seizures originate rapidly from bilaterally distributed brain networks
i.e. generalized seizures affect the entire brain [10]. The ILAE recognize generalised
seizures as described in table 1.1. [11]
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Table 1.1: Generalized seizures recognized by the ILAE.
Name Description
Tonic-clonic seizures Initial phase of stiffness (tonic) followed by jerking (clonic) and a
loss of consciousness. Gradual recovery with minute/hours of post
ictal confusion
Clonic seizures Similar to tonic clonic seizures without stiffness
Typical absence seizures Sudden, brief (generally <10s) periods of loss of awareness
with behavioural arrest (staring episodes) with rapid recovery,
occasional eye movements and automatisms
Atypical absence seizures Longer than typical absences and frequently associated with
myoclonic or atonic attacks. Start and finish more gradually,
focal features more prominent, and more retained awareness, than
typical absences
Myoclonic absence seizures Very brief (<1 sec) ‘electric-shock’ muscle contractions with
sudden onset and cessation. Single muscle to generalised jerking.
Consciousness generally not impaired
Tonic seizures Sustained muscular contraction lasting <1 minutes with rapid
recovery
Eyelid myoclonia Quick upward jerk of the eyelids lasting around 3 seconds
Myoclonus Spasmodic jerks or twitches in various muscles (positive) or brief
laspes in concentration (negative)
Atonic seizures Sudden loss in muscle strength causing the patient to drop to floor.
Sometimes called ”drop attacks”
1.2.3 Focal seizures
Focal seizures originate from one hemisphere in the brain in which some types may
cause absences and loss of consciousness. Additionally some types of focal seizures
can spread to the entire brain which are called secondary generalised seizures. The
ILAE recognizes focal seizure types as described in table 1.2.
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Table 1.2: Focal seizures recognized by the ILAE
Name Description
Focal sensory seizures Brief disturbance in taste, touch, smell or sight usually lasting no
more than 2 minutes
Focal motor seizures A seizure with localized motor activity. There may be spasm or
clonus (jerking) of one muscle or a muscle group and this may
remain localized or it may subsequently spread to adjacent muscles
Frontal lobe Frequently occurring during sleep. Brief, rapid onset and
cessation. Prominent motor features, sometimes with posturing
and head version. Frequent bizarre automatisms / behaviours and
vocalisation
Temporal lobe ”Generally longer in duration than frontal lobe seizures. Variety of
sensory disturbances including psychic (d´ej‘a vu , jamaisvu, fear),
gustatory and olfactory hallucinations. Sensation of epigastric
disturbance. Oro-facial automatisms (e.g. chewing, sucking) or
fidgety hand movements. Frequently altered awareness. Auditory
features with lateral temporal lobe involvement”
Gelastic seizures A rare type of seizure that involves a sudden burst of energy,
usually in the form of laughing or crying.
Hemiclonic seizures Entirely 1-sided, unilateral, clonic convulsions
Secondarily generalized
seizures
Focal seizures evolving into generalized seizures, most often with
tonic-clonic convulsions. The partial seizures, which were once
limited to one hemisphere of the brain, progress to encompass the
entire brain bilaterally
1.2.4 Causes of epilepsy
The causes of epilepsy can be broadly defined as either symptomatic where there is
a physically identifiable change in structure of the brain, or genetic where there is
no apparent change in structure of the brain and is therefore assumed to be caused
by a genetic mutation inherited from a person’s parents. Both types of epilepsy
each account for around 50% of all epilepsies respectively. Symptomatic epilepsies
are usually caused by injury to the brain through birth trauma, neurodegenerative
diseases, brain neoplasms, cerebrovascular disease and brain malformations. For
symptomatic epilepsy to be ruled out in the presence of epileptic seizures i.e. genetic
epilepsy, there must be no evidence of structural changes in the brain to be detected.
There exists a grey area over what constitutes symptomatic epilepsy or genetic
epilepsy in that some conditions cause various deficiencies in the supply of glucose to
the brain caused by a known genetic mutation, in which no structural changes are
present in the brain, yet the patient is classified as having epilepsy.
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1.2.5 Genetics of epilepsy
For the 50% of epilepsies that are caused by genetic mutation, the incidence of genetic
epilepsy passed on to first degree relatives have been shown to be up to 4 times that
in the population than those that do not have a first degree relative with epilepsy
[12]. Mutations found in a small amount of genes have been found to cause Idiopathic
Generalized Epilepsy (IGE). Multiple family studies and twin studies have found
that IGE has a common gene origin, but it is likely that some forms of epilepsy
have multi-gene modes of inheritance [13] [14] [15]. There is evidence for different
sets of genes producing different epilepsy syndromes such as Juvenile Myoclonic
Epilepsy (JME) [16] [17]. Currently, mutations on the SCN1A voltage-gated sodium
channel gene account for the largest amount of IGE syndromes [18] [19] with over
150 mutations attributed to infantile and childhood onset epilepsy. In general,
seizure-related syndromes are accounted for by mutations across multiple genes that
code for ion channel proteins, where examples of such proteins are given in table
1.3.
Table 1.3: A list of ion channel domains and proteins and how mutations correlate to
epilepsy phenotypes.
Channel Mutations in Epilepsy
Ion Channel Gene Phenotype Inheritance
Acetylcholine receptor CHRNA2 ADNFLE Single Gene
CHRNA4 ADNFLE Single Gene
CHRNB2 ADNFLE Single Gene
Calcium CACNA1A CPS,GTCS Single Gene
CACNA1H CAE,IGE Complex
CACNB4 IGE Complex
Chloride CLCN2 IGE Single Gene
GABA receptor GABRG2 CAE/GEFS+/FS Single Gene
GABRA1 JME,CAE Single Gene
Potassium KCNQ2 BFNC1 Single Gene
KCNQ1 BFNC1 Single Gene
KCND2 mTLE2 Single Gene
Sodium SCN1A GEFS/SMEI Single Gene
SCN2A BFNIC Single Gene
SCN1B GEFS+ Single Gene
Despite some clear single gene relationships for various epilepsy syndromes there is
also evidence for single gene overlap, and thus the relationship between known genes
in epilepsy appears to be more complex[14]. Many factors determine development
of the disease outside of an observed mutation such as mode of inheritance and
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gene expression, so presence of a mutation that is known to cause epilepsy in one
person, may not cause epilepsy in another. Recruitment of families with an extensive
history of a disease is the first challenge in furthering our understanding of the
complex relationships of genes and disease. Sourcing cohorts of patients comprising
of such families is a lengthy and expensive process - family history needs to be
determined as accurately as possible and blood samples need to be taken to analyse
each persons’ DNA. Processing and analysing DNA is also incredibly expensive, where
most whole genome sequencing is not done within the research department that will
analyse the resulting genome. Whole genome sequencing typically gets outsourced
to dedicated laboratories at a cost per genome. Next Generation Sequencing (NGS)
has revolutionized the process of sequencing a persons whole genome and is now the
leading method that supports whole genome/exome based research.
1.2.6 Epidemiology of epilepsy
Epilepsy prevalence has been measured in various studies [20]-[21] where it ranges
between 0.3-0.8% in developed countries and 0.43-1.4% in developing countries. In
chapter 3 of this thesis a study of epilepsy prevalence in Wales is presented that
estimated the prevalence of epilepsy to be 0.77% of the population, where higher
prevalence is found in more deprived areas (1.13%) than less deprived areas (0.49%),
a trend which is also seen in the incidence of new cases of epilepsy.
Incidence of epilepsy is typically highest in children and the elderly, with lower
incidence between the age of 18-65, and incidence is double in men over 65 than
women over 65 [22]. The majority of incident epilepsy in children are due to genetic
factors, where the incidence of epilepsy later in life is due to symptomatic factors as
the incidence of neurodegenerative diseases, brain neoplasms and stroke also increase
with age. Figure 1.1 presents the ”U-shape” curve that describes epilepsy incidence
across all ages:
25
Figure 1.1: Incidence of epilepsy from a study in Iceland showing incidence per 100,000
stratified by age and sex.
1.2.7 Anti-epileptic drugs
Anti-epileptic drugs (AEDs) are a group of drugs that aim to suppress unprovoked
seizures by suppressing the rapid firing of neurons in the brain during a seizure by
binding to specific receptors in the brain and inhibiting voltage dependant sodium
currents [23]. AEDs also aim to prevent the spread of seizures in it’s early phase
to other parts of the brain [24]. Around 50% of patients treated with AEDs have a
25-50% reduction in seizures, with other patients with more modest reduction [25].
While AEDs can be effective, around half of epilepsy patients experience adverse
effects from a first line AED [26] [26]. Prescribing trends in anti-epileptic drugs have
changed in recent years due to evidence of some such side effects of some AEDs.
A study using Welsh GP data held accessed via the SAIL Databank showed that
newer AEDs such as Lamotrigine have been prescribed as a first line AED with
increasing frequency over a ten year a period between 2000 and 2010, and older AEDs
such as Sodium Valproate have seen a reduction in prescribing in women of child
bearing age, probably due to evidence suggesting valproate can produce cognitive
dysfunction if exposed to children inutero [1] [27]. Figure 1.2 shows prescribing trends
of first line AEDs prescriptions in Wales.
26
F
ig
u
re
1
.2
:
P
re
sc
ri
b
in
g
tr
e
n
d
s
o
f
fi
rs
t
li
n
e
A
E
D
s
in
W
a
le
s
b
e
tw
e
e
n
2
0
0
0
-2
0
1
0
.
N
e
w
e
r
d
ru
g
s
su
ch
a
s
L
a
m
o
tr
ig
in
e
h
a
v
e
b
e
e
n
a
d
o
p
te
d
a
s
p
e
r
th
e
S
A
N
A
D
st
u
d
y
g
u
id
e
li
n
e
s,
w
h
e
re
a
d
e
c
li
n
e
in
v
a
lp
ro
a
te
p
re
sc
ri
p
ti
o
n
s
to
w
o
m
e
n
o
f
ch
il
d
b
e
a
ri
n
g
a
g
e
is
a
ls
o
o
b
se
rv
e
d
[1
]
27
Choice of AEDs to treat seizures doesn’t just include seizure control of the individual.
Well documented side effects of AEDs include behavioural issues, decline in cognitive
function, migraines and psychiatric disorders [28]-[29]. Various AEDs have been
studied in relation to weight gain and loss, in which some drugs such as Levetiracetam
and Sodium Valproate, while some drugs have been shown to cause weight loss,
complicating the issue of AED prescriptions in patients with conditions such as
diabetes mellitus [30]- [31].
AED choice is also important when prescribing in pregnant women. Various studies
have associated inutero exposure to sodium valproate with a variety of effects on
offspring that include reduced IQ, decline in motor and language skills as well as
general decline in cognitive abilities [27]-[32]. Recently a Danish study found that
children exposed to valproate intuero perform worse then their peers in national tests
[33]. Chapter 4 in this thesis presents a study using Welsh Key Stage 1 education
tests and AED prescribing data in pregnant women that found inutero exposure to
sodium valproate and AEDs in combination are associated with decreased educational
attainment in children aged 7 [3].
1.2.8 Burden and impact of epilepsy
The Global Disease Burden Study has estimated that epilepsy contributes to 1%
of all days lost due to ill health and that on average epilepsy forms 0.5% of total
disease burden as measured by the Disability Adjusted Life-Year (DALY) score. [34].
Epilepsy places a huge burden on those who suffer unprovoked seizures on a daily
basis, a burden which is also shared by the relatives and peers of someone with
epilepsy [35].
Epilepsy is a condition associated with a range of co-morbid conditions. Around 40%
of adolescents with epilepsy also have an additional neurological condition and 1 in 4
persons with epilepsy of any age has a learning disability [36]. Behavioural issues are
prevalent in children with epilepsy exhibited both in school and at home [37] [38].
Children with epilepsy are a stigmatized group and are twice as likely to be bullied
at school than their peers [39], and a qualitative study of children with refractory
epilepsy viewed seizures as a barrier to a normal life [40].
Seizures disrupt short term information storage, especially nocturnal seizures when
most memory consolidation takes place. The physical impact of seizures on the brain
is associated with memory loss in people with epilepsy ranging from concentration
issues to chronic forgetfulness [41]. Auras occurring before and during a seizure and
other lapses of concentration contribute to poor recall of which 1 in 4 people cannot
recall experiencing auras or lapses in concentration [42] and people with epilepsy
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fail to document around 50% of recent seizures. Poor memory loss therefore also
contributes to difficulties in learning along with increased risk of being born with
learning difficulties.
Around 80% of epilepsy is prevalent in developing countries in which there exists
not only a barrier to effective care and seizure treatment, but there is an undeniable
trend in epilepsy, social deprivation and social stigma [43] [44]. People with epilepsy
are likely to experience prejudice and discrimination in all walks of life as well as
being at high risk of abuse and violence [45] [46]. Young people with epilepsy are
often discouraged from pursuing their chosen career path [35] and face discrimination
in life ranging from diminished access to various insurance schemes and employment
opportunities [47]. One survey of employers found that 16% felt that they didn’t
have jobs for someone with epilepsy and 21% considered employing someone with
epilepsy as ”a major issue” [48].
Complimentary to the fact that epilepsy is more apparent in developing nations, lower
socio-economic status is a risk factor for epilepsy in adults [49] and the various social
struggles people with epilepsy face is a strong argument for epilepsy causing social
drift. Multiple studies have associated social deprivation with epilepsy in both new
cases of and existing epilepsies [50] [51]. There are two main hypotheses for social
deprivation in epilepsy; social causation and social drift. Social causation in epilepsy
could be explained by factors associated with both deprivation and causes of epilepsy,
namely such as perinatal hypoxic injury, head trauma, and cerebrovascular disease
[21] [52] [53]. Social drift is hypothesised to explain some of the high deprivation seen
in people with epilepsy for various reasons related to social stigma and discrimination
in employment. Chapter 4 presents a study of social deprivation in Welsh patients
with epilepsy and in both newly diagnosed patients and patients with existing
epilepsy.
1.3 Big data and patient records as a resource for
research
In this section, patient records and large linked datasets are presented as a method
for researching the epidemiology and burden of epilepsy for large cohorts. The SAIL
Databank is presented as such a resource that is utilized in this thesis to conduct
population level epilepsy research in Wales.
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1.3.1 Electronic Healthcare Records
Up to 1990 in the UK, patient records were largely paper based. Large scale Electronic
Healthcare Record (EHR) linkage as a research method has grown as a direct result
of embedding computer systems in primary care to make the transition from paper
based records to electronic records. In 1987, two GPs from Egton, Yorkshire Dr
Peter Sowerby and Dr David Stables formed the Egton Medical Information Systems
Group (EMIS) to develop software that could capture paper based records into
electronic format. The result was a commercial rollout of the EMIS software in
1990, and EMIS, as well as many other clinical audit systems that followed, enabled
GPs to capture routinely collected information at point of care and have instant
access to those records at a later time. As thousands of GP practices started to
employ such systems, the resulting records were quickly used to monitor trends and
performance of GP practices [54] and measure outcomes in patient care. After years of
patient interactions with GPs being recorded electronically, large scale retrospective
epidemiological were made possible because access to patient records were much faster
compared to sourcing paper based records.
Using the first EHRs as a form of research was a success mainly because the data
collected by GPs to inform patient care was mutually beneficial to inform public health.
GPs not only recorded patient details important to building a picture of patient care
such as diagnoses and medication, they recorded patient details using clinical coding
systems to summarise their interactions. In 1990 the READ clinical coding system
had matured for 8 years and was considered for use in computerised coding systems
[55]. Developed from the early 1980’s onwards and still being developed today, Dr
James Read built a clinical coding system consisting of 250,000 codes that could be
used to describe the details of a patient’s medical notes. While clinical coding systems
such as ICD have existed for over a hundred years [56], the READ code system was
the first in the UK that could classify disease, symptoms, prescriptions and referrals
in one heirachy. The real advantage of using computerised records and embedding
coding systems such as READ used in GP practices, and ICD-10 used in secondary
care is how EHRs can be queried using computer languages such as SQL. Patient
information can be rapidly accessed and partitioned by these coding structures to
create cohorts of certain disease or medication retrospectively. This is by far more
efficient and reliable than having to process free text such as medical notes manually,
a problem still being solved today through Natural Language Processing - discussed
later on in this chapter. The electronic patient record, when combined with clinical
coding systems are a potential data source for fast, large scale research.
However, a fundamental understanding of the purpose and context of why and
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how EHRs are recorded must be taken into account if intended for use in research.
Patient records are designed to be collected at point of contact which usually means
a consultant or GP. The records are therefore a reflection of how a patient should
be cared given their presentation at point of contact, and are certainly not designed
for research purposes. For example, a record of a prescription does not necessarily
mean the patient has adhered to a treatment plan, or a diagnosis code used by a
GP could indicate a diagnosis subject to a specialist referral rather than a definite
diagnosis. Even when administrative staff take more of a role in entering details
of patient records, the ability to generate factually correct patient records relies
on communication with consultants or specialized training to translate consultants
finding into clinical codes. While technology moved forward the ability to create
patient records more efficiently, the sources of error remain the same as when paper
records were used. For research purposes this broadly means that any conclusions are
limited by the quality of data entered into patient records, or to put more crudely -
garbage in, garbage out.
Aside from data entry being influenced by how patient records will be used in-house
by medical professionals, incorrect data is ingrained in patient records. Human error
is a factor in any data entry tasks, but data entry in a live healthcare setting is
arguably more difficult than most data entry tasks. Clinical coding is a fast growing
profession within secondary care that requires a strict set of exams to qualify as a
clinical coder. Their job is to sift through consultants, surgeons, junior doctors and
pharmacists notes to build a patient profile and turn them into discrete episodes of
care described by ICD-10 and OPCS-4 codes. This process is detective-like by nature,
often having to piece together conflicting medical opinions, sifting through short-hand
patient notes and assigning a subset of the 16,000 codes ICD-10 codes to describe
disease and morbidity, and OPCS-4 codes to describe operations [57]. The potential
for error is large without the high standard of training and continuous communication
with the various healthcare professionals that are responsible for treating the patients.
In contrast to the use of clinical coders, GPs are expected to enter data into patient
records at point of care. While clinical audit systems such as EMIS aim to help GPs
accomplish this task, it is incredibly difficult for GPs to have a working knowledge of
the 250,000 code list in the READ code system while entering data and caring for
patients in an average consultation time of just 11 minutes. Under these pressures it
is easy to imagine why GPs may be forced to cut corners or omit certain aspects of
coding. This can lead to systematic error in coding such as using codes that do not
accurately describe the patient or limiting their use of READ codes to a very small
subset regardless of what the patient presents with.
The electronic patient record has however become the cornerstone informing medical
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practice through either research or immediate feedback of data at point of care. The
explosion of research based on information in EHRs has no doubt furthered the
case for more emphasis to be placed on accuracy and maintenance of EHRs and
making EHRs as robust as possible. There have been incentives such as the Quality
of Outcomes Frameworks (QOF) that pay GPs to use a wide variety of READ codes
in clinical practice in which the effectiveness of well coded EHRs post-QOF showed
reduction in mortality, hospital admissions and the improvements in the management
of chronic conditions such as diabetes [58] [59].
Consequently, the demand for a patient record for both healthcare and research has
evolved beyond what is recorded in primary and secondary care. Various national
health registers and audits ranging from the Office of National Statistics Deaths and
Births register, Congenital Anomaly Register and Information Service (CARIS) [60],
Welsh Cancer and Intelligence and Surveillance Unit (WCISU) and various biobank
datasets from clinical trials all feed into the patient record. Social care datasets and
tertiary health programs provide useful measures of patient care outside of first and
second line services, as well as administrative and demographic data such as the Welsh
Demographic Service to explore geographical and social deprivation effects on health.
Perhaps the most exciting addition to the patient record is genetic data due to the
potential for deeper understanding inherited disease and the opportunity to develop
personalised medicines. The patient record is beginning to include information that
is not even found in database format or collected via traditional auditing methods
- namely free texts such discharge letters and consultant reports that contain far
richer data than any of the datasets previously mentioned, if it can be processed.
Any dataset that can feed into the patient record is beneficial, especially for research,
a prospect which becomes eve more powerful when such datasets are successfully
integrated together.
1.3.2 The SAIL Databank
The linkage of big data is a corner stone of public health research. The potential to
mine patient profiles from national datasets produces novel research that directly
impacts policy. While randomized control trials are the benchmark for studying
health interventions and drug use, retrospective, longitudinal studies produced from
linked data is much cheaper, faster and statistically more powerful. There are many
established data centers that take advantage of linking routinely collected data, but
the largest government funded initiative for using data linkage in health research in
the UK is the Farr Institute of Health Informatics Research. The Farr Institute was
a collaboration of 21 academic and health institutions in the UK, where the four
main data centers are co-ordinated through The Health e-Research Center at the
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University of Manchester, University College London, University of Dundee and the
SAIL Databank at Swansea University. Since then the Health Data Research (HDR
UK) initiative was set up to continue innovation in big data linkage for research, of
which new centers such as the Sanger Institute are now included as a means to bring
genetic data to the patient record.
The SAIL Databank is a repository for national health datasets in Wales, hosted at
the HDR UK cite at Swansea University, that contains linked anonymised health
records at a patient level [61] [62]. Developed in 2006, the SAIL databank aimed to
take advantage of emerging technologies to capture patient level data and provide
a platform to link datasets on a large scale. National datasets such as primary and
secondary care, mortality and birth records, geographic and socio-economic status
all have routinely collected data that date back 25 years and when linked together
produce research potential greater than the sum of it’s parts. Figure 1.3 shows the
different types of data held in the SAIL databank:
Figure 1.3: The core SAIL datasets. Each dataset can be linked anonymously via an
encrypted NHS number
1.3.3 Anonymous patient records
Datasets held in SAIL are anonymised using a split file procedure. Each data provider
splits their dataset into 2 parts - one containing all demographic data which is sent to
a trusted third party (TTP), and the other containing only clinical data that is sent
directly to SAIL. An internal system ID that bears no relation to the patient ID is
the only field shared between the split files. The TTP, in this case the National Welsh
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Information Service and SAIL each encrypt the split datasets, and are then combined
using a shared encryption key. The result is a completely anonymised dataset that
can be linked to all other datasets within SAIL.
Users can assess the repository through the SAIL gateway - a remote server with
a Graphical User Interface (GUI) front-end. The SAIL databank is powered by
an IBM Blue-C supercomputer which provides extremely fast database queries,
capable of completing queries on databases of millions of records within seconds. The
data is warehoused and made available as a repository of relational databases, in
which the data can be queried using IBM DB2 Structured Query Language (DB2
SQL). As data is anonymised there is no ethical approval needed to query data.
However an independent Information Governance Research Panel (IGRP) consisting
of multi-disciplinary professionals in the field of health care and health care research
exists, to which project studies plans are scrutinized to ensure the research question
is valid and answerable using SAIL data, as well as ensuring that no individuals can
be identified. Once a project is approved, data can be requested out of the SAIL
gateway. An internal team of researchers view all outputs to ensure no sensitive data
leaves the SAIL gateway.
1.3.4 SAIL studies
The SAIL databank has been used in a diverse range of healthcare studies. The main
type of studies conducted are retrospective longitudinal studies that take advantage
of millions of person-years of data across multiple health datasets, although follow up
studies from patient recruitment have also been carried out.
Child Health and Births
The Wales Electronic Cohort for Children (WECC) is an e-cohort of children in Wales
set up to study a range of social and environmental determinants and outcomes of
child health. The WECC cohort is the largest e-cohort for children in health (804,290
children, 375,025 mothers between 1998-2008) and was built from routinely collected
data in the SAIL Databank [63]. Several studies have used the WECC cohort to
research health and social outcomes in children. One study found a 4 fold increase
in hospital admissions for children born at a gestational age of 33 weeks (41.5 per
100 child years) compared to gestational age of 40 weeks (9.8 per 100 child years)
[64]. The impact of skull fractures and inter-cranial injury was associated with poorer
academic performance in Key Stage 1 assessments compared to a control group, and
a higher risk of hospital admission was observed in children with a mental health
disorder or living with parents that had an alcohol misuse problem recorded in GP
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records [65] [66]
The Congenital Anomaly Register and Information Service for Wales (CARIS) dataset
was linked to ONS birth records in the SAIL Databank to estimate the prevalence of
Turner Syndrome to 1 in 4901 female births [67]. An example of bespoke datasets
being linked to the SAIL Databank is a study using data from the Singleton Hospital
Maternity Ward at Swansea University that were linked to primary and secondary
care datasets to study the relationship of BMI during pregnancy and health utilization.
Based on data of 484 pregnancies it was found that healthcare costs during pregnancy
was 37% higher in obese women compared to those with normal weight. Demographic
data was linked to Key Stage 1 education data showing that a clear trend in reduction
of educational attainment was seen with increasing numbers of house moves, even in
children that moved prior to the Key Stage 1 assessment period (< 5 years of age)
[68].
Mental Health
A cohort ascertainment study using GP records in the SAIL Databank specified sets
of READ codes to define anxiety and depression. Using results of the Caerphilly
Health and Social Needs Survey (CHSNS), combinations of depression and anxiety
diagnoses, medication and symptoms showed that high positive predictive value could
be achieved, but it is likely that depression and anxiety are under reported in GP
records[69]. A further analysis of GP recording of depression showed that diagnoses
recorded in GP settings have declined while antidepressant prescribing has increased
in adolescents, indicating GP coding habits change over time and highlights the
importance of understanding reference data for epidemiology studies from routinely
collected healthcare data [70].
The Suicide Information Database Cymru (SID-Cymru) was set up using mortality
and secondary care data in the SAIL databank to identify 2664 cases of suicide in
Wales between 2003-2011 [71]. The SID-Cymru dataset was used to obtain suicides
following alcohol related emergency admissions to hospital which showed that women
were at double the risk of suicide than men and that 10% of suicides took place within
4 weeks of admission [72].
Multiple Sclerosis
The UK MS Register was set up to obtain rich patient and clinically reported
information on patients with MS. Patients can upload their medical data via web
forms and social media, to which they have consented for this information to be used
in healthcare research. All data is hosted by the SAIL Databank and is available
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to be linked to existing datasets in SAIL [73]. Responses from the web-portal were
used to assess how MS patients fair on the Hospital Anxiety and Depression Scale
(HADS), where HADS measures anxiety and depression using a scoring system
(0-7 neither reported, 8-10 mild, 11-14 moderate and 15-21 severe). The results of
4178 respondents showed that the median HADS score was 15.7, with over half of
respondents score ≥ 8 for depression and just under half scoring ≥ for anxiety [74]. A
follow study correlated increasing prevalence of anxiety and depression with increasing
physical disability where anxiety or depression was reported in 38% of people with
mild physical disability, 66.7% with moderate physical disability and 71% with high
disability [75]. Patients in the MS Register also answered a survey to determine their
generic health status from an EQ-5D in which people with MS scored 22% less than
the UK mean of 82% [76]
Diabetes
A study of ONS birth records in the SAIL Databank identified 1250 pregnancies where
the mother had existing diabetes and 1358 gestational diabetes in which contrary to
hypotheses of ”obesity programming” in children born to mothers with diabetes, little
evidence of this effect was found unless the mother was also found to be in the highest
weight tertile during pregnancy [77]. 1577 children between the ages 0-15 with type-1
diabetes from the Brecon Group Register were linked to hospital admissions in SAIL.
The study found a 480% incidence of hospital admissions in which the incidence rate
decreases 15% with each increasing 5 year age band [78].
HbA1c measurements recorded in GP records were compared before and after an
incident stroke in patients with existing type-2 diabetes. 1741 diabetes patients were
identified having HbA1c measurements before or after an incident stroke and were
age and sex matched 1:4 to a control group of patients with diabetes that had not
had a stroke. On average there was a 7.5% decrease in HbA1c measurement after the
incident stroke, indicating increased monitoring post-stroke in patients with diabetes
may result in better glycemic control [79].
Cardiovascular Disease
A study linking hospital records for patients admitted for acute myocardial infarction
(AMI) (n = 30,633), stroke (37,888) and sub arachnoid haemorrhage (SAH) (1753) to
ONS Death certificates in the SAIL Databank explored the effects of social deprivation
on 30 day mortality following admission. Baseline 30 day mortality rates for AMI,
stroke and SAH were 14.3%,21,4% and 35.6% respectively, however a 24%,24% and
32% increase in mortality was observed when comparing the lowest deprived quintile
to the highest [80]. Statin use in patients presenting with incident acute coronary
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syndrome (ACS) to the Cathlab Unit in Morriston hospital was studied to investigate
if guidelines were being taken up to prescribe statins post ACS. 80% of patients were
prescribed statins with simvastatin most common, however only 38% were prescribed
a high dose, leading to the conclusion that statin use post-ACS is under utilized in
Wales [81].
Cathlab data for patients with aortic stenosis was used to show that Transcatheter
Aortic Valve Implantation (TAVI) was more effective than being medically managed
in terms of prospective health utilisation and mortality over a 2 year period. Mortality
rates were half that in the TAVI group (19.2% vs 41.7%) and experienced less hospital
stay length (0.86 vs 1.84% person days per year) and costs within primary and
secondary care was half that than the medically managed group (£6059 vs £11001)
[82]. In contrast to many studies indicating worse health and social outcomes in
people from deprived areas, including many SAIL studies, a study of patients with
coronary artery disease (CAD) found no health utilization or treatment inequality
across Welsh Index of Multiple Deprivation deciles [83].
Epilepsy
An algorithm using GP records was developed to identify cases with epilepsy using a
combination of AEDs and epilepsy diagnosis codes. This algorithm was used to study
prescribing trends of first line AEDs in people with epilepsy between 2000-2010. The
study showed a sharp decrease in Sodium Valproate prescribing to women of child
bearing age, and that recent guidelines from the MHRA to prescribe lamotrigine
as a first line AED prescription had been taken up in Wales. [1]. The effects of
sodium valproate, lamotrigine, levetiracetam, topiramate and carbamazepine on
weight change were explored in a cohort 1423 epilepsy patients. Significant weight
gain (+1% body weight) in levetiracetam and significant weight loss (-2.62% body
weight) in topiramate was found, where the other 3 AEDs showed no significant
change in weight [84].
A collaborative study between Manchester University and Swansea University found
that people with epilepsy are twice as likely to die from suicide than people without
epilepsy, are 3 times more likely to die accidentally, are 5 times more likely to die of
accidental medication poisoning and are 3.5 times more likely to die of intentional
medication poisoning [85]. Emergence admissions of patients with epilepsy who had
attended ED for reasons specific to epilepsy were studied in which social deprivation
and living alone were identified as risk factors for ED attendance and of these patients,
and psychiatric co-morbidities and learning disabilities than epilepsy patients who
had not attended ED for epilepsy specific reasons [73].
37
1.4 Natural Language Processing: Using clinic
letters as a data source for research
Natural Language Processing (NLP) is a multi disciplinary field of linguistics and
computer science that aims to construct computer algorithms that can automatically
parse unstructured text into more manageable forms. Typically these algorithms
are aimed at unstructured texts reflective of human language such as clinic letters,
and a suitable task for NLP might be to automatically extract letters where a
diagnosis of a certain disease is written in the text. At present, only patient records
stored in structured databases are immediately accessible for healthcare research
and epidemiology. For decades researchers have been able to take advantage of the
codified format of these datasets to make quick gains in epidemiological research.
ICD-10, READ and SNOMED-CT codes can quickly be used to manipulate cohorts
of patients with structured query languages, but other forms of medical information
are slowly starting be adopted into a big data patient record. While huge efforts
go into producing an organised patient record at point of care, a large amount of
patient information is still recorded only by free text. These include consultant
notes, discharge letters, GP correspondence, radiology reports and even structured
databases may contain so fields that store free text. Free text in is seen as a rich
source of patient information not found in the structured patient records. but remains
a challenge to bundle the information into a database format that lends itself to data
manipulation. While there is no agreed way to process free text correctly, a number
of scientific disciplines have come together to address this problem.
Natural Language Processing (NLP) is a discipline that aims to process free text
into easily accessible information, such as a summary or database. NLP draws upon
advances in statistical theory, machine learning, artificial intelligence and computer
science to create programs or models that understand the nuances of human (natural)
language.
Early NLP techniques developed in the 1960’s and 1970’s used rule sets and pattern
matching techniques to infer meaning from text [86],[87],[88]. These early works
focussed on creating extensive hand crafted rules that used the relationships between
text units such as nouns, verbs and adjectives to extract structured items of
information. Using complicated human rule sets to parse language relies solely
on human knowledge of text to predict patterns in advance that would capture items
of interest and the context they are found in. The scale of this problem has required
more sophisticated approaches to be developed. The advent of machine learning in the
1980’s provided ways to parse text not through fixed sentences, but through teaching
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a computer to learn the role of each word in a sentence [89]. Part Of Speech (POS)
tagging abandons highly conceptual human rule sets declared to a computer algorithm
prior to analysis, and analyses the relationships of verbs, adjectives and nouns in
relation to a dictionary of words of interest i.e. medical terminology. Machine learning
allows a ground truth such as phrases known to confirm disease or symptom, be used
to train an algorithm to recognize the patterns between each word in a sentence and
words of interest. This machine learning approach does not rely on complex rules sets,
but rather learns the language used to describe cohort characteristics. Structured
concepts such SNOMED terminology can be ”mined” out of free text, including
information that would go unseen or undefined by prior rule sets. In the methods
chapter various NLP techniques are described and tested to define characteristics
about patients with epilepsy from clinical notes.
1.4.1 Part of Speech Tagging
Part of Speech (POS) Tagging involves assigning word classes such as verbs, nouns,
adjectives as well as more complex classes such as qualifiers, prepositions and adverbs
to tokens in text. This cannot be achieved by a simple lookup because words can be
assigned as different word classes based on context. For example the word haemorrhage
in the phrase ”there is a chance she will haemorrhage” is classed as a verb, but used in
the phrase ”she has had a haemorrhage” it is classed as a noun. Assigning the correct
word class for each token is crucial to NLP tasks such as information extraction where
word classes can be built into rules or machine learning processes as basic building
blocks that help identify concepts within text.
The development of POS tagging has relied on analysing large corpora of many
of documents such as the Brown Corpus [90] and the Cobuild project [91] so that
common data sources can be used to both develop and benchmark POS tagging
algorithms. The Brown Corpus consisted of 1 million words of English prose from
randomly selected scientific publications and was used to develop custom tagsets
to encapsulate detailed tags that extend beyond basic word classes. The Brown
Corpus was manually annotated over many years and served as a target tagset for
computerized algorithms. The first attempt to develop a computerised algorithm
from the Brown Corpus used human logic such as an article followed by a noun can
occur i.e. ”Dr House”, but in general an article followed by a verb does not occur.
This approach yielded an initial accuracy of 70% [92].
Both larger corpora and machine learning approaches were adopted to increase
POS Tagging accuracy. Hidden Markov Models - a probability state classifier was
tested on the Lancaster-Oslo-Bergen Corpus [93] of British English. Hidden Markov
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Models were able to take bi-grams, tri-grams and n-grams as input from the manually
annotated POS tags to calculate the probability of a TAG for each element of an
n-gram. This was a popular method of POS-tagging which used the scalability of
dynamic programming to produce fast and accurate taggers [94], [95], [96]. Some of
the most widely used POS taggers are rule-based. The Brill tagger [97] uses a set of
rules that recursively updates tags during repeated phases. An initial phase is run
generating most likely tags, in which set of conditions are imposed to correct each
tag. This process is repeated until a threshold is met in terms of the proportion of
tags corrected. The Penn Treebank POS tagset project annotated POS tags over a
corpus consisting of 4.5 million American-English words from the Brown Corpus and
the Wall Street Journal using a combination of Church’s PARTs method [94] and
manually correcting any errors, in which this method was measured to be twice as
fast as a fully manual annotation method [98]. While most POS tag studies up to this
point published an automated algorithm for POS tagging, the original Penn Treebank
paper does not describe such a method but provides a widely used benchmark corpus
for training POS taggers (machine learning, rule based or hybrid) for unseen samples
of text. Table 1.4 shows the PENN treebank tags that are commonly used to tag
texts:
Table 1.4: A table of PENN treebank POS tags. https://www.ling.upenn.edu/courses
/Fall_2003/ling001/penn_treebank_pos.html
Tag Description Tag Description
CC Coordinating conjunction PRP$ Possessive pronoun
CD Cardinal number RB Adverb
DT Determiner RBR Adverb, comparative
EX Existential there RBS Adverb, superlative
FW Foreign word RP Particle
IN Preposition or subordinating conjunction SYM Symbol
JJ Adjective TO to
JJR Adjective, comparative UH Interjection
JJS Adjective, superlative VB Verb, base form
LS List item marker VBD Verb, past tense
MD Modal VBG Verb, gerund or present participle
NN Noun, singular or mass VBN Verb, past participle
NNS Noun, plural VBP Verb, non-3rd person singular present
NNP Proper noun, singular VBZ Verb, 3rd person singular present
NNPS Proper noun, plural WDT Wh-determiner
PDT Predeterminer WP Wh-pronoun
POS Possessive ending WP$ Possessive wh-pronoun
PRP Personal pronoun WRB Wh-adverb
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1.4.2 Shallow parsing
Shallow parsing or ” text chunking” is the process of grouping tokens into n-grams
such as sentences, phrases as well as further sub-units commonly known as chunks.
The sentence ”The radiologist was able to observe the tumours visible against the
background” can be split up into five chunks ”The radiologist” ”was able to observe”
”the tumours” ”visible” ”against the background”, in which one chunk usually provides
context to other chunks in close proximity. Chunks are defined as sub-units of text
that contain a ”potential governor” - a handle placed at the rightmost part of a chunk
[99]. The potential governors in the above phrase would be ”radiologist”, ”observe”,
”tumours”, ”visible”, ”background”.
The Brill POS tagger algorithm and PENN treebank tagsets were used as input to
develop a rules based noun phrase chunker that defined noun phrase chunks such as
”she has epilepsy” and ”her seizures are frequent” [100]. Further algorithms were
introduced to classify verb phrases (VP), prepositional phrase (PP), adjective phrases
(ADJP) and adverb phrases (ADVP) [101]. The Conll-2000 shared task [2] defined 13
different chunk types as targets for classifiers to learn by providing a fully annotated
version of the Penn Treebank Corpus. These chunk types are shown in table 1.5.
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Table 1.5: The chunk types defined as part of the CONLL-2000 shared task [2]
Chunk Type Definition Examples
NP
Noun phrase - phrases beginning with a
noun
”Mr Jones”, ”He was”,
”a year”
VP
Verb phrase - phrases beginning with a
verb
”may want to increase”,
”could be a”, ”broke the”
PP
Prepositional phrase - a phrase to place
context to nouns
”at night”, ”because of
”, ”due to”
ADVP
Adverb phrase - pre or post modifier to a
verb or verb phrase
”very well”, ”overdosed
earlier”, ”quickly”
SBAR
Subordinated clause - conjunction between
other phrase types
”so that”, ”even if”,
”until”
ADJP
Adjective phrase - phrases beginning with
an adjective
”upset with her seziures”,
”prolapsed disk”
PRT
Particles - verb/adverb attached to non
inflected words
”look up”, ”on and
off”, ”in and out”, ”get out”
CONJP
Conjunction phrase - multiword
conjuntions to list additional phrases
”as well as”, ”not
only”, ”but also”
INTJ
Interjection - phrase containing an
ubrupt remark
”oh”, ”alas!”,
”good grief!”
LST List marker - denotes a list
”firstly. . . ”, ”1.”,
”lastly”, ”a,b,c”
Eleven algorithms were submitted to the Conll-2000 shared tasks and the most
accurate algorithm achieved an F-score of 93.4% [102]. Shallow parsing algorithms
have usually focussed on employing machine learning and statistical learners such
as Hidden Markov Models, Support Vector Machines, Naive Bayes and Conditional
Random Fields [103], [104], [96], [105].
1.4.3 Named Entity Recognition
Named Entity Recognition (NER) is the process of tagging specific words or phrases
and labelling them into entities and such as persons, addresses, identification numbers,
diseases, symptoms or medication. NER tasks usually involve mapping entities to a
user specified dictionary. NLP tasks focussing on healthcare typically map entities
to medical ontologies such as as MetaMap, The Unified Medical Language System,
SNOMED-CT and ICD-10 [106],[107]. NER has advanced significantly since scientific
events and competitions were set up in the 90’s, with the Messaging Understanding
Conference (MUC-6) [108] set up specifically to bring together groups researching
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NER. Many other annual conferences such as HUB-4 [109], the Information Retrieval
and Extraction Exercise (IREX) conference for Japanese NER [110] and the Automatic
Content Extraction (ACE) [111] conference have since been set up to maintain a
focus on NER and are still running today.
The main challenges for NER tasks are:
 Word ordering - the order of words within a phrase can change the meaning of
entities to be labelled. For example the phrase ”she had a blood pressure check”
identifies that this person has had a blood pressure measurement, but ”to check
her blood pressure” implies this is something that should happen in the future
and not be assumed this person has had a blood pressure measurement at the
current time.
 Inflexions - suffixes and prefixes can change to indicate a different meaning for
a word. For example ”big/biggest”, ”vomit/vomited”, ”informed/uninformed”
etc.
 Homopgraphs - the same words can have different meaning. The word ”fine”
can mean something is normal or it can describe a procedure or wound. Research
in word-sense disambiguation is dedicated to addressing homographs.
 Synonymy - the opposite of homographs in that multiple entities can mean
the same concept i.e. ”Focal seizures/ partial seizures”.
 Negation - certain trigger words such as ”not/no/never/unlikely” indicate
that an entity has not been found, and therefore should not be attributed to a
positive finding in text. It is common to tag entities with negation status.
 Word relationships - and extension of negation. The surrounding words
around an entity dictate it’s context. For example the phrase ”if the results are
positive, prescribe Lamotrigine” suggest a prescription of Lamotrigine is only
positive given the context of a result prior to the word Lamotrigine.
 Temporal qualifiers - describing a temporal feature attached to an entity
involves measuring the proximity and order of trigger words relating to past,
present or future tenses.
43
1.4.4 NLP tools and software
Table 1.6: A list of common NLP software
Toolkit Description
Stanford Natural Language
Processing Toolkit [112]
Open source Stanford CoreNLP toolkit. Contains standard
NLP applications (POS taggers, chunker, NER). Developed
by Stanford University.
NLTK [113] Natural Language Toolkit developed in Python
Apache UIMA [114] Open source Java based Unstructured Information
Management Application developed by the Apache Software
Foundation
Apache OpenNLP [115] Open source NLP toolkit adopted by the Apache Software
Foundation and developed by the open source community
Apache cTakes [116] Open source healthcare information extraction system
developed by the Mayo Clinic
GATE [117] The General Architecture for Text Engineering. An open
source NLP architecture developed at Sheffield University.
Contains a variety of standard NLP applications as well as
user contributed plugins. Has a rich GUI and can be run in
embedded systems.
IBM WATSON Content
Analytics [118]
A proprietary NLP product produced by IBM. Makes use of
the UMIA framework and has a rich GUI.
Spacy [119] A python library that supports many NLP tasks including
deep learning and pre-annotated corpora
Open NLP (R package) [120] An R package that interfaces to the Apache OpenNLP tools
written
TM (R package) [121] A text mining framework written in R. Contains many NLP
applications
Apache UIMA RUTA [122] A UIMA framework for executing rule based scripts for NLP
applications
Gensim [123] A python library for vector space modelling of large text
corpora. Developed at Mararyk University
Word2Vec [124] An algorithm to produce words embeddings for topic
modelling. Developed at Google trained on a Google News
corpus.
GloVe [125] An algorithm developed at Stanford University to produce
word embeddings
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1.4.5 Validating NLP algorithms
Any algorithm proposed for an NLP task can be measured against a human annotator,
or multiple annotators. Annual shared tasks such as CoNLL specify a problem
statement as well as providing or using large, annotated corpora to compare against
algorithm submissions. Comparison between a human annotator and an NLP
algorithm on a binary classification results in true positives (target class labelled as
target class by algorithm), false positives (non-target class labelled as target class),
true negatives (non-target class not identified as target class) and false negatives
(target class not identified as target class). By assigning each item identified by both
human annotator and an algorithm as a true positive, true negative, false positive or
false negative, the overall accuracy can be measured in various ways. In NLP tasks
precision, recall and F1-score [126] are widely used and are defined as as:
Precision =
TP
TP ∗ FP
Recall =
TP
TP ∗ FN
F1score =
Precision ∗Recall
Precision+Recall
Recall is a measure of the proportion of all possible target classes identified by the
algorithm, where precision is a measure of the proportion of classes identified by the
algorithm are true. The F1-score is the mean of precision and recall and is usually
reported as the overall accuracy.
NLP algorithms can be compared against multiple annotators by scoring algorithms
against the agreement of multiple annotators, as measured by Cohen’s Kappa statistic.
A Kappa-like statistic was presented by Galton in 1892 as a method of identifying
fingerprints using human raters where a match was identified if a certain percentage
of raters could agree that a unseen sample matched that of a known fingerprint.
Cohen’s Kappa statistic was formally introduced in 1960 [127] and is defined as:
κ = 1− po
pe
where po is the probability of an observed class by multiple raters and pe is the random
chance of observing all possible classes. κ therefore represents the class agreement by
multiple raters normalized by the probability of all classes where the class agreement
45
is 100% when κ = 1. Agreement measures such as Cohen’s Kappa statistic are
employed for inter-annotator agreement for NLP tasks [98]. This is useful to estimate
the relevant difficulty of a task in which some tasks may yield low inter-annotator
agreement and therefore sets a lower expectation for an algorithm’s ability to perform
the task.
Human annotation is time consuming and has been listed as one of the major
challenges in NLP for healthcare applications. Annotation tools such as BRAT[128]
ehost [129] provide a method of rapidly annotating documents in which data files
(xml, custom output) store all the annotations in each document. These output files
are designed to be read into NLP applications to directly compare annotations picked
up by humans annotators and those identified by the algorithm. Thus allows for
computation of accuracy measures to be automated and therefore many NLP models
can be validated automatically.
1.4.6 NLP clinical information applications
There have been extensive studies focussing on creating clinical extraction NLP
systems for specific disease areas. The NLP system developed as part of the Linguistic
String Project (LSP) was one of the first systems to be used for clinical information
extraction [130],[131]. Developed in 1987, a qualitative study first described a system
comparing human annotated notes with an automated extraction system in radiology
reports, reports and discharge summaries [132]. The Medical Language Extraction
and Encoding System (MEDLEE) was developed to detect disease mentions from
radiology reports and was scored against physicians’ interpretations of 230 radiology
reports, achieving 87% recall and 78% precision across all disease mentions [133],[134].
Medlee has also been extended to detect breast cancer from mammogram reports,
as well as forming the basis of the GENIES that extracts molecular pathways from
journal articles [135],[136].
The SymText NLP application [137] was used to detect bacterial pneumonia from chest
X-ray scans. The majority vote of 3 physicians was used to manually score 292 X-ray
reports from the LDS hospital in Utah and compare the annotations to extracted
annotations using SymText. The SymText system uses a syntactical rule-based
approach combined with a Naive Bayes Classifier to extract 76 different radiographic
findings and 89 different diseases from chest x-ray reports [138]. Pneumonia
concepts were split into 4 categories: acute bacterial pneumonia, infiltrate pneumonia,
aspiration pneumonia and support pneumonia. Physician average precision and recall
for acute bacterial pneumonia compared favourably with that of three physicians and
outperformed annotations by lay-persons.
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The i2b2 project used cTAKES and HITex (Health Information Text Extraction) to
extract Crohn’s disease, Ulcerative Colitis, multiple sclerosis (MS), and Rheumatoid
arthritis [139]. A recent study on patients with known MS identified from electronic
healthcare records used NLP techniques to accurately extract attributes specific to
MS, namely: Expanded Disability Status Scale, Timed 25 Foot Walk, MS subtype
and age of onset [140]. A study used clinic letters, available at www.mtsamples.com,
to determine whether sentences containing disease and procedure information were
attributable to a family member using the BioMedICUS NLP system and variety of
phenotype data was extracted from 300 randomly chosen journal titles [141],[142]
There have also been several epilepsy based NLP studies and applications developed.
The rule based Epilepsy Data Extraction and Annotation (EpiDEA) system was
developed to extract epilepsy information from epilepsy monitoring unit discharge
summaries. Categories of information included EEG pattern, past medications
and current medication extracted from 104 discharge summaries from Cleveland
hospital [143]. The rule-based Phenotype Extraction in Epilepsy (PEEP) pipeline was
developed to extract epileptogenic zone, seizure semiology, lateralising sign, interictal
and ictal EEG patterns from epilepsy monitoring discharge summaries as Cleveland
hospital [144]. A machine based learning NLP pipeline was also developed to identify
a rare epilepsy syndrome from discharge summaries and EEG reports [145]
Medication extraction has also been an area of interest for NLP research. The
Medication Information Extraction system (MedEx) was developed to extract
prescription information, including drug name, dosage, strength and frequency. On
a validation set of 50 discharge summaries and 25 clinic notes MedEx was able to
achieve an F-score of 93.2% and 90% respectively. CPRD prescription data was used
to validate 220 prescriptions from anonymised GP records, in which a rule based
system was able to achieve 91% accuracy [146] A rule-based NLP application was
developed and applied to the NHS Scotland Prescribing Information System (PIS)
[147]. On a validation set of 15,593 prescriptions the system achieved 94.7% accuracy
when extracting full prescription information and was able to generate structured
outputs for 92.3% of 458,227,687 dosage instructions in the PIS.
There has been a particular focus on mapping extracted terms from NLP applications
to existing clinical ontologies. This is particularly important for linking extracted
terms to routinely collected data that use ontologies such as SNOMED-CT and
ICD-10. A study using 23 citations in the Annals of Internal Medicine and the expert
opinion of three physicians described a system that mapped 89% of terms identified
by the physicians to MeSH terms [148]. Various studies have focussed on mapping
extracted terms to UMLS concepts for it’s ability to map to many other ontologies such
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as SNOMED-CT, READ and ICD-10. A study evaluated the use of UMLS concepts
as look up terms for congestive heart failure, chronic obstructive pulmonary disease,
acute bacterial pneumonia, neoplasm, pleural effusion without congestive heart failure
compared to manually curated lists by clinicians. This study found that using UMLS
concepts improved retrieval of terms over than of clinician specified terms[149],[106]
and further studies have used a variety of patient information sources such as patient
charts, MEDLINE citations and surgical notes [150],[151],[152]. The MetaMap project
used UMLS codes to retrieve medical terms from Medline citations and compared the
results to the use of NLM MeSH terms. By using UMLS concepts they reported a 14%
improvement on using MeSH terms and is now one of the most widely used algorithms
in the NLP community to patient information to UMLS codes. SNOMED-CT terms
are widely used in patient records and several studies have proposed methods to map
free text to SNOMED-CT. Several studies have used veterans’ patient records as a
source to validate varying accuracy across a variety of conditions including acute
renal failure, venous thromboembolism, pneumonia, myocardial infarction, sepsis
(82%,38%,59%,64% and 89% accuracy respectively).
1.4.7 Genetic Mutation
Single Nucleotide Polymorphisms (SNPs) are the most prevalent type of genetic
mutation in the human genome, with most genes having multiple non-synonymous
SNPs and accounting for around 90 percent of genetic variation [153], [154]. SNPs
appear in both the coding and non-coding region of the genome in which both have
been associated with disease phenotypes. The human genome consists of around 3.2
billion pairs of DNA, with SNPs appearing every 1000-2000 base pairs (between 2-3
million per genome) [155] and on average one person will have 250-300 potentially
damaging SNPs that are directly or indirectly associated with disease [156],[157].
SNPs fall into three broad categories.there Nonsynonymous (or missense) SNPs
represent a mutation in nucleotide base triplets that cause a change in the amino
acid the nucleotides code for. Synonymous SNPs, while containing mutations in
nucleotides, do not cause a change in the resulting amino acid. This is due to the
fact that there are multiple combinations of nucleotide triplets that code for the
same amino acid. Frameshift SNPs involves a deletion or insertion in the amino acid
sequence. Multiple insertions and deletions can also occur, but SNPs are estimated
to contribute to over 90% of all known genetic mutation [154] of which 50% of SNPs
have shown to be common ( 20% of the population have a given SNP) [158].
SNPs can fall anywhere in the genome meaning they are found in regions of DNA that
do not code for protein sequences ( 99% of the human genome) and in coding regions
that do code for proteins, known as the exome. Non coding regions have controversially
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been labelled in the past as ”junk DNA”, where it was assumed that mutations in
non-coding regions of the human genome would not contribute to disease, however
the ENCODE project showed that over 80% of non-coding regions serve some purpose
such as promotors, enhancers and silencers - all important roles in gene regulation
[159]. Despite SNPs in non-coding regions shown to cause diseases such as pancreatic
agenesis [160], juvenile idiopathic arthritis [161] and auto-immune conditions [162],
the majority of genetic mutation research, especially in non-synonymous SNPs has
been focussed on coding regions in the exome as this demographic has been shown to
be responsible for around 50% of human inherited disease [163].
1.5 Pathogenicity of SNPs
Pathogenicity in terms of genetic mutation can be described as the ability of a genetic
mutation to cause disease. The American College of Medical Genetics and Genomics
stated that pathogenic mutations can be determined on two types of evidence: a
variant has been previously reported as the cause of disease, or the variant has not
been reported as the cause of disease but is expected to be declared as such in future
[164]. These categories are broad and problematic for the definition of pathogenicity
as illustrated by a study of 402 published severe disease mutations showing that 27%
of these were either common or lacked direct evidence for pathogenicity [165]. Further
guidelines such as those proposed by The US National Human Genome Research
Institute have suggested 5 categories of mutation associated with causation of disease
[166]:
 Pathogenic: contributes mechanistically to disease, but is not necessarily fully
penetrant (i.e., may not be sufficient in isolation to cause disease).
 Implicated: possesses evidence consistent with a pathogenic role, with a defined
level of confidence.
 Associated: significantly enriched in disease cases compared to matched controls.
 Damaging: alters the normal levels or biochemical function of a gene or gene
product.
 Deleterious: reduces the reproductive fitness of carriers, and would thus be
targeted by purifying natural selection.
These definitions are far more reflective of that fact that genetic mutation and it’s
association with disease can range from single-gene, single-mutation causation of
disease (high penetrance), such as in cystic fibrosis [167] or Huntington’s disease [168]
than can be discovered through familial inheritance studies through to common-disease,
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common-variant associations where multiple mutations common in the population
sum to causative effects (low penetrance) such as Alzheimer’s disease [169] that
require large-scale GWAS studies to identify disease risk. The ClinVar dataset
curates a record of all variants that can be defined as pathogenic, likely pathogenic,
likely benign, benign and uncertain following review of aggregated submissions and
publications [170]. Other databases such as dbSNP [171] and Uniprot/Swissprot also
record pathogenicity/benign status where the entry point in terms of association to
disease meets at least the minimum requirement as set out previously in [166], that
is, a variant deemed as pathogenic at least contributes to a disease phenotype.
1.6 Whole genome sequencing and the need for
SNP prediction paradigms
Frederick Sanger introduced dideoxynucleotide sequencing, or Sanger sequencing of
DNA [172] were manual techniques harnessed to sequence individual genes and cells.
More sophisticated techniques such as shotgun sequencing were introduced in which
bacterial genomes such the influenza genome (2 million DNA base pairs) was able to
be sequenced [173], with the first eukaryote genomes, a strain of yeast - Saccharomyces
cerevisiae ( 12 million base pairs) and a type of worm - nematode elegans (100 million
base pairs) were sequenced [174],[175]. Next Generation Sequencing technologies
were developed to allow high-throughput sequencing of large genomes such as the
common fruitfly - Drosophila melanogaster (135 million base pairs) [176] and finally
in 2001 the human genome (3 billion base pairs), costing an estimated £750 million
US dollars [177]. The cost of whole genome sequencing has vastly decreased since
Craig J Venter sequenced his genome in 2001 as part of the Human Genome Project
from £750 million US dollars to £1000 US dollars today. This remarkable decrease
in cost is owed to advances in sequencing technology over the past 15 years, and
to highlight this, Figure 1.4 shows the decrease in whole genome sequencing when
compared to what the decrease might be if following Moore’s Law.
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Figure 1.4: Decrease in whole genome sequencing since the Human Genome Project
when compared to the expected rate of decrease following Moore’s Law
The relatively low cost of whole genome sequencing has enabled whole genome /
exome cohort projects such as The 1000 Genomes Project [178], The 100,000 Genomes
Project [179], UK Biobank [180], ExAC [181] and aggregation services such as the
Genome Aggregation Database (gnomAD) that contains 15,496 genomes and 123,136
exomes for unrelated individuals. The number of variants processed from whole
genome sequencing outstrips the ability for genetic research to comprehensively study
each and every variant through traditional laboratory techniques [182]. Typically
whole genome sequencing one person will generate 3,000,000 variants and whole
exome sequencing will generate 30-50,000 variants and it is therefore vital to find
ways of focussing on variants likely to impact disease in advance of more thorough
analyses [183].
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1.7 Common features used in prediction of
pathogenicity
There are a variety of hypotheses that help when considering the pathogencity of
SNPs. A study of 561 disease causing SNPs and from the SWISSPROT database
that contained details of 2D and 3D structure found that over 70% of these SNPs
were found in structurally important regions such as binding sites and sites with
low solvent accessibility [184]. The allele frequency on non-synonymous SNPs that
caused disease was found to be lower than that of non-synonymous SNPs, indicating
that nature selects against pathogenic SNPs and that disease causing SNPs may be
found at sites that are conservative [153]. The BLOSUM62 matrix was developed
to produce a system that scored all possible 210 amino acid substitution of the 20
standard amino acids based on an alignment of 500 protein sequences (BLOSUM62
matrix shown in Figure 1.5).
Figure 1.5: The BLOSUM 62 matrix where higher scores indicate higher frequency of
substitution. Each amino acid substitution is scored in accordance to it’s frequency,
where lower frequency substitutions are said to be conserved and potentially selected
against by natural selection.
On average 5 of the possible 19 substitutions for a given amino acid has found to be
non-conservative and is a potential predictor for SNPs associated with disease [153].
A study comparing the distributions of 1169 disease associated non-synonymous
SNPs and 741 neutral SNPs found a significant difference when plotted against
BLOSUM62 scores inferring that lower frequency substitutions are associated with
pathogenicity [185]. The Sifting Intolerant From Tolerant predictor[186],[187] was
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developed from the hypothesis that position specific information of where a SNP is
found might be a predictor of disease/neutral status given that the plasticity of proteins
can change across sequences [188], [189],[190]. To test this, the SIFT study took
datasets that collected variants found in the Laci, HIV-1 and T4 lysozyme proteins
[191],[192],[193],[194] and performed a multiple sequence alignment to other proteins
in their respective families using PSI-BLAST [195] and compared disease/non-disease
SNPs in these proteins to the position of the multiple sequence alignment. The
results showed that the accuracy of SIFT was 66%, 86% and 45% for the SNPs in
each protein respectively and that using position specific information from multiple
sequence alignment was able to correctly identify the disease status of 14% more
SNPs overall when compared to using BLOSUM62 scores. The study showed that
position specific information was however more important in some proteins than
others, in particular the low prediction accuracy of the T4 lysozyme proteins.
Figure 1.6: A multiple sequence alignment of transmembrane proteins from different
species. Conserved regions are in red where alignment of different proteins shows no
difference in amino acids across all proteins in this position. Conserved regions are
therefore hypothesized not to tolerate geneitc variation and are deemed hotspots for
pathogenic mutations.
The PolyPhen-2 prediction server was developed with a range of features that included
multiple sequence alignments and molecular function information [196]. Prominent
features used by PolyPhen was difference position specific scores for both wild type
and mutant based on multiple sequences alignments [197], predictions of functional
region such as transmembranes [198], coils [199] and peptide signals [200] as well as
known 2D and 3D structure from DSSP and PDB [201],[202]. The study used a Naive
Bayesian classifier, a type of machine learning classifier, to take these features as input
and classify into three categories: benign, possibly damaging and probably damaging.
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The HumDiv (3,155 damaging and 6,231 benign SNPs) and HumVar (13,032 damaging
and 8,946 benign SNPs) datasets, datasets annotated with damaging/benign status
from Uniprot, were used for training/testing of the Naive Bayes classifier using a
5-fold cross validation technique where training and testing sub-sets were randomly
sampled. The PolyPhen method was able to achieve 93% and 72% true positive rates
for damaging SNP detection using a 20% false positive rate on the HumVar and
HumDiv datsets respectively [203].
1.7.1 Machine learning classification for SNP
pathogenicity
Machine learning classification is a staple of SNP prediction techniques. They are
used effectively when a large number of SNPs in both benign and pathogenic classes
are used to train a model with features hypothesized to be useful in discriminating
between pathogenic and benign SNPs. Machine learning techniques use the interaction
of every feature against all other features to make a prediction, meaning that even
features not thought to have a strong influence on classification may be useful to
increase accuracy by a small amount overall, or increase accuracy substantially in
subsets of samples that do not adhere to common hypotheses such as position specific
sequence information or structural features.
The PolyPhen server uses a Naive Bayes classifier, but many other machine learning
techniques have been used in SNP prediction as shown in Table 1.7.
Table 1.7: Commonly used SNP prediction programs that utilize machine learning
Algorithm Citation Machine Learning Classifier
DANN [204] Convolutional Neural Network
MetaLR [205] Logistic regression
MutationAssessor [206] SNP prediction application
REVEL [207] Random Forest
FATHMM [208] Hidden Markov Model
PolyPhen [196] Na¨ıve Bayes
CADD [209] Support Vector Machine
MetaSVM [205] Support Vector Machine
VEST3 [210] Random Forest
PHD-SNP [211] Gradient Boosting Learner
PolyPhred [203] Decision Tree
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1.7.2 SNP datasets
A number of databases provide pathogenic/benign status. There are many public
databases that record SNPs from population studies such as the National Center
for Biotechnology Information (NCBI) SNP database, dbSNP [171], ClinVar [212]
and the Human Genome Variation database, HGVBase [213]. Other databases
focus on curating SNPs known to be associated with causing disease (rather than
pathogenicity) such as the Online Mendelian Inheritance in Man (OMIM) [214], the
Genetic Association Database (GAD) [215] and The Human Gene Mutation Database
(HGMD) [216]. One of the most widely used datasets along with HGMD (FATHMM,
REVEL, CADD, DANN) is the humvar dataset https://www.uniprot.org/docs
/humsavar curated by Uniprot, which as of June 2018 contains over 70,000 SNPs
with known status and has been used to train classifiers such as PolyPhen, VEST3,
MetalR, MetaSVM and PHD-SNP.
Currently the REVEL classifier has the highest published accuracy when compared
with other existing scores in two independent test sets, Clinvar and SWISSVAR,
achieving AUC measures of 0.83 and 0.95 respectively. REVEL is perhaps unique in
that it only uses a relatively small set of 13 features, none of which are derived from
protein features such as secondary structure or multiple sequence alignments, but
instead it uses the output of 13 SNPs prediction classifiers and combines the results
using a Random Forest classifier [207]
1.7.3 Bioinformatics software and annotation programs to
obtain SNP features
As well as obtaining SNPs with known pathogenicity status, it is important for machine
learning classifiers to obtain many features such as multiple sequence alignments and
region annotation. There are various bioinformatics pipelines that can help source
these features. There exists many multiple sequence alignment programs that can be
used to obtain conservation measures at each position of a sequence. These include
BLAST [217], PSIBLAST [195], MUSCLE [218], CLUSTAL [219], UBLAST [220]
and HMMER [221]. In addition to multiple sequence aligners for conserved regions
of sequences, there are various tools exist such as GERP (Genome Evolutionary Rate
Profiling) and phyloP [222], phastcons [223] and SiPHy (Site Specific Phylogenetic
analysis) [224] that compute conservation as a function of evolutionary selection over
all positions of protein sequences.
Region annotation is useful to detect if a SNP falls with certain functional regions
such as transmembranes or binding sites. While databases such as DSSP and PDB
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exist that catalogue such features, there are many programs that compute or predict
such features. The PSIPRED server can be used to predict if positions in an amino
acid sequence are likely to be in a coil, helix or sheet category of secondary structure
[225], and various programs can predict functional regions such as binding sites [226],
transmembrane regions [198] and protein-protein interaction sites [227].
There are also annotation aggregation services that take a SNP as input (usually
rsID, BED or HGVS format) and query large pre-computed databases to gather a
vast range of features that include multiple sequence alignments, regional annotations,
scores from many prediction software (dbNFSP [228]) and allele frequency measures
computed as part of 1000 genomes, exAC and gnomAD. Three commonly used
aggregation tools are Variant Effect Predictor [229], snpEFF [230] and Annovar [231].
Such tools are available as web services and standalone programs and particularly
useful in SNP annotation because their databases storing many SNP features are
kept up to date, making them a one-stop shop for SNP annotation.
1.8 Chapter Summary
This thesis is summarised as follows:
 Epilepsy is prevalent in 1% of the population and can be caused by inherited
genetic mutation of acquired through lesions in the brain due to injury. Epilepsy
can be presented in many sub-types and seizure types of which many different
types are attributed to inherited genetic mutation in certain genes. Severity of
epilepsy can range in terms of seizure frequency, and various treatment regimes
using anti-consultants exist to control seizures
 The burden of epilepsy can be measured in other ways than seizure frequency.
Patients living with epilepsy are known to have lower socio-economic status
and those with poorly controlled epilepsy perform poorer in education than
their peers.
 Epilepsy research in epidemiology is restricted to using routinely collected
healthcare records that often contain rich data desired for impactful studies
in epilepsy. Large data banks such as the SAIL Databank can provide data
linkage across multiple health and social care datasets, however this still does
not solve the problem of data shortage for people with epilepsy
 Natural Language Processing is an emerging field in healthcare that has benefited
from machine learning and the explosion of big datasets. Natural Language
Processing offers the potential to collect data form clinic letters that does not
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end up in routinely collected datasets.
 The emergence of Next Generation Sequencing has enabled genetic research to
be conducted on a much larger scale and help with genetic discoveries. The
sheer volume of data recorded poses a problem in how to make sense of millions
of variant data per individual. Consequently prediction paradigms are necessary
to prioritise which variants require thorough genetic analysis to make genetic
research cost effective.
 Various prediction techniques have been developed with the aid of machine
learning and adopted for genetic research. Such programs exist as part of larger
pipelines that filter pathogenic variants from benign variants, however many
lack the specificity to prevent large amounts of benign variants being needlessly
analysed in molecular assays.
 Linked data of routinely collected data, clinic letters and genetics will play an
important role in the future of healthcare research, and efforts must be made
to facilitate the linkage of emerging data types at scale.
1.9 Summary of aims and objectives
A summary of the aims and objectives are:
1. Using routinely collected healthcare data stored in the SAIL databank to identify
persons with epilepsy
2. Link primary care records of persons with epilepsy to other datasets within
the SAIL databank to study societal burden of epilepsy and the effects of
antiepileptic drugs
3. Explore the possibilities of incorporating clinical free text into existing patient
records by using NLP techniques. Target information will consist of data that
is difficult to obtain or non-existent within the SAIL databank
4. Investigate various methods of determining or predicting pathogenicty of SNPs,
in particular to study SNPs found within epilepsy associated genes.
5. Create an algorithm that accurately predicts pathogenicity for missense SNPs in
epilepsy to aid SNP prioritisation for downstream structure/functional analysis
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Chapter 2
Methods
The following chapter describes the methods and materials used to mine health
trends in data from the SAIL databank, extract information from unstructured
clinic letters using NLP building a pipeline for assessing the impact of SNPs, with
a focus on how the outputs of NLP and SNP analysis could potentially enrich data
audited from routinely collected healthcare records. The SAIL databank holds a large
all-Wales database of routinely collected electronic healthcare records that can be
potentially be enriched by linking bespoke datasets, such as clinic letters (unstructured
text) and whole genome/exome (NGS) data. Patient records at the SAIL databank
anonymous - specifically by use of an encrypted NHS number, so that these records
can be linked anonymously across different datasets i.e. GP records and hospital
admissions. The NLP methods described in this chapter and chapter 4 are intended
to be used to extract information from clinic letters using an automated computer
algorithm in which the results could be linked to the SAIL databank and provide
rich patient information that doesn’t exist in SAIL. Similarly, the SNP pipeline
described in this chapter and chapter 5 is designed to take in SNP information,
filter it on various criteria and output the data in a format that can be linked to
patient data in the SAIL Databank. Much of the code underpinning the methods
is written in SQL, R, perl, bash for calling open source bioinformatics programs, as
well as an array of UNIX/GNU programs such as sed and awk. Complete code is
found at www.github.com/https://github.com/arronlacey/Epilepsy-GATE-app
(Chapter 3).
2.1 The SAIL Databank
The SAIL databank holds many routinely collected electronic healthcare databases,
where a person’s records can be identified and linked between datasets by an encrypted
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NHS number called an ALF (Anonymous Linking Field). Figure 2.1 shows the
anonymisation and linkage process that ensure SAIL uses encrypted NHS numbers or
Anonymous Linking Fields (ALFs) to perform linkage.
Figure 2.1: SAIL Databank split file procedure. Data is split at source into identifiable
data and clinic data. The identifiable data sent to The NHS Wales Information Service
where each NHS number is encrypted before being sent to the SAIL Databank. The
clinic data is sent directly to the SAIL Databank, and is joined to the encrypted
identifiable data by an internal system ID that is present in both datasets.
2.1.1 Ethics and Governance
All proposed SAIL projects undergo a review process by an IGRP (Information
Governance Review Panel) for approval. Researchers must complete an IGRP form
that details the scope of the project and what datasets are required. Approved
projects must be deemed feasible and present no risk to patient identification. While
all NHS numbers are encrypted in SAIL, it may be possible for Clinicians, without
taking data out of the SAIL databank to identify a patient with a rare combination
of information in their medical records e.g. a 35 year old man living in the ABMU
health board area that has Becker’s muscular dystropy, focal seizures with secondary
generalisation and being prescribed multiple anti-epileptic drugs for multiple seizures
per day. SAIL does not allow individual level data to be taken out of the gateway
and must be summarized so that it conforms to small number disclosure rules of
never reporting on groups with less than 5 persons. Data must be requested out and
reviewed by the SAIL Analyst Team to enforce these rules.
2.1.2 Assessing the burden of disease using the SAIL
Databank
The work of this thesis focuses largely on how to identify disease phenotypes, their
effects on quality of life and how to treat and manage the disease. The Wales
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Epilepsy Research Network (WERN) at Swansea University has conducted world
class research into epilepsy genetics, and has both clinical and research expertise in
the field of epilepsy. The SAIL databank presents an ideal opportunity to further our
understanding of the burden of epilepsy in health care. Where exome analysis can
identify the exact cause and mechanisms of epilepsy, patient records within SAIL can
answer questions on social outcomes, health utilisation and drug efficacy for patients
with epilepsy. Being a member of WERN and integrating into the wide variety of
researchers has helped form novel and important questions for this thesis.
2.1.3 Forming Research Questions
In 2008 a group survey conducted on behalf of the DUETs (Database of Uncertainty
about the Effects of Treatments) and James Lind Alliance brought together patients,
clinicians, patient carers and researchers to address questions regarding treatment
of conditions, including epilepsy www.library.nhs.uk/duets. In addition, all the
Neurology Consultants across Wales were asked to contribute research questions that
SAIL may or could answer. Many of the items highlighted form the research basis for
this thesis involving SAIL data, with an emphasis on:
1. Research into better treatments and seizure control
2. Research into ensuring current treatments are as effective as possible
3. Research into stigma associated with epilepsy
4. Research into epilepsy and other medical conditions
5. Research into patient information
These questions set many challenges when using data in the SAIL databank and
were considered to prioritise the studies described in chapter 3 of this thesis. The
first problem is to correctly identify epilepsy phenotypes within routinely collected
primary care data, and the second is to obtain treatment and social status of those
with epilepsy. A scoping exercise was carried out to identify datasets that would
contain the required data build an epilepsy patient profile within SAIL data. Four
core datasets were identified within the SAIL databank to obtain epilepsy metrics -
General Practice dataset, Secondary care dataset (PEDW), the Welsh Demographic
Service dataset and the Office of National Statistics (ONS) Deaths dataset.
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2.2 SAIL Datasets
The following section describes the core datasets in SAIL, including those used in
this thesis.
2.2.1 GP dataset
Each GP practice in Wales uses a clinical information system to capture patient
records. The Primary Care IM& T Programme developed a piece of software called
Audit+ that is provided free of charge to all Welsh GPs. It was designed to facilitate
the capture and transfer of GP data to external sources. A SAIL module is built into
Audit+ that automatically two data extracts: file 1 contains demographic data and
file 2 contains clinical data, where an internal system ID is shared between both files.
Both files are securely transferred to SAIL and are anonymised via the encryption
process outlined in [61]. Each GP practice in Wales has been invited to participate,
where only those consenting have their data transferred into SAIL. Over length of
study of this thesis, SAIL GP participation has increased from 40% of Welsh GP
practices to 75%.
The dataset contains two unique identifiers: patient ID (encrypted NHS Number)
and GP ID (also encrypted). Demographic data available includes week of birth, sex
and dates of the beginning/end of registration with a given GP practice. Clinical
information includes reason for attendance via version 2 READ codes, date of
attendance and any laboratory result such as blood pressure. There are over 300,000
READ codes that can be used to define diseases, drug prescriptions, symptoms,
referrals to specialists and laboratory results. A subset of READ codes were used to
define:
1. Epilepsy diagnosis
2. Anti-epileptic drugs (AEDs)
Using a combination of these two categories, a diagnosis of epilepsy in the SAIL
dataset is defined as a patient that has a diagnosis code for epilepsy followed by a
repeat anti-epileptic drug prescription within 6 months. A repeat AED prescription is
used as a pre-cautionary measure to prevent suspected, unconfirmed epilepsies being
used in any epilepsy cohorts generated. The reasoning behind this is that epilepsy
and treatment plans are confirmed by a specialist, not in a GP setting. It is possible
a GP may use a diagnosis code for epilepsy to denote suspected epilepsy as well as
a code to refer to a specialist. The repeat prescription is indicative of that patient
being seen by a specialist and prescribed a AEDs beyond a potential trial period.
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Defining epilepsy in the GP dataset held within SAIL is useful because it can be used
to build up a patient profile of epilepsy at first point of health care in Wales, as well
as link to other datasets.
2.2.2 Secondary Care dataset
The SAIL databank receives an annual extract of all Welsh inpatient hospital data.
This dataset is processed using the same split file procedure where the National Wales
Information System (NWIS) acts as a TTP and processes the extract useable within
SAIL called PEDW. PEDW contains all hospital admissions in Wales from 1998 and
uses the ICD-10 coding system to record admissions to inpatients. Each hospital
employs teams of clinical coders to records the reason for admission as determined
from consultation of doctors’ notes, as well as any operations and costs associated
with the admission. Other variables included within PEDW are date of admission,
length of stay and consultation speciality. Date recorded in PEDW is designed to
reflect the care pathway of an admission to secondary care, and with careful use
of ICD-10 code selection, it is possible to identify patients that are admitted to
secondary care and the reason for being admitted. In particular there are ICD-10
codes for seizures and status epilepticus, as well as other common outcomes associated
with epilepsy such as seizures and stroke.
2.2.3 Welsh Demographic Service
The Welsh Demographic Service (WDS) was introduced in 2009 to manage
administrative and demographic data for NHS patients in Wales. It contains
address information as recorded by a patients’ GP, which is mapped to Lower
Super Output Area (LSOA), Middle Super Output (MSOA) and Local Health
Board (LHB) by the address postcode. These are geographical units with LSOA’s
accounting for between 5-10 postcodes and can be mapped to The Welsh Index of
Multiple Deprivation (WIMD) to measure social deprivation. The Welsh Government’s
official measure of deprivation is the Welsh Index of Multiple Deprivation (WIMD)
http://wales.gov.uk/topics/statistics/theme/wimd/?lang=en and is readily
available in the SAIL databank for any person registered with a Welsh GP. It
comprises of 8 domains:
1. Income
2. Employment
3. Health
4. Education
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5. Access to Services
6. Community Safety
7. Physical Environment
8. Housing
where a deprivation score can be obtained for each domain or combined into one score.
The WIMD is therefore one way of measuring social deprivation to some degree in
those living with epilepsy. An explanation of how the WIMD score is calculated is
given in Figure 2.2.
Figure 2.2: Flow chart of how the WIMD score is calculated from 8 different domains.
Taken from http://webarchive.nationalarchives.gov.uk/20150505155421/http://gov.wa
les/docs/statistics/2011/110831wimd11summaryen.pdf
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2.2.4 ONS deaths
SAIL contains both annual and monthly extracts from the ONS database. This
dataset contains date of death, primary and secondary causes of death, location of
death (LSOA), place of death (hospital,home etc) and age of death. ONS deaths
contains all deaths in Wales from 2003 onwards. Causes of mortality are not well
understood in epilepsy related deaths, and death certificate information alone can
only provide so much evidence. For example Sudden Unexpected Death in Epilepsy
(SUDEP), an uncommon outcome of epilepsy rarely gets recorded in death certificates
due to the cause of death not being clear, and so the amount of people dying from
SUDEP is thought to be underestimated in the epilepsy population. In some cases
it is thought to be preventable, however the risk factors are not well understood
and there is currently no genetic explanation for SUDEP, and as such a research
priority in epilepsy. The work in this thesis hypothesizes that linking death certificate
information from ONS into GP and secondary care records can provide further insights
into risk factors associated with SUDEP.
2.3 Data Linkage
2.3.1 Structured Query Language
SQL (Structured Query Language) queries use set theory to join multiple datasets
together and aggregate individual records into groupings for statistical analysis.
Unique identifiers are present in all datasets within SAIL, this is usually the encrypted
NHS number of a patient called an Anonymous Linking Field, ALF. For example,
consider the two tables and SQL code used to join them by the ALF:
## ALF_E GNDR_CD DRUG GP_DATE GP_PRACTICE
## 1 20000001 M LTG 2001-01-01 SW1
## 2 20000001 M VPA 2001-04-02 SW1
## 3 20000002 F CBZ 2001-04-10 NEA
## 4 20000003 M CBZ 2001-11-04 NEA
## 5 20000004 F VPA 2001-01-31 CAF4
## 6 20000005 F LTG 1999-04-06 POW2
## ALF_E HOSP_DATE HOSP_ID
## 1 20000001 2001-05-10 7AE
## 2 20000003 2001-11-11 ONA
## 3 20000004 2001-02-14 9DN
## 4 20000005 2007-03-04 G4K
## 5 20000006 2009-03-15 7AE
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1 s e l e c t d i s t i n c t gp . ALF E , gp .GNDR CD, gp .DRUG, gp .GP DATE,
2 hosp .HOSP ADMIS, hosp .HOSP DATE
3
4 FROM
5 SAILGP gp inner j o i n SAILHOSP hosp
6
7 on gp . ALF E = hosp . ALF e
8 where hosp .HOSP DATE between gp .GP DATE and gp .GP DATE + 3 months
Figure 2.3: A simple SQL script to return encrypted patient identifiers along with the
gender and date of birth of the patient where the patient must be female and born
after the 1st of January 1990.
The first table is GP data containing prescriptions for anti-epileptic drugs, and the
second table is hospital admissions for seizures. It is possible to find persons who have
been admitted to hospital for a seizure within 3 months of a drug prescription. The
code in figure 2.3 demonstrates how to join the GP data and hospital data together,
and the results are shown in figure 2.3.1.
## ALF_E GNDR_CD DRUG GP_DATE HOSP_ADMIS HOSP_DATE
## 1 20000001 M LTG 2001-01-01 N NULL
## 2 20000001 M VPA 2001-04-02 Y 2001-05-10
## 3 20000002 F CBZ 2001-04-10 N NULL
## 4 20000003 M CBZ 2001-11-04 Y 2001-11-11
## 5 20000004 F VPA 2001-01-31 Y 2001-02-14
Once a basic data linkage is established amongst SAIL datasets the aim is to filter
the linked datasets down to a ”final” dataset ready for statistical analysis.
2.3.2 Quality checking routinely collected data
It is important to note that routine healthcare datasets were not designed for research
purposes, rather collected at point of care for costing purposes or to supplement
decision making processes. With this in mind, any routinely collected healthcare
dataset requires careful consideration of how to interpret the data and understand the
limitations. The majority of the data is entered manually by trained professionals,
but there is still the potential for human error in data entry in which it is impossible
for some error to be rectified by retrospectively cleaning the data.
Data cleansing refers to removing or transforming data so that is is meaningful when
used in statistical analysis. For example, blood measurements such as cholesterol can
be expressed in millimoles per litre (mmol/L) or milligrams per decilitre mg/dL.
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In the UK it is usually the case that the former is used to record cholesterol, however
this is not always the case and the units are not attached. Limits of normality must
be defined to determine if a reading is likely to expressed in certain units or not
by looking at the value recorded. While there is an obvious difference in the values
recorded within different units it is possible for two extreme measurements of each
of the scale of different units to have a similar value. Some values may even appear
outside of any limits of normality of any units of measurement and might require
from the study.
Cleansing on measurement values are relatively more straightforward than making
assumptions on how other items of data are recorded. Two examples of this are the
dates GP records are documented and the reason for admission to secondary care. In
the first example you assume that a recording of a prescription in a GP database was
made on that date appearing in the records. However this could have been entered
by administrative staff retrospectively, or even entered by both the GP and staff
where it appears that the same prescription was made on two separate days. Many
diagnosis codes for epilepsy appear before electronic records were even integrated into
healthcare systems, suggesting that historical information is entered by GPs where
the date appearing in the records is an approximation of when someone was first
diagnosed with epilepsy.
In the second example, ICD-10 codes are used to record episodes of care in secondary
care. For each episode 14 ICD-10 codes may be entered to record the details of care
required. This can lead to some interesting codes being used at point of admission as
it may be in the interest of hospital staff to include background information about
patients to tailor their care through an inpatient stay. Chronic conditions such as
diabetes or asthma often get recorded even if they are unrelated to the admission.
A distinction has to be made because codes that are entered to detail care required
does not directly translate to reason for admission. These 14 diagnostic positions are
ordered by priority of care, however this leads to many of the high priority positions
being taken up by generic symptoms such as ”chest pain” or ”out of breath”, and
for complicated episodes of care there could be multiple valid reasons for admission.
There is clearly no ”one-size fits all” approach into which positions are used as a
proxy for reason for admission as the actual reason for admission is not known. This
rules out an opportunity to conduct a sensitivity analysis to determine how many
positions are included.
Finally, some other obvious errors appear in large datasets that are common and
well known, but nevertheless have to be taken into account. These are errors such as
men appearing to be pregnant (incorrect gender code assigned), patients seeing their
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GP after they have died (incorrect date of death) and people still alive longer than
the known human life span (incorrect date of birth). A particularly painful error to
identify in large datasets are when NHS numbers are incorrectly entered at point of
care. For example there are records in SAIL that suggest one person has seen two
different GPs in different health boards on the same day, where this behaviour can
be traced back for numerous years. While it isn’t impossible for this to be happen, it
is most likely that the multiple persons are sharing an NHS number due to a mistake
at the point of registration. In this instance cross checking with other datasets may
help determine which person the NHS number truly belongs to, and therefore which
set of records to exclude.
All of these cleansing considerations were taken into account for the various studies
in this thesis when using the SAIL databank.
2.3.3 Statistical Analysis
The SAIL gateway contains various software packages to analyse linked datasets in
SAIL. Studies in this thesis use the open source R statistical software language to
produce statistics and figures. SAIL has strict guidelines on what data is allowed to
be taken out of the secure gateway and be included in publications. The results of
statistical analysis must not contain data that could potentially identify a person,
even from anonymous data. Therefore number of persons in group outputs may
not be reported below 5 persons as persons in this group could potentially be
identified through linking many datasets together and building a detailed patient
profile. Individual level data is therefore restricted from being reported as part of
any statistical analysis.
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2.4 Natural Language Processing
To construct NLP algorithms and validate their ability to extract important items of
text from clinic letters, clinic letters were sourced from Morriston Hospital 1. Patients
with known epilepsy were sourced form clinic letters held in the Swansea Epilepsy
Database that stores patient data from the Epilepsy unit in Morriston hospital, and
patients without epilepsy were sourced from general neurology clinics. All letters
were de-identified by replacing identifiable information with fake information. These
letters were then made available to aid constructing an automated NLP algorithm
to extract epilepsy specific information from the clinic letters. The clinic letter in
Figure 2.4 is representative of the clinic letters used in this study.
Figure 2.4: A example clinic letter. The letter contains real patient data, but all
identifiable information has been anonymized
2.4.1 Software
The open source GATE v8.4.1 (General Architecture for Text Engineering) https:
//gate.ac.uk/ framework was used to construct an algorithm to extract epilepsy
specific information from clinic letters, as other details such as clinic date, patient
NHS number and date of birth. GATE allows users to build rule sets by combining
custom gazetteers (user defined dictionaries) with mechanisms form specifying word
1performed by Ms Beata Fonferko-Shadrach
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ordering by writing JAPE (Java Annotation Pattern Engine) scripts. GATE also
provides plugins to perform common NLP tasks such as POS (Part-of-Speech) tagging,
NER (Named Entity Recognition) and phrase identification, while also allowing the
user to put together such plugins as modules in a pipeline. A GATE pipelines are
constructed with a provided GUI (Graphical User Interface).
2.4.2 Part of Speech tagging
POS tagging formed the basis of information extraction for this study. Words in
text are classified into grammatical units such as verbs, adjectives and nouns. The
following phrase:
Mary has focal epilepsy and has been taking Lamotrigine for five years
can be tagged in the following way:
Mary—NNP has—VBZ focal—JJ epilepsy—NN and—CC has—VBZ
been—VBN taking—VBG Lamotrigine—NNP for—IN five—CD
years—NNS
where tags are in red. The ANNIE POS Tagger is used to POS tag clinic letters used
in the epilepsy NLP algorithm, in which the possible tags are given in table 2.1.
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Table 2.1: ANNIE POS tags and their descriptions
POS tag Description
CC coordinating conjunction: ’and’, ’but’, ’nor’, ’or’, ’yet’, plus, minus, less, times
(multiplication), over (division). Also ’for’ (because) and ’so’ (i.e., ’so that’).
CD cardinal number
DT determiner: Articles including ’a’, ’an’, ’every’, ’no’, ’the’, ’another’, ’any’, ’some’, ’those’.
EX existential ’there’: Unstressed ’there’ that triggers inversion of the inflected verb and the
logical subject; ’There was a party in progress’.
FW foreign word
IN preposition or subordinating conjunction
JJ adjective: Hyphenated compounds that are used as modifiers; happy-go-lucky
JJR adjective comparative: Adjectives with the comparative ending ’er’ and a comparative
meaning. Sometimes ’more’ and ’less’.
JJS adjective superlative: Adjectives with the superlative ending ’est’ (and ’worst’). Sometimes
’most’ and ’least’.
LS list item marker: Numbers and letters used as identifiers of items in a list.
MD modal: All verbs that don’t take an ’s’ ending in the third person singular present: ’can’,
’could’, ’dare’, ’may’, ’might’, ’must’, ’ought’, ’shall’, ’should’, ’will’, ’would’.
NN noun singular or mass
NNP proper noun singular: All words in names usually are capitalized but titles might not be.
NNPS proper noun plural: All words in names usually are capitalized but titles might not be.
NNS noun plural
NP proper noun singular
NPS proper noun plural
PDT predeterminer: Determiner like elements preceding an article or possessive pronoun such as
’all/PDT his marbles’, ’quite/PDT a mess’.
POS possessive ending: Nouns ending in ”s’ or ”’.
PP personal pronoun
PRP possessive pronoun,such as ’my’, ’your’, ’his’, ’his’, ’its’, ’one’s’, ’our’, and ’their’.
RB adverb: most words ending in ’ly’. Also ’quite’, ’too’, ’very’, ’enough’, ’indeed’, ’not’, ’n’t’,
and ’never’.
RBR adverb comparative: adverbs ending with ’er’ with a comparative meaning.
RBS adverb superlative
RP particle: Mostly monosyllabic words that also double as directional adverbs.
STAART start state marker (used internally)
SYM symbol: technical symbols or expressions that aren’t English words.
TO literal ”to”
UH interjection: Such as ’my’, ’oh’, ’please’, ’uh’, ’well’, ’yes’.
VBD verb past tense: includes conditional form of the verb ’to be’; ’If I were/VBD rich...’.
VBG verb gerund or present participle
VBN verb past participle
VBP verb 3rd person singular present
VB verb base form: subsumes imperatives, initiatives and subjunctives.
VBZ verb 3rd person singular present
WDT ’wh’ determiner
WPH possessive ’wh’ pronoun: includes ’whose’
WP ’wh’ pronoun: includes ’what’, ’who’, and ’whom’.
WRB ’wh’ adverb: includes ’how’, ’where’, ’why’. Includes ’when’ when used in a temporal sense.
2.4.3 Gazetteers
The GATE framework makes extensive use of dictionaries, or gazetteers to tag words
with higher level information than simple grammatical units. The Bio-YODIE plugin
for GATE was used to find biomedical references in the clinic letters. Bio-YODIE
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Table 2.2: UMLS representation of a subset of epilepsy terms. The CUI (Concept
Unique Identifier) is a code assigned to biomedical concepts. The source column
represents the original coding system the term exists in, and the SCUI column is the
source code used within a particular system. For example ”Epilepsy” exists in both
ICD10 and READ coding systems, but map to the same CUI in UMLS despite having
unrelated SCUIs.
CUI Term SCUI Source
C0014544 Epilepsy G40 ICD10
C0014544 Epilepsy F25 READV2
C0014549 Tonic-Clonic Epilepsy F2510 READV2
C0014558 Other Epilepsy G40.8 ICD10
C0477371 Progressive myoclonic epilepsy F1321 READV2
C1827284 Intractable occipital lobe epilepsy 425054007 SNOMEDCT US
C1827878 Refractory localization-related epilepsy 422724001 SNOMEDCT US
C1827284 Refractory occipital lobe epilepsy 425054007 SNOMEDCT US
C1827691 Intractable frontal lobe epilepsy 425237009 SNOMEDCT US
C1827974 Refractory parietal lobe epilepsy 425349008 SNOMEDCT US
C1827974 Intractable parietal lobe epilepsy 425349008 SNOMEDCT US
which the UMLS (Unified Medical Language System) - 600 healthcare coding systems
such as ICD-10, READ and SNOMED CT combined into a unified coding system -
to form the basis of a gazetteer that maps any text found in a document to a UMLS
code.
The Bio-YODIE plugin scans all text in a document, and where it finds a match to
a term the text is tagged and assigned a CUI code (mapping shown in Table 2.2).
Custom gazetteers were also defined to incorporate information such as certainty
levels (”likely”,”probably”,”doubtful”....) or hypothetical modifiers (”to see”,”we
may”,”to determine”...) to help define the context to which UMLS mappings are
found.
2.4.4 Context Algorithm
The Context algorithm developed by Harkema et al [232] was used to determine if
terms are negated e.g. ”Mary does not have epilepsy” or if they are attributed to
someone other than the patient, such as a family member. The Context algorithm also
tags symptoms in terms of their temporal context such as historical or hypothetical.
The GATE plugin implements the Context algorithm through multiple gazetteers
that contain trigger words for various contexts, such as pre and post negation
terms, temporal triggers and triggers for family members. These triggers are related
to biomedical terms found in the text by writing rules in the JAPE scripting
language.
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2.4.5 JAPE rules
Implementing POS tagging and gazetteer mapping provides information ranging from
simple grammatical units to meaningful biomedical concepts and contextual terms.
The JAPE scripting language was used to weave together sequences of tagged terms
to form rules. After tagging, a phrase containing prescription information might look
like:
He is taking Lamotrigine 250 mg twice a day
PRP VBZ VBG NNP CD NN RB DT NN
person current DRUG number unit word-num temporal
patient C0064636 quantity quantity calendar
where each word has been assigned multiple tags by mapping to various user defined
gazetteers. Further context can be built by combining words, for example ”250” and
”mg” is a unit of measurement that could be annotated and used for downstream
processes.
He is taking Lamotrigine 250 mg twice a day
PRP VBZ VBG NNP CD NN RB DT NN
person current DRUG number unit word-num temporal
patient C0064636 quantity quantity calendar︸ ︷︷ ︸
Measurement
︸ ︷︷ ︸
Frequency
A JAPE script that could create this rule is shown would be:
In general, larger rules are built by layering smaller rules. For example, if Measurement
and Frequency have previously been defined by JAPE rules, those annotations can
be used in further JAPE rules.
He is taking Lamotrigine 250 mg twice a day
PRP VBZ VBG NNP CD NN RB DT NN
person current DRUG number unit word-num temporal
patient C0064636 quantity quantity calendar︸ ︷︷ ︸
Measurement
︸ ︷︷ ︸
Frequency︸ ︷︷ ︸
Prescription
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1 # this is a comment that is ignored when running the script
2
3 Phase: Measurement
4 # phase to be run in larger pipeline
5 Input: Number Unit
6 # Input type i.e. read in gazetteers for Number and Unit
7 Options: control=appelt
8
9 /*
10 * Find measurements from combining numbers and units
11 * i.e. 250 mg
12 */
13 Rule: find_measurement
14 # when Number and Unit appear consecutively
15 (
16 ({ Number }):num
17 ({Unit}):unit
18 ):match
19 -->
20 # create new annotation called "Measurement" containing the following information
21 :match.Measurement = { Rule = findMeasurement ,
22 Quantity = :num.String ,
23 Unit = :unit.String # Unit i.e. mg
24 }
Figure 2.5: A JAPE script to annotate measurements. Gazetteers are used as input
to the JAPE script, and depending on the order of words tagged by a gazetteer, a rule
can be triggered and create a ”Measurement” annotation.
1 # this is a comment that is ignored when running the script
2
3 Phase: Prescription
4 # phase to be run in larger pipeline
5 Input: Drug Measurment Frequency
6 # Input type i.e. read in gazetteers for Number and Unit
7 Options: control=appelt
8 /*
9 * Find prescriptions from combining numbers and units
10 * i.e. Lamotrigine 250 mg once per day
11 */
12 Rule: find_prescription 1
13 # combination of annotations for prescription
14 (
15 ({Drug}):drug
16 ({ Measurement }):measure
17 # Frequency is optional - denoted by ?
18 ({ Frequency }?):frequency
19 ):match
20 -->
21 # create new annotation called "Prescription" containing the following information
22 :match.Measurement = { Rule = findPrescription , # rule reference
23 Drug = :drug.Name # Drug name
24 Quantity = :measure.Quantity ,
25 Unit = :measure.unit ,
26 Num_Dose = :frequency.num ,
27 Frequency.period = :frequency.calendar
28 }
Figure 2.6: A JAPE script to annotate prescriptions. Previous annotations writtin in
JAPE rules can be directly used as input to build larger rules.
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The are additional operators than can be used such as the ? operator used in figure
2.6.
Table 2.3: List of JAPE operators than can be applied to any annotation
Operator Description
? optional
* zero or more
+ one of more
! any other than specified annotation
[x] exact length of annotation
[x,y] range length of annotation
| OR
, AND
== exact match
!= not equal to
==∼ partial match via regex
!=∼ not equal to regex
contains annotation contains specified annotations
!contains annotation doesn’t contain other specified anotations
within annotation exists with specified annotation
!within annotation does not exist within specifided annotation
2.5 Predicting functional impact of Single
Nucleotide Polymorphisms
2.5.1 Pipeline to determine the effect of SNPs
The SNP pipeline aims to determine the effect of SNPs and their impact on
presentation of a disease phenotype, in this case if the SNP is implicated in disease
or not. This largely revolves around collecting and processing data that builds a
final dataset of protein features for any given SNP, often called annotation. Machine
learning methods are applied on the final datasets to predict whether a SNP has the
potential to be pathogenic and candidates for disease causality.
2.5.2 Data sources
The prediction of functional impact of SNPs largely relied on obtaining biological
annotations from publicly available reference data. The main type of data required
are meta-data for a given SNP, such as the protein affected, the region that the SNP
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is expressed and the conservation score at the position of the SNP. The following list
of databases were used to source SNP features:
 University of California Santa Cruz (UCSC) Genome Browser -
provides protein level reference data from chromosomal SNP co-ordinates.
Datasets used were snp144, kgXref and knownGene. - https://genome.ucsc.
edu/.
 Uniprot - Stores various reference data on proteins, in particular the FASTA
sequence files - http://www.uniprot.org
 Humvar - a set of SNPs used to train the machine learning algorithms in the
pipeline - http://www.uniprot.org/docs/humsavar
2.5.3 Obtaining Protein Features
Figure 2.7 describes the various steps in the pipeline to collect the necessary data to
make a prediction for a SNP. Given a list of SNPs in chromosomal format each SNP
goes through the following pipeline architecture. At each point various cleaning and
data wrangling are performed and fed into downstream programs, each accumulating
protein features that are useful with regards to protein annotation, but also important
for predicting the effects of SNP in terms of disease.
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Input SNP
VEP Uniprot
R script PSIPREDCombine
R script
Annotate SNP Amino acid sequence
Secondary structureSelect features
Machine Learning
Figure 2.7: A flow chart of the pipeline. Purple nodes are databases and green nodes
are processes. The user can specify SNPs in chromosomal format as input to the
pipeline. The end result is the SNP data with protein level data that includes indexes
generated by downstream programs and database annotation.
SNP format
SNPs are expressed as chromosomal co-ordinates when called from NGS pipelines.
However many protein annotation, prediction and filtering programs require SNPs to
be expressed in protein co-ordinates, with various meta-data also included such as
gene name and protein ID. The first step of the pipeline is to make this conversion.
There are various methods to do this however the conversion was performed on many
thousands of SNPs without human interaction. The University of California Santa
Cruz (UCSC) genome browser hosts an online database that can be queried with
MYSQL scripts. With the chromosome number, position, wild type and mutation
nucleotides it was possible to search for the protein co-ordinates and gene information
using the code in figure 2.8.
An important piece of data for this pipeline are the raw amino acid sequences in the
form of FASTA files. The protein IDs in the previous script can be used in conjunction
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1 mysql --user=genome --host=genome -mysql.cse.ucsc.edu -A hg19 -D hg19 -e
2 "select distinct substr(S1.chrom ,4,2) as chrom ,
3 S1.chromStart ,
4 S1.chromStart ,
5 substr(S1.observed ,1,1) as wild ,substr(S1.observed ,3,1) as snp
6 X.geneSymbol ,X.spID ,S1.class ,
7 S1.bitfields ,S1.name
8 from snp144 as S1, knownGene as K, kgXref as X
9 where X.geneSymbol = '"$1"'
10 and K.chrom = S1.chrom and X.kgID = K.name
11 and S1.chromStart >= K.cdsStart
12 and S1.chromStart < K.cdsEnd and S1.class = '"$2" ';"
Figure 2.8: MYSQL script to retrieve protein descriptors from chromosomal position.
1 // #!/bin/bash
2
3 // download fasta seqs given file of uniprot ids
4
5 // file name is first parameter of command
6 file=$1
7
8 // protein IDs are contained in first column
9 ids=($(cat ${file} | awk '{print $1}'))
10
11 // loop through IDs and get fasta using uniprot API
12 for i in "${!ids[@]}" ; do
13 curl -sS "http ://www.uniprot.org/uniprot/"${uniqids[i]}".fasta"
14 >> $file.out.fasta ;
15 done
Figure 2.9: FASTA file retrieval using the Uniprot API. SNPs are substituted into
each sequence and passed onto downstream programs
with the Uniprot web interface to retrieve FASTA files. These can essentially be
accessed via a unique uniprot URL i.e. http://www.uniprot.org/uniprot/P23415.
fasta. These can either be typed into an internet browser or programmatically
retrieved using webscraping tools such as GNU cURL. Figure 2.9 shows how cURL
can be implemented via a bash script to download fasta sequences from the Uniprot
API.
This again allows automation and no human interaction - providing that the protein
IDs are passed on from previous programs. Using the Uniprot web interface also does
not require storage of FASTA files on a local computer, where each FASTA file is
downloaded in a few seconds. Later on in the pipeline a GNU AWK program is used
to programmatically substitute the mutant SNP in place of the wild type. This is
particularly useful for structural modelling where higher dimensional structures are
built from raw amino acid sequences.
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Protein annotation with Variant Effect Predictor
Variant Effect Predictor (VEP) https://www.ensembl.org/Tools/VEP was used to
annotate SNPs. VEP accepts SNPs in chromosomal format, bed format or dbSNP
rsID and can scan 35 publicly available datasets ranging from SNPs reported in
national GWAS studies, functional prediction scores, binding site locations and
regional sub-sequences within proteins. The following features (dataset name) are
collected using VEP and used for functional prediction in the pipeline:
 Conserved genomic elements (phastCons,siPhy,GERP)
 Binding sites
 Cytogenic band
 Variants disrupting microRNAs
 Variants disrupting binding sites
 Reported structural variants
 SNP predictions from existing tools
 1000 genomes frequency annotations
 ExAC frequency annotations
 gnomAD frequency annotations
The last 3 items are used to filter SNPs - frequency based filtering from 1000 Genomes
and ExAC allow common SNPs, rare SNPs and unseen SNPs to be separated,
where SNPs found in DbSNP contain any published links to clinically observed
pathogenicty.
Existing prediction programs
The scores of existing programs for a given SNP is used for both comparison against
the algorithm developed as part of this thesis, but also used as input features to
the classification process. Many of these programs provide bespoke protein features
used with each algorithm and vary between higher sensitivity and specificity and so
are useful to include as input features. The Variant Effect Predictor algorithm was
used to annotate SNPs against the dbNSFP https://sites.google.com/site/jp
opgen/dbNSFP and table 2.4 lists all of the existing SNP prediction software used as
features in the SNP pipeline.
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Table 2.4: List of popular SNP prediction software
Name Website
Polyphen2 http://genetics.bwh.harvard.edu/pph2
SIFT http://sift.jcvi.org/
FATHMM http://fathmm.biocompute.org.uk/
Provean http://provean.jcvi.org/index.php
MetaSNP http://snps.biofold.org/meta-snp/
LRT http://www.genetics.wustl.edu/jflab/index.html
MutationTaster http://www.mutationtaster.org/
MutationAssessor http://www.mutationtaster.org/
FATHMM http://fathmm.biocompute.org.uk/
MetaSVM http://wglab.org/research
MetaLR http://wglab.org/research
VEST - http://karchinlab.org/apps/appVest.html
CADD http://cadd.gs.washington.edu/
GERP++ http://mendel.stanford.edu/SidowLab/downloads/gerp/
DANN https://cbcl.ics.uci.edu/public_data/DANN/
fitCons http://compgen.cshl.edu/fitCons/
Phylop http://ccg.vital-it.ch/mga/hg19/phylop/phylop.html
SiPhy http://portals.broadinstitute.org/genome_bio/siphy/index.html
REVEL https://sites.google.com/site/revelgenomics/
Predicting secondary structure using PSIPRED
There are many secondary structure prediction servers that accurately predict which
amino acids in a sequence belong to certain types of secondary structural folds, namely
beta sheets, alpha coils and helices. The Critical Assessment of protein Structure
Prediction (CASP) [233] is a community driven initiative to enhance knowledge of
structural prediction. Held bi-annually from 1994, many open source applications
have been developed and tested for comparison, where the PSIPRED structural
prediction server [225] has regularly featured as one of the most accurate programs of
predicting secondary structure from amino acid sequences. PSIPRED is used in the
pipeline to predict the difference in secondary structure change between wild type
amino acid sequences and sequences with a SNP substituted in. Due to the relatively
long processing time (between 15-30 minutes per sequence), the part of the pipeline
where PSIPRED is run is hosted on the HPC Wales cluster. This reduces running
time to a few minutes per sequence, where sequences can also be run in parallel across
the many compute nodes within the HPC Wales cluster.
PSIPRED uses PSIBLAST alignments of proteins with know secondary structure
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Figure 2.10: PSIPRED algorithm: multiple sequence alignments of known protein
structures are built up from an input sequence. Position specific scoring matrix is
used to train a neural network to predict the secondary structure of novel proteins.
and then trained with a two-step artificial neural network [234]. For a given protein
sequence, PSIBLAST efficiently finds similar sequences via string matching and aligns
all the sequences where a scoring matrix is calculated to determine the similarity
of each position of each sequence. These position specific scores are used as input
to the two stage neural network, along with the ground truth of known secondary
structure. The most likely predicted secondary structure fold at each point along the
multiple sequence alignment is then assigned by the output of the neural network. It
is important to note that the predicted secondary structure at each amino acid in
the sequence is determined by which proteins are assigned to the multiple sequence
alignment by PSIBLAST. Because PSIBLAST searches on sub-sequences of proteins
before building up the alignment, SNPs have the potential to source a small set of
proteins not found in an alignment built from the wild type. This small set of proteins
can make a difference (albeit small) in the final prediction.
PSIPRED requires amino acid protein sequences in FASTA file format. To compare
the output of wild type protein sequences and sequences containing a SNP, the AWK
script in figure 2.12 was written to automatically substitute in the SNP to the wild
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Figure 2.11: PSIPRED output comparing the predicted secondary structure of a
wild type GLRA2 sequence with the same sequence having a clinically benign SNP
at position 355 of the sequence. The secondary structure prediction is normalised
between coil, helix and sheet, where the absolute difference between the wild type and
SNP are calculated in the three rightmost columns. The red line indicates the SNP,
where other lines are neighbouring amino acids and predictions. It can be seen that
while the predicted secondary structure doesn’t change, the amino acids closer to the
SNP have a larger change in the raw score than those further out from the SNP.
1 BEGIN { FS="_" }
2 /^>/ {
3 id=$1;p=$2; wild=$3;subs=$4; c=$NF; next
4 }
5 {
6 s=1
7 e=length($0)
8 print id"_"p"_"wild"_"subs" >\n"substr($0,s,p-1) c substr($0,p+1,e)
9 }
Figure 2.12: An AWK script to substitute a SNP in place of a wild type amino acid
within a FASTA sequence. The script takes in 4 parameters that can be read from a
text file in the form of 4 columns (protein ID, position of the SNP, amino acid of the
wild type, P, and the amino acid of the SNP. These are then used tho subsitute the
wild type in the position of the SNP with the SNP of the amino acid whilst preserving
the original protein flanking either side of the SNP)
type sequence. The fasta header is also modified in this step to contain SNP position,
wild type and reference for easy comparison between the wild type and SNP secondary
structure output files.
2.5.4 Predicting SNP Impact Using Machine Learning
The R programming language was used to train various machine learning models
to classify a SNP as either pathogenic or benign using protein features. A ground
truth dataset was established by obtaining protein from the Clinvar ftp://ftp.ncbi
.nlm.nih.gov/pub/clinvar/ database for epilepsy SNPs and the Humvar https:
//www.uniprot.org/docs/humsavar database for disease non-specific datasets that
contain information on a SNP known to cause disease or is benign. These datasets
were then annotated using the methods described previously..
The following machine learning algorithms shown in Table 2.5 were used and tested
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on both datasets:
Table 2.5: Machine learning algorithms used in SNP prediction in chapter 5
Classifier R package CRAN link
Random Forest randomForest https://cran.r-project.org/web/packages/randomForest/randomForest.pdf
C45 Decision Tree rpart https://cran.r-project.org/web/packages/rpart/rpart.pdf
Support Vector Machine e1071 https://cran.r-project.org/web/packages/e1071/index.html
Logistic Regression base r NA
Artifical Neural Networks nnet https://cran.r-project.org/web/packages/nnet/nnet.pdf
Na¨ıve Bayes naivebayes https://cran.r-project.org/web/packages/naive-bayes
2.5.5 Training and testing
The machine learning process was split into 2 phases: training and testing. The
training phase used 75% of the humvar data to train each classifier with the remaining
25% used as an unseen test set to predict pathogenicty status. A sampling method
called cross validation was used where the 75-25% split is selected randomly, in
this case 5 times so that 5 unique models are generated on 5 unique training-test
sets.
2.5.6 Receiver Operator Curves
Receiver Operator Curves (ROC) are used as a means to validate the accuracy of
each classifier. Figure 5.11 shows a ROC curve for multiple classifiers:
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Figure 2.13: ROC curve comparing the classifier from this thesis (black) to scores from
other classifiers when predicting disease/benign status on the humvar test set
ROC curves are useful in that each point in the curve plots the sensitivity vs specificity
of an algorithm at discrete scoring thresholds. The result is a curve in which the ideal
sensitivity vs specificity point can be read off ( i.e. 95% sensitivity or 95% specificty)
and reproduced for unseen samples with the associated threshold value. Two other
interesting properties of ROC curves are the Area Under the Curve measure - a
measure of accuracy of the classifier, and the two diagonal lines indicating the line of
chance (bottom left to top right) and the line of accuracy (bottom right to top left).
Classifiers can easily be compared to the line of chance to see how better it performs
than random choice, and the section of the ROC curve that intersects with the line
of accuracy is the point denoting the highest accuracy achievable by the algorithm.
A ROC curve approaching the top left of the graph indicates a perfect score.
2.6 Chapter Summary
 The SAIL Databank was used to carry out retrospective longitudinal studies in
people with epilepsy
 SQL queries were used extensively to link datasets together within the SAIL
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databank and extract data in a format ready for statistical analysis
 The R programming was used to carry out statistical analysis
 240 epilepsy clinic letters from Morriston hospital were used to conduct an NLP
study for extracting epilepsy specific information from clinic letters
 The open source GATE application was used as a framework for NLP
development. The main concepts behind algorithm development was the
inclusion of dictionaries used for tagging terms of interest, such as UMLS
codes and writing JAPE scripts that declare rule sets to produce annotations
based on tagged terms. Standard NLP applications are also used as part of
GATE such as tokenization, POS tagging and chunking
 An epilepsy clinician reviewed 200 test letters and these were compared against
the algorithm
 Two SNP datasets were used to test a bespoke SNP classifier for
pathogenic/benign status. The Humvar data contains over 70,000 disease
non-specific SNPs that were used to trian the classifier, and the Clinvar dataset
was used to obtain epilepsy SNPs
 Various open source bioinformatics programs were used for SNP annotation data.
The Varaint Effect Predictor was used to annotate SNPs with conservation and
frequency data as well as existing SNP prediction scores. PSIPRED was used
to calculated the difference in secondary structure prediction between wild type
sequences and mutation sequences
 Machine learning was used to test various classifiers, of which this was
programmed in R. These were compared against existing scoring software
obtained from dbNSFP annotations from VEP
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Chapter 3
Results: Analysing Routinely
Collected Healthcare Records for
Epilepsy Research
The first of the three results chapters show how epilepsy and its impact on health
and social factors can be studied using routinely- collected health records in the SAIL
databank. Using Welsh GP records an algorithm was created to determine people
with robustly-confirmed epilepsy. By comparing GP records in SAIL to patient details
in the paediatric neurology department in Morriston Hospital , the algorithm is able
to categorise 85% of patients as having epilepsy while excluding nearly all cases where
a lack of clinical evidence confirms the absence of an epilepsy diagnosis . Antiepileptic
drugs (AEDs) are studied in terms of how GPs prescribing habits have changed over
time, as well adverse effects of AEDs including weight gain and cognitive decline in
children born to mothers prescribed AEDs during pregnancy. The relationship of
social deprivation and epilepsy is explored where people diagnosed with epilepsy tend
to come from areas of higher social deprivation. This chapter presents the strengths
and limitations of studying the impact of epilepsy using routinely-collected data.
Each study formed the basis of a published paper, in which footnotes are used to
account for any specific work undertaken by co-authors.
3.1 Prevalence, Incidence and the Social
Deprivation Profile of Epilepsy in Wales
The aim of this retrospective study was to determine if prevalence and incidence of
epilepsy is due to social drift or social causation by using GP records and demographic
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data between 2004-2010. The first objective was to identify people with epilepsy
within SAIL. The GP dataset in SAIL (see 3.1) contains READ codes pertaining an
interaction with a GP that was recorded in a patient’s GP record. Various codes can
be entered such as diagnoses, prescriptions, symptoms, laboratory tests and medical
advice. This dataset was used to query codes for both diagnosis codes for epilepsy as
well as anti epileptic drug prescriptions (AED). In discussion with clinicians within
the Swansea Neurology Research Group, an appropriate method discussed to extract
epilepsy cases was to use a combination of repeat AED and epilepsy diagnosis codes.
This would pick people with unresolved epilepsy while also excluding people with
AED prescriptions exclusively for mental health disorders and pain management. The
use of a repeat AED prescription was also included to exclude uses of diagnosis codes
used as a way to recorded suspected diagnoses that require follow up.
Table 3.1: SAILWGPV.EVENT ALF E is a table in the SAIL Databank that stores
GP patient records.
Field name Description
PRAC CD E Encrypted General Practice code
ALF E Anonymous linking field representing an encrypted NHS number
WOB Week of Birth - defaults to Monday of week of birth
GDNR CD Gender code 1=male, 2=female, 9=unknown
LOCAL NUM Local number identifier - a unique patient number
EVENT CD VRS Determines code type such as READ v2, SNOMED etc
EVENT CD Recorded clinical information during the event
EVENT VAL The value associated with the recorded event
EVENT DT Date of the event
EPISODE Denotes if event is due to ongoing care or first recording of diagnosis
SEQUENCE The number of records for a specific event
The EVENT CD column was queried with a list of READ codes that defined AED
prescriptions and epilepsy diagnosis, and the WOB column was used to define week
of birth for splitting patients into age bands, particularly between adults and children
as a child’s social deprivation is unlikely to be effected by an epilepsy diagnosis.
3.1.1 Defining Epilepsy in the SAIL Databank
The Quality of Outcomes Framework (QOF) https://www.nice.org.uk/standards-
and-indicators/qofindicators aims to encourage GPs to keep patient records as
complete as possible. By providing a paid incentive to use certain READ codes
to record patient details, finding patients with diseases such as epilepsy should be
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possible by querying GP records. The usage of READ codes used to record details of
patients with epilepsy was explored to determine if it is possible to select people with
known epilepsy.
Figure 3.1: Table 1 of 2 defining QOF codes for recording information on epilepsy in
patient records. Table taken from https://www.epilepsy.org.uk/sites/epilepsy/files
/primary-care-resource/A18-Tool.pdf
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Figure 3.2: Table 2 of 2 defining QOF codes for recording information on epilepsy in
patient records.Table taken from https://www.epilepsy.org.uk/sites/epilepsy/files/p
rimary-care-resource/A18-Tool.pdf
Using the READ codes tables in figures 3.1 and 3.2 an algorithm based on the presence
of an epilepsy diagnosis code and a repeat AED prescription was used to determine if
a person is known to be living with epilepsy on a given day by querying their GP
records. Figure 3.3 depicts a timeline of how a combination of AED prescriptions and
epilepsy diagnosis code entered into a GP record and are used to identify epilepsy,
and figure 3.4 provides SQL code to implement the process.
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Figure 3.3: Visual explanation of the algorithm used to capture epilepsy diagnoses. All
AED prescriptions are first found using GP records (D1), in which AED prescriptions
pairs within 6 months after the initial prescription are classed as a repeat AED
prescription (D2). Epilepsy diagnosis codes appearing in GP records 12 months either
side of the first prescription of each of the AED pairs are queried, and where there is
a match a person is classified by the algorithm as having an epilepsy diagnosis at the
time of the first AED in the pair.
The SQL query in figure 3.4 was looped through the years 2004-2010, where for
those who had a new diagnosis in a given year, all previous years were checked for
absence of a diagnosis (incident cases). Those with both new and known epilepsy
from previous years that satisfy the extraction criteria in later years contribute to
the prevalent population of people with a diagnosis of epilepsy.
The SQL query in 3.4 was also used to determine prevalence and incidence of epilepsy,
where prevalence is defined as the number of people with known epilepsy divided by
the number of people in the population, and incidence is defined as the number of new
cases of epilepsy in a given year divided by the number of people in the population.
Annual prevalence between 2004 and 2010 was calculated by identifying the number
of people with known epilepsy living in Wales on the 1st of January of a given year
and dividing by the total number of people living in Wales on the same day. Annual
incidence of epilepsy was also calculated by identifying all newly diagnosed patients
in a given year, divided by the total number of persons registered as living in Wales
in the same year.
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1 -- first AED D1
2 SELECT DISTINCT D1.ALF_E , MIN(D1.EVENT_DT) AS FIRST_AED FROM
3 (SELECT DISTINCT ALF_E , EVENT_DT FROM SAILWLGPV.EVENT_ALF
4 WHERE EVENT_CD LIKE 'dn\%'
5 OR EVENT_CD LIKE 'do\%'
6 -- READ codes beginning with dn/do are AEDs
7 AND EVENT_DT BETWEEN '2000-01-01' AND '2000-31-12'
8 -- find first AED prescription in a given year
9 ) \textbf{D1}
10
11 INNER JOIN
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13 -- repeat AED D2
14 (SELECT DISTINCT ALF_E , EVENT_DT FROM SAILWLGPV.EVENT_ALF
15 WHERE EVENT_CD LIKE 'dn\%'
16 OR EVENT_CD LIKE 'do\%'
17 AND EVENT_DT BETWEEN '2000-01-01' AND '2001-06-01'
18 -- find potential repeat AEDs up to 6 months after first AED
19 ) \textbf{D2}
20 ON D1.ALF_E = D2.ALF_E
21 -- match ALF_E in tables D1 and D2
22 AND D2.EVENT_DT BETWEEN D1.EVENT_DT AND D1.EVENT_DT + 6 MONTHS
23 -- search up to 6 months after first AED
24
25 INNER JOIN
26 -- epilepsy diagnosis code
27 (SELECT DISTINCT ALF_E , EVENT_DT FROM SAILWLGPV.EVENT_ALF
28 WHERE EVENT_CD LIKE 'F25\%'
29 -- READ codes beginning with F25 is an epilepsy diagnosis
30 AND EVENT_DT BETWEEN '1999-06-01' AND '2001-06-01'
31 -- allow 6 months before and after possible repeat
32 -- AED windows (i.e. suspected epilepsy)
33 ) \textbf{EP}
34 ON D1.ALF_E = EP.ALF_E # match ALF_E in tables D1 and EP
35 AND EP.EVENT_DT BETWEEN D1.EVENT_DT - 6 MONTHS AND D1.EVENT_DT + 6 MONTHS
36 -- search up to 6 months before/after first AED
37 }
Figure 3.4: An SQL query to extract epilepsy cases using a combination od diagnosis
and AED READ codes. In this example, the first known confirmation that a person
has epilepsy in 2000 is given by the first AED prescription in their GP record, while
also having a repeat AED within 6 months as well as an epilepsy diagnosis up to 6
months either side of the first identified repeat prescription window
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3.1.2 Social deprivation
The Welsh Demographic Service dataset was used to obtain social deprivation, which
contains WIMD score that are assigned to 1896 geographical Lower Super-Output
Areas (LSOAs) in Wales, each with around 1,500 people. Each LSOA is ranked from
most deprived to least deprived according to its corresponding WIMD score and
then grouped into deciles, with decile 1 being the most deprived and decile 10 the
least deprived. For this specific study, WIMD 2011 deciles were used to measure
an individuals’ social deprivation where for each person in the study it was possible
to query their demographic records to determine what LSOA code they live within
on any day of the year, in which the 1st of January was chosen for each study year.
Tables 3.2 and 3.3 were used to obtain a person’s address and link it to their WIMD
score by linking the LSOA CD between both tables:
Table 3.2: The SAILWDSDV.AR PERS table in the SAIL Databank holds individuals
address, provided as the address when registering with a GP. Each address is
also assigned to a Lower Super Output Area (LSOA) which is a geographical area
comprising of around 1500 individuals.
Field name Description
PERS ID E Encrypted Person Identifier
RALF E Encrypted Residential address sourced from address given
at GP registration
LSOA CD Lower Super Output Area code - approx 1500 person per
area
FROM DT Day resident started living at address
TO DT Day resident stopped living at address
Table 3.3: The SAILREFRV.WIMD2008 OVERALL INDEX table in the SAIL
Databank contains a link between an LSOA code and various Welsh Index of Multiple
Deprivation measures.
Field name Description
LSOA CD Lower Super Output Area code ∼1500 people
LSOA DESC Name of geographic area
SCORE Raw score comprising of 8 indicators
RANK LSOA rank based on raw score. 1=most deprived
DECILE Decile LSOA belongs to. 1=most deprived
QUNTILE Quintile LSOA belongs to. 1=most deprived
For each ALF E in the study it was possible to determine the WIMD Decile at the
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1 select distinct arp.alf_e , w.wimd2008_QUINTILE
2 -- Get ALF_E from Welsh Demographic Service dataset
3 from SAILWDSDV.AR_PERS
4 inner join SAILWDSDV.AR._PERS arp
5 on arp.pers_id_e = argp.pers_i d_e
6 -- Get address data
7 join SAILWDSDV.AR_PERS_add AR
8 on arp.pers_id_e = ar.pers_id_e
9 -- Get WIMD quintile at 1st January 2004 i.e. census date
10 join sailx031v. LSOA_refr w
11 on w.lsoa_cd = ar. lsoa_cd
12 and '2004-01-01' between AR.from_dt and AR.to_dt
13 -- ensure ALF_e is in contibuting SAIL gp practices
14 join SAILWLGPV.PATIENT_ALF_CLEANS ED GP
15 on ARGP.prac_cd_e = GP.prac_cd_E
16 }
Figure 3.5: An SQL query to link an ALF E to their address in the Welsh Demographic
dataset in SAIL, and how to linke the WIMD quintile to the address on a given day
i.e. 1st January 2004
start of each year on the study window using the SQL query in Figure 3.5 and was
used to compare the prevalence and incidence epilepsy across WIMD quintiles:
Sex and age were included as covariates where age groups were categorized as 0-5; 6-12;
13-21; 22-45; 25-45; 46-64, and 65 years or over in relation to their age in the study
year. Figure 3.6 shows a summary flowchart of how the cohort was selected and Table
3.4 compares the study population in 2010 with that of the Welsh population.
Figure 3.6: Flow chart of cohort selection. GP records were used to identify
people with epilepsy (and therefore those that did not have epilepsy). The Welsh
Demographic Service dataset was then used to sample age bands, sex and WIMD
deciles on the first of January in each study year. For every unique combination of
covariates, incidence and prevalence was calculated.
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Table 3.4: Study population characteristics in 2010 as compared to the Welsh
population (measured by the 2011 WIMD data). Table taken from [4]
Study population in
2010
Wales
population
Total Number 1,178,558 3,169,594
Sex Male 588,476 (49.9%) 1,582,144 (49.9%)
Female 590,082 (50.1%) 1,587,446 (50.1%)
Age (years) 0-5 73,716 (6.3%) 206,148 (6.5%)
06-12 86,809 (7.4%) 235,681 (7.4%)
13-21 142,333 (12.1%) 367,981 (11.6%)
22-45 374,090 (31.7%) 999,254 (31.5%)
46-64 290,612 (24.7%) 793,247 (25.0%)
>64 210,998 (17.9%) 567,282 (17.9%)
Deprivation
(WIMD decile)
1 109,703 (9.3%) 318,275 (10.0%)
2 122,291 (10.4%) 315,689 (10.0%)
3 91,478 (7.8%) 315,983 (10.0%)
4 124,033 (10.5%) 317,000 (10.0%)
5 121,894 (10.3%) 313,995 (9.9%)
6 127,573 (10.8%) 325,662 (10.3%)
7 101,077 (8.6%) 309,675 (9.8%)
8 113,994 (9.7%) 324,457 (10.2%)
9 124,752 (10.6%) 307,093 (9.7%)
10 141,763 (12.0%) 321,954 (10.2%)
Over the study period, the mean epilepsy prevalence was 0.77% (95% CI 0.76 to
0.79%) and there were 2,390 incident cases of epilepsy, giving a mean incidence
rate of 29.5/100,000 per year (95% CI 28.3 to 30.7). A breakdown of prevalence
and incidence for each year is given in Table 3.5. Given that the sensitivity
of the epilepsy algorithm in the validation study was 84% and the prevalence
of epilepsy in the UK in 2011 was reported to be 0.97% by the Joint Epilepsy
Council (http://www.epilepsyscotland.org.uk/pdf/Joint_Epilepsy_Council
_Prevalence_and_Incidence_September_11_%283%29.pdf), the mean prevalence
of 0.77% seems reasonable.
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Table 3.5: Breakdown of epilepsy prevalence and epilepsy incidence by WIMD decile. Table taken from [4]
Deprivation
(WIMD decile)
Mean epilepsy prevalence 2004-2010 Epilepsy incidence 2004-2010
Number of cases Mean
population
Mean
prevalence
(%)
Number of
cases
Patient years
at risk
Incidence/100,000/year
1 1211 107,464 1.13 304 752,250 40.41
2 1164 119,990 0.97 305 839,931 36.31
3 845 89,671 0.94 228 627,696 36.32
4 969 121,421 0.8 270 849,944 31.77
5 989 119,345 0.83 257 835,416 30.76
6 911 125,983 0.72 247 881,878 28.01
7 712 99,640 0.71 186 697,479 26.67
8 742 111,456 0.67 197 780,195 25.25
9 734 122,153 0.6 208 855,069 24.33
10 684 140,053 0.49 188 980,374 19.18
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Figure 3.7 shows that the mean prevalence of epilepsy is double in most deprived
(1.13%) compared to least deprived (0.49%), and the mean incidence of epilepsy is
also double in most deprived (40.41 per 100,000) compared to least deprived (19.18
per 100,000), identifying a strong trend that epilepsy is associated with increased
social deprivation.
Figure 3.7: Plots of (A) epilepsy prevalence and (B) epilepsy incidence by WIMD
(deprivation) decile. Error bars indicate 95% confidence intervals. Figure taken from
[4]
The mean prevalence and incidence was calculated for each WIMD decile
together with confidence intervals using binomial and Poisson models,
respectively. The LSOA WIMD decile data for prevalence and incidence
of epilepsy aligned with a 2001 LSOA shape file from the Office of
National Statistics https://data.gov.uk/dataset/fa883558-22fb-4a1a-8529-
cffdee47d500/lower-layer-super-output-area-lsoa-boundaries to produce a
geographical representation of deprivation, epilepsy prevalence, and epilepsy incidence
in Figure 3.8 1. Geographical areas were excluded where GP information was not
available for at least 5% of the population of that area.
It is possible to see a correlation of deprived areas (dark blue) with areas that have
a high prevalence and incidence of epilepsy. Due to densely populated urban areas
skewing deprivation on an LSOA level, it can be seen in enlarged portions of the
map (Swansea, Cardiff and Newport) that while it is possible to see the correlation
1With assistance from Dr Joanne Demmler
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Figure 3.8: Maps of Wales showing each LSOA (areas with population of around 1,500); Yellow areas represent with low data coverage (¡5%
of the population) and are not shown. (A) Deprivation measured by WIMD decile, (B) epilepsy prevalence, and (C) epilepsy incidence.
Enlarged areas represent the densely populated areas of the cities of Swansea, Cardiff, and Newport (left to right). Figure taken from [4]
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between social deprivation, prevalence and incidence of epilepsy, the correlation is not
as clear when viewing Wales as a whole. Odds and incident rate ratios are presented
in Table 3.6 for WIMD deciles, sex and age bands, where a WIMD decile of 1, males,
and age band 0-5 are used as a reference where ORs and IRs were calculated using
multiple logistic regression and Poisson regression models respectively 2. It can be
seen that even after adjusting for WIMD deciles, there is still a significant effect of
epilepsy prevalence and incidence.
Table 3.6: Variable Adjusted epilepsy prevalence odds ratio Adjusted epilepsy
incidence rate ratio The odds and incidence rate ratios for deprivation (second row of
the table) are given per WIMD decile when compared to the population in decile 1,
for example, the odds ratio of epilepsy prevalence in WIMD decile 3 = 0.922 x 0.94
when compared to the population in decile 1. Table taken from [4]
Variable Adjusted prevalence odds
ratio
Adjusted incidence rate
ratio
Deprivation (per
WIMD decile)
0.922 (0.920 to 0.925; p <0.001) 0.936 (0.923 to 0.950; p <0.001)
Sex
Male 1.0 (ref) 1.0 (ref)
Female 0.981 (0.966 to 0.997; p = 0.018) 0.853 (0.787 to 0.924; p <0.001)
Age (years)
0-5 1.0 (ref) 1.0 (ref)
6-12 2.572 (2.372 to 2.792; p <0.001) 0.999 (0.828 to 1.207; p = 0.993)
13-21 3.419 (3.169 to 3.694; p <0.001) 0.950 (0.799 to 1.134; p = 0.565)
22-45 5.570 (5.183 to 5.994; p <0.001) 0.573 (0.488 to 0.676; p <0.001)
46-64 6.371 (5.928 to 6.859; p <0.001) 0.567 (0.479 to 0.673; p <0.001)
>64 6.778 (6.304 to 7.300; p <0.001) 1.098 (0.935 to 1.296; p = 0.261)
3.1.3 Follow up cohort
A cohort of adults aged older than 18 years with a new diagnosis of epilepsy between
January 1, 2000 and December 31, 2002 was selected as a follow up cohort to measure
any difference in WIMD decile 10 years after their diagnosis. Only adults were
selected, as a child’s deprivation status is determined by their parents’ deprivation
status and children move with their parents. For each person in this cohort who
remained within the study population, a comparison of WIMD decile between time
of diagnosis and either 10 years after diagnosis or time of death was used to test
the hypothesis that social drift plays a role in increased deprivation for people with
epilepsy.
2Statistical Analysis performed by Dr Owen Pickrell
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Table 3.7: Summary of follow up statistics for 10 year follow up cohort. Table taken from [4]
Number Mean length of
follow-up in years
(SD)
Mean length of
follow-up in years
(SD)
(Mean change in WIMD
Decile (p-value)
All 582 52.42 (20.2) 7.9 (3.3) 0.04 (p = 0.85)
Alive 352 42.96 (16.4) 10 (0.0) -0.02 (p = 0.83)
Younger than 41 years at diagnosis 172 28.85 (6.4) 10 (0.0) 0.05 (p = 0.87)
41 years or older at diagnosis 180 56.44 (10.7) 10 (0.0) -0.08 (p = 0.56)
Died 230 66.91 (16.7) 4.7 (3.3) 0.13 (p = 0.62)
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613 new cases of epilepsy were identified in adults between January 1, 2000 and
December 31, 2002. Thirty-one patients (5%) had moved out of the study population.
Of the remaining 582 cases: 352 (60%) remained alive and were followed for 10 years;
230 (40%) died and were followed for a mean of 4.7 years (standard deviation [SD]
3.3 years). A Wilcoxon signed-rank test was used in the cohort study to test the null
hypothesis that there was no significant change in WIMD decile following diagnosis.
Table 3.7 summarizes the cohort population and figure 3.9 shows a graph of the
change in WIMD decile.
Figure 3.9: Changes in WIMD decile over 10 years for with incident epilepsy diagnosed
between January 1, 2000 and December 31, 2002. Figure taken from [4]
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3.2 Validating epilepsy status from electronic
healthcare records
The previous study used an SQL algorithm to determine an epilepsy diagnosis from
GP records and compare those identified as having epilepsy with patients in the
Cardiff Epilepsy database. However, it was not possible to measure the specificity
of the algorithm due to a lack of a comparison cohort of people that definitely did
not have epilepsy. This study aimed to validate the accuracy of algorithms using GP
records to identify people with epilepsy from anonymised, linked, routinely-collected
Welsh healthcare data contained within the SAIL databank.
3.2.1 Study population
To validate epilepsy status through the use of READ codes in the SAIL GP records, a
”gold standard” dataset of patients with known epilepsy was sourced using the Swansea
Epilepsy Database within Morriston Hospital 3. A comparison cohort of patients
without epilepsy was sourced from general neurology clinics in Morriston Hospital.
There were 918 patients from the Swansea Epilepsy Database with known epilepsy
(283 (29%) generalised epilepsy, 510 (53%) focal epilepsy, 125 (13%) unclassifiable
epilepsy and 42 (4%) with an uncertain diagnosis), of which 100 adults and 50 children
were randomly selected to form the validation set of known epilepsy. A further 300
letters from general neurology clinic letters were manually reviewed to exclude those
with known epilepsy, and 100 adults and 50 children were randomly selected to form
the validation set of non-epilepsy patients. The 300 person cohort was then linked to
their corresponding GP records in the SAIL databank.
3.2.2 Algorithm validation
Three different algorithms were tested to identify people with epilepsy within the
SAIL Databank. Using a READ codes within GP records, diagnosis codes for epilepsy
as well as AEDS were used in the following way
 A) individuals with an epilepsy diagnosis code and two consecutive anti-epileptic
drug (AED) prescription codes within 12 months of diagnosis
 B) individuals with an epilepsy diagnosis code only
 C) individuals with two consecutive AED prescription codes only.
For a full list of READ codes used to define epilepsy please see the code list in
3Data sourced by Beata Fonferko-Shadrach
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the appendix item 1. 145 of the 150 reference cases with epilepsy (97%) and 143
of the 150 reference cases without epilepsy (95%) were registered with a SAIL GP.
True positive (TP) cases had a hospital diagnosis of epilepsy and were identified
within SAIL as having epilepsy; true negative (TN) cases did not have epilepsy as
confirmed by hospital records and were not identified as having epilepsy within SAIL;
false positive (FP) cases did not have epilepsy as confirmed by hospital records and
were identified as having epilepsy within SAIL; and false negative (FN) cases had a
hospital diagnosis of epilepsy and were not identified as having epilepsy within SAIL.
Positive predictive value (PPV) was defined as TP/(TP+FP); sensitivity TP/(TP
+ FN); specificity TN/(TN+FN) and false positive rate (FPR) as FN/(FN+TN).
Youden’s index (J) was then calculated using sensitivity plus specificity, as a measure
of the accuracy of the algorithms. J ranges from -1 to 1 (J=1 for a perfect test)[235].
Confidence limits were calculated using the exact binomial method. The sensitivity,
specificity, positive predictive value, false positive rate and accuracy of each of the
three algorithms are shown in Table 3.10.
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Figure 3.10: The accuracy of algorithms A,B and C in being able to determine epilepsy status from GP records. Table taken from [5]
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The results show that anonymised GP records can be used to accurately identify
patients with epilepsy diagnosed by a hospital specialist in the UK. Since maximizing
specificity was most important, while aiming to keep sensitivity as high as possible,
algorithm A (specificity 99%, sensitivity 84%) is best suited to identify epilepsy from
GP records, where algorithm C could be exclusively used for children(specificity 98%,
sensitivity 98%). Algorithm B shows that using a diagnosis code for epilepsy alone
also achieves a high level of accuracy in adults (specificity 98%, sensitivity 88%),
which is a 1% increase in specificity over algorithm A, but when combining adult and
children it has lower specificity than algorithms A and C respectively. These results
compare well to other epilepsy validation studies conducted in Australian, Italian and
American healthcare systems that report similar accuracy (specificity 100%, 99.8%,
94% and sensitivity 85.9%,81%,82%) [236–238], and this study is the first epilepsy
validation study using gold standard patient records accuracy in the UK.
There is a clear difference in epilepsy reporting in GP records between adults and
children. It appears that GPs record a diagnosis code for a lower proportion of
children than adults, resulting in only 79% sensitivity for children using algorithm
A, but this is likely due to the many years required to determine a clear diagnosis
of epilepsy in children. There is a large difference in specificity between adults and
children for algorithm C (61%-98%) where it is likely conditions other than epilepsy
in adults (e.g. migraine, mental health disorders and neuropathic pain) are classified
as having epilepsy by the algorithm, but AEDs are rarely prescribed for anything
other than epilepsy in children in the UK [239].
There was little difference in performance between algorithms A and B. Algorithm A
(epilepsy + a repeat prescription) had slightly higher specificity than algorithm B
(epilepsy diagnosis only) and algorithm A had slightly higher sensitivity, but their
overall accuracy was comparable as seen by their Youden’s Index measurement. From
this study, it seems that GP diagnosis codes for epilepsy could be used on their own
to identify people with epilepsy form GP records in the UK, which can be explained
in that an epilepsy diagnosis should be made in secondary care by a specialist in the
UK, and then recorded by GPs in GP records [240].
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3.3 Educational attainment of children born to
mothers with epilepsy
There are currently many AEDs used for seizure control, but some methods of
seizure control during pregnancy can have effects on the unborn child. Valproate
is the most effective drug for treating genetic generalized epilepsy,[26] but recent
prospective psychometric studies have demonstrated cognitive impairment and
neurodevelopmental disorders in 30-40% of children exposed to valproate inutero,[241,
242] as well as a significant decrease in intelligence quotient(IQ)[27, 243]. Women
with epilepsy who have satisfactory control with valproate and are planning a
family therefore have a difficult decision to make. In the United Kingdom the
Medicines and Healthcare Products Regulatory Agency (MHRA), issued stringent
guidance for all clinicians prescribing valproate to women of child-bearing potential
in 2015. An International League Against Epilepsy (ILAE) task force made seven
recommendations, the first of which is where possible, valproate should be avoided
in women of childbearing potential. Women with epilepsy who are taking AEDs are
presently advised to continue them throughout pregnancy, primarily because of the
risks of convulsive seizures to mother and her unborn child.
To be able to counsel mothers adequately about the risks of uncontrolled seizures
during pregnancy and cognitive outcomes for their children, it is important to know
whether the psychometric differences demonstrated in research conditions translate
to children in the community. This study was conducted to investigate the effect of
AED exposure inutero on the educational attainment of children born to mothers
with epilepsy using anonymised, routinely-collected healthcare records and the results
of a standard national educational assessment.
3.3.1 Cohort selection
The Child Health dataset in the SAIL databank was used to select encrypted identifiers
for children as well as a linked ID to the mother. Gestational age, maternal age were
also extracted as covariates used for control matching between mothers with epilepsy
at time of birth and those without. All fields in the Child Health dataset are given in
table 3.8.
104
Table 3.8: SAILCHDV.CHILD is a table in the SAIL Databank that contains birth
records and relates each child’s NHS number to their mother.
Field Name Description
CHILD ID E Internal child ID
ALF E Encrypted NHS number of child
MAT ALF E Encrypted NHS number of mother
MAT WOB Week of Birth of mother
WOB Week of Birth of child
BIRTH WEIGHT Weight of the child at birth.
BIRTH WEIGHT CAT Derived variable. Classes for birth weights.
BIRTH TM Time of birth
GNDR CD Sex of child
APGAR 1 APGAR score taken at 1 minute
APGAR 2 APGAR score taken at 5 minutes
GEST AGE Best estimate of gestation at time of delivery
TOT BIRTH NUM Number of deliveries for multiple births
BIRTH ORDER Order of deliveries for multiple births, by ALF E
MAT AGE Age of mother in years at delivery
PROV SITE CD Hospital provider site code
STILLBIRTH FLG Stillbirth flagged only in case of stilbirth
DOD Date of death of child
LHB CD Local healthboard code
DEL CD Delivery code indicating type of delivery
LABOUR ONSET CD Method of labour onset
MOTHER CARE CD Type of maternity care allocated for mother
BREASTFEED BIRTH FLG Breastfeeding at birth
BREASTFEED 8 WKS FLG Breastfeeding at 8 weeks
LSOA CD Lower Super Output Area containing mother’s address
For each birth record, the mother’s data was linked to their social deprivation as
described in the social deprivation study earlier in this chapter. WIMD quintiles
at the time birth were used as an additional covariate during the control matching
procedure. These data were then linked to the GP dataset in SAIL using algorithm A
from the epilepsy validation study (epilepsy diagnosis + repeat AED prescription) to
determine if the mother had known epilepsy during the pregnancy. A control group
was created (with 4:1 matching) matched for maternal age, week of gestational age,
and WIMD decile at the time of birth between mothers who had known epilepsy
during pregnancy and those that did not have epilepsy.
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3.3.2 Education dataset
Educational attainment data for Key Stage 1 from the Department for Children
Education, Lifelong Learning and Skills (DCELLS) dataset was available in the SAIL
databank between the years 2003-2008. The DCELS dataset contains attainment
for children in mathematics, language (English or Welsh) and science in which each
subject is awarded a level between 1 (lowest) and 3 (highest). In certain circumstances
children may obtain an unclassified or working towards meaning that they do not
achieve the required grade to pass the year. The core subject indicator (CSI) is
defined as the proportion of children achieving a minimum standard in all three KS1
subjects, that being a level 2 or higher in each subject. Given that KS1 results (taken
at the age of 7) were only available within SAIL for the years 2003-2008, SAIL GP
records were queried for women with epilepsy who gave birth between 1996 and 2001.
Table 3.9 shows all field available within the Key Stage 1 dataset:
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Table 3.9: SAILDCELV.PRE16 KS1 is a table in the SAIL Databank contains
all-Wales education data between 2003-2008 for Key Stage 1. Three subjects
(Maths,Science,Engish/Welsh) as well as a Core Subject Indicator are provided to
indicate the level of attainment per child
Field name Description
BATCH NUM Batch number
LEA Local education Authority code
ESTAB E Encrypted educational establishment code
PUPIL IRN E Internal pupil reference number
CSI Core Subject Indicator
EN1 English teacher assessment 1
EN2 English teacher assessment 2
EN3 English teacher assessment 3
ENSUB English teacher assessment subject level
MA1 Maths teacher assessment 1
MA2 Maths teacher assessment 2
MA3 Maths teacher assessment 3
MASUB Maths teacher assessment subject level
SC1 Science teacher assessment 1
SC2 Science teacher assessment 2
SC3 Science teacher assessment 3
SC4 Science teacher assessment 4
SCSUB Science teacher assessment subject level
CY1 Welsh teacher assessment 1
CY2 Welsh teacher assessment 2
CY3 Welsh teacher assessment 3
CYSUB Welsh teacher assessment subject level
YEAR Census year
URN Internal school reference number
NEWBES Pupils from non English/Welsh education system
Each child who was born to mothers with known epilepsy during pregnancy was
then linked to their education data and compared to those children not born to
mothers with epilepsy. Figure 3.11 shows each step of the cohort ascertainment and
linkage:
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Figure 3.11: Flow chart of cohort ascertainment. 4 datasets were queried: General
Practice, ONS Births, Welsh Demographic Service and Welsh Education Dataset.
3.3.3 Results
A total of 440 children were identified with KS1 results available between 2003
and 2008 who had mothers with epilepsy diagnosed before their pregnancy, and
the mothers were stratified into five groups based on AED prescription during
pregnancy (carbamazepine, lamotrigine, sodium valproate, multiple AEDs or no
AEDs prescription) - see table 3.12. Only prescription information was available, but
it is not expected that adherence differs across different AED prescriptions.
The proportion of children in each group achieving at least a level 2 in each subject
is shown in figure 3.13.
108
Figure 3.12: Descriptive statistics of the study cohort. The control group comprised of a 1:4 match on maternal age, gestational age and
Welsh Index of Multiple Deprivation (WIMD) quintile. WIMD quintiles are a measure of deprivation (see method) with quintile 1 being
the most deprived and quintile 5 being the least deprived. sd=standard deviation. *p-values are for comparisons between each group within
the ”Mothers with Epilepsy” group with the control group. Table taken from [3]
109
Figure 3.13: Key Stage 1 results stratified by subject and study groups. Each group
was compared to the matched control group. Significant differences in attainment (*
p ¡ 0.05, ** p ¡ 0.005) between each group and the matched control are shown. The
p-values have been Bonferroni corrected for multiple testing (see Methods section).
The All Wales group is shown as a regional comparator only and not used to test for
significance. Figure taken from [3]
These results show that children born to mothers with epilepsy being prescribed
sodium valproate during pregnancy have a significantly lower level of achievement in
KS1 tests across all indicators, with fewer children achieving the minimum standard
when compared to the matched control group by (CSI = -12.7% less than the control
group, mathematics = -12.1%, language = -10.4%, science = -12.2%). Also fewer
children born to mothers with epilepsy being prescribed multiple AEDs during
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pregnancy achieved the national standard in KS1 tests when compared to the
matched control group by (CSI = -20.7% less than the control group, mathematics
= -21.9%, language = -19.3%, science = -19.4%). There was no significant decrease
in attainment in children born to mothers with epilepsy that were not prescribed
an AED during pregnancy according to their GP records. Excluding children with
epilepsy and mothers who were recorded as smoking during pregnancy did not change
the significance of these results.
3.4 Chapter summary
This chapter has presented various epidemiological studies in epilepsy using linked,
anonymized healthcare data in the SAIL Databank. A study of GP coding of epilepsy
was undertaken by comparing epilepsy diagnoses in GP records held in the SAIL
databank to a gold standard dataset in Morriston hospital of patients with and
without an epilepsy. The results showed that using a repeat AED prescription as well
as an epilepsy diagnosis code is important in capturing epilepsy patients with high
specificity, while also maintaining good sensitivity. Using this algorithm the incidence
and prevalence of epilepsy in Wales was linked to social deprivation using the Welsh
Index of Multiple Deprivation and showed that in more deprived areas there is both a
higher incidence and prevalence of epilepsy. In a follow up study of newly diagnosed
epilepsy patients, there appeared to be no increase in social deprivation leading to the
conclusion that social deprivation in epilepsy is due to social causation rather than
social drift. Finally, the effects of AEDs prescribed during pregnancy on children’s
Key Stage 1 educational attainment was explored. Children born to mothers that
were prescribed sodium valproate or multiple AEDs in combination perform worse
than a control group and has important cognitive outcomes for pharmaco-exposed
children.
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Chapter 4
Using Natural Language
Processing techniques to extract
clinical information from
unstructured text
This chapter aims to explore the potential of extracting rich information from epilepsy
clinic letters using NLP techniques. The motivation for extracting information from
clinic letters when routinely collected information is already available for research
purposes, is that the information available is often limited in detail. For example, in
all of the studies presented in the previous chapter they each lack specific epilepsy
and seizure type, dosage details for prescribed drugs as well as finer details such
as results from EEG and MRI scans. These data are available in other sources of
information, namely free texts in healthcare settings. Manually reading through clinic
letters to obtain rich information is time consuming, and so an automated method
would be desirable to extract this data. The results in this chapter present an NLP
method to extract rich epilepsy information from clinic letters stored in Morriston
hospital and the Swansea Epilepsy Database.
4.1 Clinic letters
The Swansea Epilepsy database was used to source patients with epilepsy that
had clinic letters written by epilepsy specialists at Morriston hospital. Such letters
contain very detailed information regarding a patient’s epilepsy such as seizure type,
seizure frequency and results of examinations and investigations, and even contains
information where a patient experiences symptoms similar to epilepsy that is in fact
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due to non-epileptic attack disorder. Permission to use clinic letters from the Swansea
Epilepsy database was given under the condition all patient details were psuedo
anonymized, where validation of any algorithm was undertaken by a clinician. 240
clinic letters were manually de-identified hospital clinic letters and used to build and
test the algorithm 1. 40 letters were used for training purposes to build rule sets, and
a validation set of 200 letters to test the accuracy of the algorithm. The validation
set contained letters originating from various outpatient clinics (145 adult epilepsy, 37
paediatric epilepsy, and 18 general neurology), from first and follow-up appointments,
and written by eight different clinicians.
4.2 A rule based NLP approach to extract
epilepsy information from clinic letters
Two approaches were considered when developing the NLP pipeline - machine learning
and manually constructing rule sets. Machine learning based approaches require
vast amounts of training data for the algorithm to achieve high accuracy where rule
sets can take advantage of human knowledge when constructing rules. Given that
only 240 letters were available for this study, this limitation was considered when
deciding between a rule based and machine learning based NLP approach to analyse
these letters. Due to the very large training datasets required for machine learning
purposes (tens of thousands), a rule based approach in which human knowledge could
be quickly built into logical rules and processed by a computer program was favoured.
Therefore a rule based NLP approach was used to build an epilepsy clinical extraction
pipeline that could capture data within epilepsy clinic letters.
4.2.1 The General Architecture for Text Engineering
The General Architecture for Text Engineering (GATE) framework was used to build a
rule based NLP pipeline. Two open source applications freely available and configured
for GATE were used - the biomedical named entity linking pipeline (Bio-YODIE
plugin) and the South London and Maudsley medication application (SLaM). The
main focus was to map clinical terms found in text to the Unified Medical Language
System (UMLS) concepts so that a structured dataset could be constructed, much
like the datasets that exist within the SAIL Databank. The ANNIE pipeline was
used for basic POS tagging and sentence boundary detection, and the JAPE scripting
language was used to program various rule sets using items of information tagged
using Bio-YODIE, SLaM, ANNIE as well as custom dictionaries defined to supplement
1De-identification performed by Beata Fonferko-Shadrach
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these plugins. Figure 4.1 shows a flow chart of the various pipeline components:
Figure 4.1: Overview of the GATE pipeline and the various components used to
generate annotations
A list of predefined categories specified by a neurologist 2 formed the basis of the
important information to be extracted from the clinic letters:
2List provided by Dr Owen Pickrell
114
Table 4.1: Definitions of each category intended to be extracted
Category Details
Clinic date The date the patient visited the clinic.
Date of Birth The patient’s date of birth.
Epilepsy
diagnosis
Items of information which confirmed a diagnosis of epilepsy e.g.
”this lady has a diagnosis of focal epilepsy” or ”... has recurrent
unprovoked generalised tonic-clonic seizures”. Frequently there is
diagnostic uncertainty in epilepsy clinic letters e.g. ”this lady probably
has frontal-lobe epilepsy” or ”I am uncertain whether the blackouts are
epileptic”; and so we defined five levels of certainty (1=no diagnosis,
2=unlikely, 3=uncertain, 4=likely, 5=definite) to each information item
associated with an epilepsy diagnosis. We specified that the epilepsy
diagnosis must be attributable to the patient (e.g. not a family member);
and did not include items of information that described epilepsy clinic
attendance, or a discussion about epilepsy in general, as confirmation of
an epilepsy diagnosis.
Epilepsy type Whether the patient had focal or generalised epilepsy or an epilepsy
syndrome where epilepsy type could be inferred. For example generalised
epilepsy if the letter confirmed juvenile myoclonic epilepsy. This was
based on the UMLS CUI extracted with the epilepsy diagnosis information.
We only used explicit mentions of epilepsy types or syndromes within
the clinic letters, and did not use other information, such as seizure type
or investigation results, to infer epilepsy type.
Seizure type Specific seizure types e.g. ”focal motor seizures” or ”absence seizures”.
Seizures types were categorized into focal seizures or generalised seizures
at the validation stage.
Seizure
frequency
The number of seizures in a specific time period e.g. ”two seizures per
day”, ”seven seizures in a year”, or ”seizure free since last seen in clinic.”
Medication An identifiable drug name with a quantity and frequency e.g.
”Lamotrigine 250mg bd”.
Investigations The type of investigation and classification of results (normal or
abnormal). UMLS CUI codes were used to assign a normal / abnormal
value to investigation results, using the simplified abnormal outcomes
gazetteers. We categorised the investigation results into CT, MRI, and
EEG results at the validation stage.
4.2.2 Defining rules
The following sections demonstrates the specifics of how the rules for each category
were built using the components in 4.1.
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1 Phase: Dates
2 # accept TIMEX3 and Lookup2 annotations
3 # Lookup2 are user defined Lookups desgined to signify keywords
4 Input:TIMEX3 Lookup2
5 Options: control=appelt
6
7 Rule: ClinicDate
8
9 ( #includes words such as "clinic", "hospital", "outpatient" etc
10 ({ Lookup2.majorType == "organization", Lookup2.minorType == "health_term"})
11 # followed by a TIMEX3 annotation where date is explicit i.e. full date
12 ({TIMEX3.foundByRule == "date_r1b-explicit"}|
13 {TIMEX3.foundByRule == "date_r0h-explicit"})
14
15 ):match
16 -->
17 # create new annotation "ClinicDate"
18 :match.ClinicDate = {rule = ClinicDate1, value = :match.TIMEX3.timexValue}
Figure 4.2: JAPE script to obtain clinic datae given an input of TIMEX3 and customs
annotations relating to clinic visits (LOOKUP2)
4.2.3 Clinic date and date of birth
Within each letter there were various dates pertaining to different items of information
such as referring to previous clinic visits, date of scans and prescriptions, as well as
clinic date, date of birth and date the letter was typed up by administrative staff.
The TIMEX plugin available within GATE was used to extract dates written in a
variety of ways (01/01/2001 or 1st of January 2001 etc.) that were also found within
the context of words/phrases suggesting clinic visits defined by custom gazetteers.
The JAPE script in figure 4.2 was used to extract clinic dates.
Similarly date of birth was captured by combining TIMEX3 annotations that specify
full dates i.e. day/month/year with strings such as ”D.O.B”, ”DOB:” and ”Date of
birth”.
4.2.4 Epilepsy diagnosis, epilepsy type and seizure type
Rules were built to capture phrases related to an epilepsy diagnosis attributed to a
patient. Some sample phrases, where only the first two phrases would be considered
to have a confirmation of epilepsy using the algorithm developed in this chapter
are:
I suspect he has generalized epilepsy
She was diagnosed with focal epilepsy
She doesn’t have epilepsy, but has non-epileptic attacks
I saw this gentleman regarding epilepsy
The first step was to identify words within phrases that indicate a mention of
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1 select distinct CUI ,STR ,SAB ,CODE from mrconso where STR = "epilepsy";
2 +----------+----------+-------------+-----------+
3 | CUI | STR | SAB | CODE |
4 +----------+----------+-------------+-----------+
5 | C0014544 | Epilepsy | ICD10 | G40 |
6 | C0014544 | Epilepsy | MTH | NOCODE |
7 | C0014544 | Epilepsy | SNOMEDCT_US | 267698007 |
8 | C0014544 | Epilepsy | SNOMEDCT_US | 84757009 |
9 +----------+----------+-------------+-----------+
10 4 rows in set (0.00 sec)
Figure 4.3: MySQL script used to query the UMLS RRF files. The table MRCONSO
contains a list of all CUIs that encompass various different coding systems such as
ICD 10 and SNOMED CT. By searching the STR column for the word epilepsy, the
corresponding CUI is given
epilepsy. The Bio-YODIE plugin was used to map any term found in a document
to a medical concept as part of the UMLS ontology, defined as a Lookup. To
look specifically at epilepsy concepts, a gazetteer of epilepsy terms was built by
specifying CUI codes relating to epilepsy and used to filter all Lookups within a
document. Using an installation of the UMLS Metathesaurus Rich Release Format
(RRF) files https://www.nlm.nih.gov/research/umls/licensedcontent/umlskn
owledgesources.html the following MySQL scripts were used to query the UMLS
relationship datasets for sub codes of epilepsy:
The mysql script in figure 4.3 finds all possible CUIs for the description ”epilepsy” of
which there is one CUI (C0014544) that unifies other existing coding systems that
also describe epilepsy. This CUI was then used in script 4.4 to find child codes, or
sub codes of epilepsy using the relationship file MRREL:
The script example in 4.4 shows an example list, limited to 15 items (out 2532 in total)
of UMLS concepts and CUIs that are children of the epilepsy CUI by linking UMLS
concepts in the MRCONSO table to the MRREL relationship table. These CUIs were
used to build a Flexible Gazetteer which functions as a filter for annotations produced
by the Bio-YODIE plugin. Once a subset of epilepsy terms found by Bio-YODIE has
been produced, the terms found require further context to form a diagnosis. Each
Bio-YODIE Lookup annotation has multiple attributes, of which the following were
used to write a diagnosis annotator:
 Negation (Context plugin) - if the term has a negative context i.e. does not
have epilepsy
 TUI/Unique Identifier Type (UMLS) - each concept within UMLS is
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1 select distinct a.CUI1, a.CUI2, b.STR as child from mrrel a #relationship file
2 -- join relation dataset to mrconso
3 inner join mrconso b
4 -- on the parent CUI = the child CUI
5 on a.CUI2 = b.CUI
6 -- join child CUIs to mrconso
7 inner join mrconso c
8 -- on child CUI = child CUI
9 on a.CUI1 = c.CUI
10 -- specify parent as epilepsy
11 where c.CUI like "C0014544%" and REL = "CHD"
12 -- get first 15 rows only
13 limit 15;
14 +----------+----------+----------------------------------------------------+
15 | CUI1 | CUI2 | child |
16 +----------+----------+----------------------------------------------------+
17 | C0014544 | C0014544 | Epilepsy |
18 | C0014544 | C0014544 | Epilepsy NOS |
19 | C0014544 | C0014544 | Epilepsy , NOS |
20 | C0014544 | C0270850 | Idiopathic generalized epilepsy |
21 | C0014544 | C0270850 | Idiopathic generalised epilepsy |
22 | C0014544 | C0270850 | Idiopathic generalized epilepsy , NOS |
23 | C0014544 | C0494475 | Tonic -clonic seizures |
24 | C0014544 | C0494475 | Tonic -clonic seizure |
25 | C0014544 | C0494475 | Tonic - clonic seizures |
26 | C0014544 | C0477371 | Other epilepsy |
27 | C0014544 | C0477370 | Other generalized epilepsy and epileptic syndromes |
28 | C0014544 | C0014553 | Absence Epilepsy |
29 | C0014544 | C0494474 | Special epileptic syndromes |
30 | C0014544 | C2584947 | Anoxic epileptic seizure |
31 | C0014544 | C2919602 | Witnessed epileptic seizure |
32 +----------+----------+----------------------------------------------------+
Figure 4.4: MySQL script used to query the UMLS RRF files and find all child codes
of epilepsy
attributed to a semantic type e.g. ”Disease or Syndrome”, ”Procedure”, ”Sign
or Symptom” or ”Clinical Drug” with each assigned a TUI code.
 Experiencer (Context plugin) - if the term is referenced to the primary person
within the text, i.e. the patient or other such as family members
There are many components other than finding the word ”epilepsy” that determine if
an epilepsy diagnosis has been confirmed. Custom gazetteers were created to search
for terms such as ”Diagnosis:” found in structured elements of clinic letters, and
custom gazetteers were also created to specify 5 levels of certainty (5 being most
certain) of a term to differentiate phrases such as ”it is doubtful that she has epilepsy”
and ”this is probably a case of complex partial seizures” 3. Table 4.2 shows a list
of terms and their certainty levels that was used to attach a certainty level to any
Lookup:
3With assistance from Dr Owen Pickrell
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Table 4.2: A gazetteer of terms used to determine 5 levels of certainty attached to an
epilepsy diagnosis. A confirmed diagnosis must have a value of 4 or 5.
Term Level Term Level Term Level
ruled out 1 possibility of 3 suspected 4
unlikely 2 ? 3 suggestive 4
doubtful 2 uncertain 3 treated as 4
doesn’t 1 might 3 treating this as 4
doubt 2 potential 3 probably 4
unsure 2 potentially 3 suspicion 4
unclear 2 further clarification 3 I think 4
not convinced 2 further investigation 3 impression is 4
remote 2 to be confirmed 3 sounds like 4
improbable 2 to be sure 3 sound like 4
not likely 2 to see if 3 suspect 4
?? 2 could be 3 suspicious 4
remote possibility 2 to see whether 3 certain 5
unusual 2 likely 4 definite 5
possible 3 probable 4 are dealing with 5
The JAPE script in Figure 4.5 is one example of how potential diagnoses was
captured.
The UMLS CUI codes (767 in total) from running the mysql query in Figure 4.4 were
used to filter out non-epilepsy related Lookups. Figure 4.6 shows a screenshot from
GATE of the features attributed to a Lookup. These features were used to determine
if a Lookup was negated, its certainty level, type and it’s UMLS CUI code and can
be used for further downstream annotations such as only including Lookups with a
certainty level greater than 3 as a confirmed diagnosis.
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1 Phase: Diagnosis
2 Input: Lookup Sentence
3 Options: control=all
4
5 Rule: getDiagnosis
6 (
7 ({ Lookup.PREF == "Diagnosis"} | {Lookup.PREF == "Diagnosed"} |
8 {Lookup.label == "suffers"})
9 (
10 {Lookup.STY == "Disease or Syndrome"} |
11 {Lookup.STY == "Sign or Symptom", Lookup.PREF != "Fit NOS"} |
12 {Lookup.STY == "Mental or Behavioral Dysfunction"} |
13 {Lookup.STY == "Congenital Abnormality"} |
14 ({ Lookup.STY == "Diagnostic Procedure"} |
15 {Lookup.Temporality == historical })?
16 )* # allow for further/nested diagnoses within a phrase
17 (
18 {Lookup.STY == "Disease or Syndrome"} |
19 {Lookup.STY == "Sign or Symptom", Lookup.PREF != "Fit NOS"} |
20 {Lookup.STY == "Mental or Behavioral Dysfunction"} |
21 {Lookup.STY == "Congenital Abnormality"} |
22 ({ Lookup.STY == "Diagnostic Procedure"} |
23 {Lookup.Temporality == historical })?)?
24 ):item
25 ):label
26 -->
27 :item.Diagnosis = { rule = "getDiagnosis", PREF = :item.Lookup.PREF ,
28 CUI = :item.Lookup.inst ,
29 STY = :item.Lookup.STY , Negation = :item.Lookup.Negation ,
30 Experiencer = :item.Lookup.Experiencer ,
31 Temporality = :item.Lookup.Temporality ,
32 # store certainty for later i.e. >4 = diagnosis
33 Certainty = :item.Lookup.Certainty}
Figure 4.5: JAPE script to extract diagnosis using various contexts such negation,
semantic types and certainty terms
120
Figure 4.6: A Lookup for the phrase ”possible complex partial seizures”. The
”Certainty” features was added through development of custom gazetteers and JAPE
rules. The rest of the features come as default from the BIO-Yodie plugin in GATE,
and the ”Negation” feature was produced by modifying the Context plugin in GATE
to add more stop words.
4.2.5 Seizure frequency
Seizure frequency was annotated by extracting the following items of information
within text: mention of a seizure (subject to negation and certainty), number or
range of seizures and the time period over which the seizures occurred. Some example
phrases, of which the first four provide a measure of the number of seizures over a
period of time are:
She is having 5-10 seizures per week.
He describes what are probably focal seizures. These happen
at least once per day.
Since last April he has had 5 seizures.
He has had more than 20 episodes since his last visit.
She was diagnosed with epilepsy after having 5 seizures.
The approach taken was that seizure frequency can be split into three parts: mention
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1 Phase: PartialDate
2 # Token as input ensures any other annotation type stops rule from firing in between
3 # input annotations i.e. strictly day of month , followed by month , followed by year.
4 Input: DayDate Month Numeric Token
5 Options: control=appelt
6
7 Rule: partialDate
8 (
9 #gazetteer for "1st", "2nd", "3rd" etc
10 ({ DayDate })?
11 # gazetteer for months
12 {Month}
13 #any number , logically this will always be a year
14 ({ Numeric })?
15 ):match
16 -->
17
18 :match.PartialDate = {rule = partialDate ,
19 # record the day of month
20 day=:match.DayDate.value ,
21 # record the month
22 month=:match.Month.month ,
23 # record the year
24 year=: match.Numeric.value
25 }
Figure 4.7: JAPE script to define all possible ways of specifying a date including
partial ”April 25th” and full ”April 25th 1992”
of a seizure, a time period, and number of seizures. Gazetteers and JAPE rules
were written to reflect these three components. Initially seizures were filtered from
all Lookups identified by the BIO-Yodie plugin, but during the development of the
algorithm it was found that seizure mentions aren’t often specified formally e.g. ”2-4
complex partial seizures per day” but rather colloquially by both patient and clinician
e.g. ”20 episodes since his last visit” (see example 4 above) or ”15 events every
morning”. A custom gazetteer of terms was created to reflect this, but to preserve
specificity and to distinguish ”episodes” as seizures from other episodes such as
episodes of depression or anxiety, a JAPE rule was written to only associate colloquial
terms as seizures where a formal seizure type, such as complex partial seizure, is
mentioned elsewhere in the letter.
Two approaches were taken to annotate time periods. The first was to create a JAPE
rule for inferring implicit time references such as ”Since April she has had around 20
seizures” where given the clinic date, a time period could be calculated. This involved
capturing calendar references that span from month names i.e. April, to full date
references i.e. 1st April or 1st April 2005. The Jape script in Figure 4.7 show how all
of these forms are captured in a single rule using the Kleene operator for optional
arguments.
The second approach was to annotate explicit mentions of a time period such as ”10
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per week”. Custom gazetteers for temporal terms such as ”since”,”in the last” ,”per
week”, ”a day” were created with attributes for each. Table 4.3 show a sample of the
gazetteer used to define explicit time periods:
Table 4.3: A sample of phrases used to define explicit time periods.
Item Number Time Unit When
a year 1 year
a year 1 year
b.d 2 day
b.d. 2 day
b.i.d. 2 day
bd 2 day
in the evening 1 day evening
every morning 1 day morning
in the morning 1 day morning
daily 1 week
every day 1 week
in a day 1 day
in a single week 1 day
in a week 1 week
per day 1 day
o.d. 1 day
at night 1 day night
a month 1 month
The JAPE script in 4.7 and the gazetteer in Table 4.3 were used to reference various
points in time and combined with seizures mentions to annotate seizure frequency as
well the individual components to calculate the frequency:
4.2.6 Medication
The SLaM (South London and Maudsley) medication application for GATE [244]
was used and modified to annotate documents with prescription information that
include drug name, tablet size, unit of measurement and frequency. The SLaM
application comes with custom gazetteers for drugs derived from BNF code lists,
units and frequency terms which are then used as input to various JAPE rules. The
drugs annotated with the SLaM application did not contain any code reference such
as UMLS or READ, so the BNF gazetteer was swapped with the UMLS gazetteer
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1 Phase: SeizureFrequency
2 Input: NumberRange timePeriods Lookup3 Sentence startList Split
3 Options: control=all
4
5 # define one of may rules in JAPE script
6 # i.e. seizureFrequency0a, seizureFrequency0b ...
7 Rule: seizureFrequency0a
8 (
9 # could be a number or range pertaining to seizure quantity
10 ({ NumberRange }):X1
11 {Lookup3.Negation == Affirmed}
12 i.e. terms such as "since", "during"
13 {timePeriods.period ==yes}
14 # number of days/month defining a time period
15 ({ NumberRange }):X2
16 ):match
17 -->
18 :match.SeizureFrequency = { SeizureType =:match.Lookup3.PREF ,
19 rule = seizureFrequency0a,
20 PREF = "Fit Frequency",
21 CUI = "C0149775",
22 seizureNum = :X1.NumberRange.value ,
23 seizureLower = :X1.NumberRange.N1,
24 seizureUpper = :X1.NumberRange.N2,
25 timeNum = :X2.NumberRange.value ,
26 timeLower = :X2.NumberRange.N1,
27 timeUpper = :X2.NumberRange.N2,
28 period = :match.timePeriods.time -unit
29 }
Figure 4.8: JAPE script to extract certain ways of experessing seizure frequency
used by BIO-Yodie and the JAPE scripts that came with the SLaM application were
modified to accept Bio-YODIE annotations.
Other JAPE rules were also modified and supplemented with custom gazetteers to
capture further details about prescriptions, such as if a prescription mention was
historical, or if a prescription were to be made pending further follow up. This made
it possible to select current prescriptions only. The JAPE script in figure 4.9 shows
how custom gazetteers for words such as ”pending”, ”may”, ”try”, ”previously” etc.
were used to pad out prescriptions with further context:
During development of the algorithm, a common way of expressing directions to take
a prescription multiple times a day was found to include times of day:
Lamotrigine︸ ︷︷ ︸
Drug
250mg in the morning︸ ︷︷ ︸
Direction 1
, 200mg at night︸ ︷︷ ︸
Direction 2
Where both directions must be captured to sum to a daily dose of 550mg of Lamotrigine
per day. The JAPE script in figure 4.10 uses Kleene operators to accommodate
multiple directions when appearing consecutively without a Lookup (usually a drug
given this pattern) in between them:
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1 Phase: DrugStatus
2 Input: Measurement DoseFrequency Lookup Numeric ContextPrescription NewLine
3 Options: control=appelt
4
5 Rule: doseMatch0
6 (
7 # optional (?) gazetteer of terms such as "descreased ","continue","try"
8 ({ ContextPrescription })?
9 # drug tagged in Bio -YODIE or measurement
10 # i.e. Lamotrigine 200mg or 200mg Lamotrigine
11 ({ Lookup.STY=="Pharmacologic Substance"} | {Measurement })
12 # Repeat again i.e. if drg was picked up in first line
13 # logically measurement should be picked up in second , vice -a-versa
14 ({ Lookup.STY=="Pharmacologic Substance"} | {Measurement })
15 # twice a day , once in the morning etc
16 {DoseFrequency}
17 # another optional context i.e. prescribe <Presription > if.....
18 ({ ContextPrescription })?
19 ):match
20 -->
21 :match.Prescription0 = { rule = doseMatch0, drug = :match.Lookup.PREF ,
22 CUI = :match.Lookup.inst ,
23 dose -val = :match.Measurement.quantity ,
24 dose -unit =: match.Measurement.units ,
25 dose -frequency = :match.DoseFrequency.frequency ,
26 time -unit = :match.DoseFrequency.time -unit ,
27 dose -interval = :match.DoseFrequency.interval ,
28 Context = :match.ContextPrescription.context}
Figure 4.9: JAPE script to extract prescriptions
4.2.7 Investigations - CT, MRI and EEG scans
Two attempts were made to capture details of CT, MRI and EEG scans. The first
attempt used CUI subsets in a similar way to how Bio-YODIE annotations were
filter for epilepsy specific annotations, however terms relating to scan result were
too specific to map directly to language used within clinic letters. Table 4.4 shows a
sample of how UMLS concepts related to EEGs are highly specific in terms of string
matching to phrases within a text:
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12 Phase: LazyPrescription
3 Input: Measurement Token Lookup
4 # Pick up all possible mentions , rather than longest match.
5 Options: control=all
6
7
8 # JAPE rules for when multiple doses are repeated off for just one drug
9 # maximum three does per prescription are captured
10 # don 't need to worry about b.d., twice a day etc
11
12 Rule: lazyMatch
13 Priority: 100
14 (
15 # Get drug mention
16 ({ Lookup.STY=="Pharmacologic Substance"} | {Lookup.STY=="Clinical Drug"})
17 # Get first measurement (quantity and unit)
18 # Don 't need how many times per day , explicitly says "in the morning"
19 ({ Measurement }):m1
20 # Allow a toke that isn 't a Lookup ...i.e. a comma or "and"
21 ({Token ,! Lookup })?
22 # Get second measurement (quantity and unit)
23 # Don 't need how many times per day , explicitly says "at night"
24 ({ Measurement }):m2
25 ({Token ,! Lookup })?
26 # Optional further dose
27 ({ Measurement }):m3
28
29 ):match
30 -->
31 :match.Prescription = { rule = lazyMatch ,
32 drug = :match.Lookup.PREF ,
33 CUI = :match.Lookup.inst ,
34 dose -val1 = :m1.Measurement.quantity ,
35 dose -val2 = :m2.Measurement.quantity ,
36 dose -val3 = :m3.Measurement.quantity ,
37 dose -unit1 =:m1.Measurement.units ,
38 dose -unit2 =:m2.Measurement.units ,
39 does -unit3=:m3.Measurement.units ,
40 # hardcoded i.e. each unique directions will
41 # be assgned once per day
42 dose -frequency = "1", time -unit = "day"}
Figure 4.10: JAPE script to extract multiple prescription directions.
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Table 4.4: A sample of UMLS terms and the important information within each.
UMLS terms such as these shown are difficult to map directly to text within clinical
texts, where the terms of interest from within each UMLS term are much easier to
map.
UMLS term Term of interest
EEG shows generalized, bilateral, synchronous,
symmetrical discharge
symmetrical discharge
EEG with hyperventilation-induced focal epileptiform
discharges
focal epileptiform discharges
EEG with hyperventilation-induced generalized
epileptiform discharges
generalized epileptiform
discharges
MRI shows leukoencephalopathy with cavitation leukoencephalopathy +
cavitation
MRI shows congenital abnormalities of the posterior
fossa
congenital abnormalities
MRI shows short, thick corpus callosum abnormal corpus callosum
Diffuse cerebral atrophy on CT and MRI cerebral atrophy
Aplasia of posterior semicircular canal on CT scan aplasia
Low density white matter on CT scan low density white matter
In table 4.4 the UMLS terms in column 1 only get mapped to terms in text if the
exact term is found, but due to the length and specificity of some terms there was
low sensitivity in picking up investigations. Therefore custom gazetteers that use
smaller terms categorised as normal (CUI:C0560017) or abnormal (CUI:C0151611)
were produced to maximize to maximize sensitivity of investigation outcomes that
preserve what is important i.e. normal or abnormal results 4. Table 4.5 shows a list
of terms used to identify possible investigation findings:
4with assistance from Dr Owen Pickrell
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Table 4.5: A list of custom terms used to indicate a possible EEG finding
Custom term Derived
UMLS
concept
Custom term Derived
UMLS
concept
abnormal C0151611 normal C0560017
abnormal EEG C0151611 normal EEG C0560017
abnormalities C0151611 photosensitive C0151611
abnormality C0151611 photosensitive C0151611
burst suppression C0151611 photosensitivity C0151611
clear C0560017 polyspike C0151611
did not capture any
events
C0560017 poly-spike C0151611
dysrhythmic C0151611 polyspike and wave C0151611
EEG normal C0560017 right side slowing C0151611
epileptic C0151611 sharp C0151611
epileptiform C0151611 spike C0151611
epileptogenic C0151611 spike and wave C0151611
failed to alter C0560017 spikes C0151611
focal slowing C0151611 spike-wave C0151611
focus C0151611 temporal slowing C0151611
generalised slowing C0151611 unremarkable C0560017
irregular C0151611 unstable C0151611
left side slowing C0151611
Once terms were identified within the text, the JAPE rule in figure 4.11 was written
to associate them to investigation names using strings such as ”EEG”, ”MRI” and
”CT” as long as they were found after the investigation name and within the same
paragraph:
4.2.8 Validation of Algorithm
After developing the pipeline, 200 unseen letters were used to validate accuracy against
a clinician 5. For each category of information, the scope of what was expected to
be extracted or not extracted was discussed with the clinician. The clinician then
annotated every letter for each category, including multiple mentions from the same
category. Separately, the pipeline was run against the 200 test letters and annotated
5performed by Dr Owen Pickrell
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1 Phase: Investigations
2 # Investigation are Investigation types i.e. EEG
3 # InvestigationFinding are outcomes i.e. lesion
4 # p is paragraph to ensure
5 Input: Investigation p InvestigationFinding
6 Options: control=brill
7
8 Rule: getInvestigationsOutcomes
9 (
10 # get investigation type i.e. EEG
11 ({ Investigation }):invest
12 # followed by outcomes (+ means one or more)
13 (({ InvestigationFinding }):outcome)+
14 ):match
15 -->
16 :match.Investigations =
17 { rule = getInvestigationsOutcome1,
18 #store type
19 INVESTIGATION = :invest.Investigation@string ,
20 #store outcome
21 Outcome = :outcome.InvestigationFinding@string ,
22 # store outcome CUI
23 CUI = :outcome.InvestigationFinding.CUI ,
24 #store negation status
25 Negation = :outcome.InvestigationFinding.Negation}
Figure 4.11: JAPE script to extract investigation outcomes
for each category and the results of the clinician and pipeline were reviewed, where
all disagreements were manually reviewed.
Precision, recall and F1-score were used as measures to determine the accuracy of
the pipeline and are defined as:
Precision =
TP
TP ∗ FP
Recall =
TP
TP ∗ FN
F1score =
Precision ∗Recall
Precision+Recall
True positives were defined as both the pipeline and clinician identifying a positive
finding such as confirming an epilepsy diagnosis, false positives were defined as the
pipeline identifying a positive finding where the clinician did not, and false negatives
were defined as the algorithm failing to identify a positive finding where the clinician
was able to. To resolve any mention where there was a disagreement, either the
disagreement remained after manual review, or in small proportion of cases where the
clinician had made a mistake, the clinicians record was corrected. Results are given
in table 4.6 where a ”per item” score is based on every possible mention within the
categories, and a ”per letter” score assumes that identification of one true positive
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within a given category is a true positive for that category as a whole i.e. if there are
3 mentions of an epilepsy diagnosis, if the pipeline was able to identify just one, the
per letter score for epilepsy diagnosis would be a true positive.
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Table 4.6: Precision, recall and F1-score are calculated across 9 epilepsy specific categories as well as clinic date and date of birth. Two
approaches have been considered - the first measures the algorithm’s accuracy for every mention (N=1925) across all categories as identified
in the manual review by the clinician, and the second approach aggregates results from multiple mentions per category, per letter i.e. if
there are multiple true mentions regarding confirmation of epilepsy in a single letter, we assign a single true positive providing the algorithm
picks up at least one of these mentions, with the same logic used to determine false positives, true negatives and false negatives.
Variables Per item performance Per letter performance
N items Precision % Recall % F1 score % N letters Precision % Recall % F1 score %
Clinic Date 191 98.9 97.4 98.2 186 100 97.3 98.6
Date of Birth 201 100 98 99 199 100 98 99
Epilepsy Confirmed 383 88.1 99 88.5 150 94.1 94.1 94.1
Epilepsy Type 89 89.9 79.8 84.5 70 91 87.1 89.1
Focal Seizures 145 96.2 69.7 80.8 69 96.7 83.1 89.4
Generalised Seizures 151 88.8 52.3 65.8 76 89.7 68.4 77.6
Seizure Frequency 153 86.3 53.6 66.1 119 92.2 59.7 72.4
Medication 316 96.1 94 95 157 98.6 91.1 94.7
CT Scan 17 55.6 58.8 57.1 16 76.9 62.5 69
MRI Scan 109 82.4 68.8 75 66 86.7 78.8 82.5
EEG 170 81.5 75.3 78.3 79 86.6 89.9 88.2
All 1925 90.6 80.8 85.4 1187 96.6 87.2 91.7
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The pipeline obtained an overall precision, recall and F1-score of 91%, 81% and
85% on a per item basis, where high scores were obtained in prescription (F1=95%),
confirmation of an epilepsy diagnosis (93%), epilepsy type (84%) and presence of
focal seizures (81%). The algorithm was less accurate in identifying CT (57%), MRI
(75%) and EEG results (78%), seizure frequency (66%) and generalised seizure terms
(66%) given the complexity and high variance in expressing these concepts in clinic
letters. The pipeline achieved even higher overall scores for precision, recall, and
F1-score (96%, 87%, 91%) on a per letter basis, in which given how the final data is
to be used for further research purposes, a decision for each category can be made
accurately across measures such as epilepsy diagnosis, epilepsy type, seizure type and
prescriptions.
4.3 Chapter Summary
A gold standard dataset of de-identified clinic letters was used to build and test an
NLP pipeline, that was found to accurately extract novel information about epilepsy
when compared to manual review by a clinician. The use of UMLS terminologies,
in particular the ability to map findings to CUI codes can be powerful in curating
structured datasets that can be linked to other routinely collected data such as GP
and hospital patient records, where these data can be processed programmatically
rather than via manual review. Some categories such as diagnosis of epilepsy, epilepsy
type and prescriptions can be extracted with high accuracy, but some concepts such
as EEG/MRI/CT investigations and seizure frequency remained difficult to extract
and further improvements are necessary for further research purposes. However, the
information that the pipeline can extract well would improve the richness of data
such as GP records that are held within the SAIL databank.
While gold standard letters have been used, the pipeline was tested on a relatively
small number of letters sourced from one Health-board with a limited number of
writing styles and letter structures, therefore the generalizability of the pipeline may
be limited and would benefit from a larger test set. The pipeline does not however
rely on the structure of clinic letters and is designed to use free text without relying on
dedicated sections in the letters. A ”per item” and ”per letter” score was calculated
to validate both the accuracy of the pipeline, but also to validate how information
within letters can be used practically for further research by summarising all items in
a clinic letter and giving a decision boundary on the category as a whole.
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Chapter 5
Predicting functional impact of
Single Nucleotide
Polymorphisms
The aim of this chapter was to investigate the best method for indicating that a Single
Nucleotide Polymorphism (SNP) is a pathogenic consideration for epilepsy/neurology
phenotypes. Given that an exome contains 30-40 thousands SNPs it is important
to prioritise those that may contribute to disease so that they can be studied in
downstream functional validation and link to observable clinical outcomes. Various
machine -learning techniques were explored to identify the most accurate method of
classifying disease (pathogenic) and benign SNPs. These techniques were compared
to existing prediction software when tested on a disease non-specific dataset of
SNPs as well as epilepsy specific SNPs. The humvar dataset was identified from
an extensive literature review to be a commonly-used training dataset for machine
learning classification of SNPs. It contains over 70,000 pathogenic and benign SNPs
obtained from published studies. These SNPs were used to train various machine
learning algorithms which were then compared to existing prediction algorithms
widely-used in the literature. A set of SNPs found in genes associated with epilepsy
were also scored using the trained algorithm. All code used in this chapter can be
found at the following Github repository https://github.com/arronlacey/PhD-
Chapter5.
5.1 Features
An automated feature extraction pipeline was built so that for each mutation in the
humvar dataset, the pipeline obtains 30 protein features which are all used to train
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and test various machine learning algorithms. The pipeline consists of bash and
R scripts to pull data from multiple websites, public databases and derive further
features with downstream processing. Figure 5.1 shows a flowchart of the main
processes in the feature extraction pipeline:
Figure 5.1: Pipeline of SNP data collection. The data is used to train a classifier that
can be used to predict disease/benign status of a SNP.
The pipeline was built to accommodate chromosomal or amino acid co-ordinates in
BED and HGVS formats, as well as rsid format. Sections 5.1.1 - 5.1.3 document how
each process in the feature extraction pipeline was built.
5.1.1 Variant Effect Predictor
The humvar dataset rsids were used as input to the Variant Effect Predictor (VEP)
annotating system to obtain conservation scores and existing prediction software
scores for each SNP. Table 5.1 describes the 38 features collected to be used as part
of the training data for machine learning.
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Table 5.1: Features obtained from VEP
Feature Description
DANN score Deep learning SNP prediction score [204]
GM12878 fitCons score Fitness conservation score for lymphoblastiod cells [245]
GM12878 fitCons score rankscore Rankscore for lymphoblastoid cells [245]
GenoCanyon score rankscore Prediction score for non-coding function regions [246]
H1NAhESC fitCons score rankscore Fitness conservation score for human embryonic stem cells [245]
HUVEC fitCons score rankscore Fitness conservation score for umbilical vein epithelial cells [245]
MetaLR score SNP prediction score using 9 existing SNP software, trained with
logistic regression [205]
MutationAssessor score rankscore SNP prediction application for cancer variants [206]
REVEL score SNP prediction aggregation score using 8 SNP prediction software
for predicting pathogenicity of rare variants [207]
fathmmNAMKL coding score SNP prediction score using Hidden Markov Models [208]
integrated fitCons score Combined fitcons score
integrated fitCons score rankscore Combined fitcons rank score
PolyPhen score SNP prediction score using a Na¨ıve Bayes classifier [196]
SIFT score SNP prediction score using protein conservation methods [187]
CADD raw rankscore Combined Annotation–Dependent Depletion SNP prediction score
[209]
DANN rankscore DANN converted rankscore [204]
EigenNAPCNAraw rankscore SNP prediction score using unsuperivsed learning [247]
FATHMM converted rankscore FATHMM converted rankscore
GERP.. RS rankscore Conservation score in humans based on 1,092 genomes [248]
MetaLR rankscore MetaLR rankscore
MetaSVM rankscore SNP prediction score using 9 existing SNP software, trained with
SVM [205]
MutationTaster converted rankscore Mutation taster rankscore
PROVEAN score SNP prediction in non-coding regions [249]
REVEL rankscore REVEL rankscore
SiPhy 29way logOdds rankscore SIte-specific PHYlogenetic analysis [224]
VEST3 rankscore Variant Effect Scoring Tool [210]
fathmmNAMKL coding rankscore FATHMM coding rankscore
phastCons100way vertebrate rankscore Evolutionary conservation (ranked) scores in vertabrae [223]
phastCons20way mammalian rankscore Evolutionary conservation (ranked) scores in mammals [223]
phyloP100way vertebrate rankscore Score predicting non-neutral substitution rates in vertebrae [222]
phyloP20way mammalian rankscore Score predicting non-neutral substitution rates in mammals [222]
Reliability index Reliability index as calculated by SNAP2
GERP.. NR Conservation score in humans based on 1,092 genomes [248]
SiPhy 29way logOdds SiPhy log odds score
phastCons20way mammalian Evolutionary conservation scores in mammals [223]
gnomAD Genome aggregation SNP frequency in population combined
exomes and genomes
gnomAD exomes Genome aggregation SNP frequency in population in exomes
gnomAD genomes Genome aggregation SNP frequency in population in genomes
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Table 5.2: Amino acid attributes with three group classification. Each classification
is given by a unique set of amino acids. Table reproduced with permission from
https://cran.r-project.org/web/packages/protr/vignettes/protr.html
Atrribute Group 1 Group 2 Group 3
Hydrophobicity Polar Neutral Hydrophobicity
R, K, E, D, Q, N G, A, S, T, P, H,
Y
C, L, V, I, M, F,
W
Normalized van der
Waals Volume
0-2.78 2.95-4.0 4.03-8.08
G, A, S, T, P, D,
C
N, V, E, Q, I, L M, H, K, F, R, Y,
W
Polarity 4.9-6.2 8.0-9.2 10.4-13.0
L, I, F, W, C, M,
V, Y
P, A, T, G, S H, Q, R, K, N, E,
D
Polarizability 0-1.08 0.128-0.186 0.219-0.409
G, A, S, D, T C, P, N, V, E, Q,
I, L
K, M, H, F, R, Y,
W
Charge Positive Neutral Negative
K, R A, N, C, Q, G, H,
I, L, M, F, P, S, T,
W, Y, V
D, E
Secondary Structure Helix Strand Coil
E, A, L, M, Q, K,
R, H
V, I, Y, C, W, F,
T
G, N, P, S, D
Solvent Accessibility Buried Exposed Intermediate
A, L, F, C, G, I,
V, W
R, K, Q, E, N, D M, S, P, T, H, Y
5.1.2 CTD Descriptors
CDT (Composition/Transition/Distribution) descriptors were used to assign
physiochemical attributes to each SNP [250]. The protr R package contains a
function that calculates the global distribution of amino acid attributes classed into 3
categories as a percentage of all amino acids in a given sequence. These attributes
and categories are shown in Table 5.2
The protr R function was modified to output the attributes and categories for every
amino acid in a sequence so that data on both a wild type and a SNP could be
obtained and the differences compared. The modified function is shown in Figure
5.2
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1 extractCTDCraw = function(x) {
2 k<-as.numeric(x[,2])
3 prot <-as.character(x[,1]) # protein identifier
4 pos <-as.numeric(x[,2]) # SNP position
5 wild <-as.character(x[,3]) # wild type amino acid
6 sub <-as.character(x[,4]) # sub is the mutation
7
8 group1 = list(
9 'hydrophobicity ' = c('R', 'K', 'E', 'D', 'Q', 'N'),
10 'normwaalsvolume ' = c('G', 'A', 'S', 'T', 'P', 'D', 'C'),
11 'polarity ' = c('L', 'I', 'F', 'W', 'C', 'M', 'V', 'Y'),
12 'polarizability ' = c('G', 'A', 'S', 'D', 'T'),
13 'charge ' = c('K', 'R'),
14 'secondarystruct ' = c('E', 'A', 'L', 'M', 'Q', 'K', 'R', 'H'),
15 'solventaccess ' = c('A', 'L', 'F', 'C', 'G', 'I', 'V', 'W'))
16 group2 = list(
17 'hydrophobicity ' = c('G', 'A', 'S', 'T', 'P', 'H', 'Y'),
18 'normwaalsvolume ' = c('N', 'V', 'E', 'Q', 'I', 'L'),
19 'polarity ' = c('P', 'A', 'T', 'G', 'S'),
20 'polarizability ' = c('C', 'P', 'N', 'V', 'E', 'Q', 'I', 'L'),
21 'charge ' = c('A', 'N', 'C', 'Q', 'G', 'H', 'I', 'L',
22 'M', 'F', 'P', 'S', 'T', 'W', 'Y', 'V'),
23 'secondarystruct ' = c('V', 'I', 'Y', 'C', 'W', 'F', 'T'),
24 'solventaccess ' = c('R', 'K', 'Q', 'E', 'N', 'D'))
25 group3 = list(
26 'hydrophobicity ' = c('C', 'L', 'V', 'I', 'M', 'F', 'W'),
27 'normwaalsvolume ' = c('M', 'H', 'K', 'F', 'R', 'Y', 'W'),
28 'polarity ' = c('H', 'Q', 'R', 'K', 'N', 'E', 'D'),
29 'polarizability ' = c('K', 'M', 'H', 'F', 'R', 'Y', 'W'),
30 'charge ' = c('D', 'E'),
31 'secondarystruct ' = c('G', 'N', 'P', 'S', 'D'),
32 'solventaccess ' = c('M', 'S', 'P', 'T', 'H', 'Y'))
33 xSplitted = substr(x[1,5],pos ,pos)
34
35 # Get groups for each property & each amino acid
36 g1 = lapply(group1 , function(g) which(xSplitted %in% g))
37 names(g1) = paste(names(g1), '1.', sep = '.')
38 g2 = lapply(group2 , function(g) which(xSplitted %in% g))
39 names(g2) = paste(names(g2), '2.', sep = '.')
40 g3 = lapply(group3 , function(g) which(xSplitted %in% g))
41 names(g3) = paste(names(g3), '3.', sep = '.')
42 }
Figure 5.2: R function modified from the protr package to obtain CTD amino acid
groups and categories for each position of a protein sequence
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5.1.3 Secondary structure prediction
The pipeline uses the open source program PSIPRED to predict the secondary
structure state (coil, helix, sheet) at each amino acid position for both the wild
type and the variant protein sequences. For each SNP the protein sequence was
downloaded using the Uniprot API, where the SNP was swapped into the sequence.
In total 21,094 wild type sequences and 74,393 SNP sequences were processed with
PSIPRED on the HPC Wales cluster. For each SNP the probability change between
each state of the position containing the SNP and the corresponding wildtype states
were used as well as the overall predictions to produce 5 features for the final training
data. The following bash script loads SNP co-ordinates from the humvar dataset into
the uniprot API to retrieve protein sequences for each SNP:
1
2 #!/bin/bash
3
4 #download fasta seqs given file of uniprot ids
5
6 # SNP input file
7 file=$1
8 # Output file name minus extension
9 name=$2
10
11 # assign 4 columns in SNP input file to variables: protien ID, position , and alleles
12
13 ids=($(cat ${file} | awk '{print $1}'))
14 pos=($(cat ${file} | awk '{print $2}'))
15 wild=($(cat ${file} | awk '{print $3}'))
16 sub=($(cat ${file} | awk '{print $4}'))
17
18
19 # get ref fasta for each line in file , with custom header attached
20 # use cURL to retrieve from the uniport REST URL
21
22 for i in "${!ids[@]}" ; do
23 echo "#${ids[i]}_${pos[i]}_${wild[i]}_${sub[i]}";
24 curl -sS "http ://www.uniprot.org/uniprot/"${ids[i]}".fasta";
25 done |
26 sed '/^>/ d' |
27 sed -r 's/[#]+/ >/g' |
28 perl -npe 'chomp if ($.!=1 && !s/^>/\n>/)' > $name.snp.fasta
Figure 5.3: Bash script to retrieve fasta sequences for a file given in SNP format.
The awk script in figure 5.4 replaces the wild type amino acid at the SNP position
with the mutated amino acid.
The sequences containing the wild type and the SNPs were then processed using
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1 # field separator defined as _ i.e. fasta headers
2 BEGIN { FS="_" }
3 # get fasta headers and store components into array
4 /^>/ {
5 id=$1;p=$2; wild=$3;subs=$4; c=$NF; next
6 }
7 {
8 # start of sequence
9 s=1
10 e=length($0) #end of sequence
11 #substring up to mutation , substitution , substring after mutation
12 print id"_"p"_"wild"_"subs" >\n"substr($0,s,p-1) c substr($0,p+1,e)
13 }
Figure 5.4: An AWK script that replaces the wild type amino acid with the mutation
1 #!/bin/bash
2 #SBATCH --job -name psipred -array # name of job as appears in queue
3 #SBATCH --time 01-21:00 # length of time for each job to run
4 #SBATCH -o psibatchout.$I # standard output of job
5 #SBATCH -e psibatcherr.$J # error log
6 #SBATCH --array=1061-1080 # job array i.e. parallel process multiple jobs
7 #SBATCH --mem -per -cpu=4000 # memory per cpu
8 #SBATCH --ntasks=128 # number of nodes
9 #SBATCH --mail -user=user@mail.com # notify job is complete via email
10 module load compiler/gnu/4.8.0 # compiler
11 module load R/3.2.3 # external dependencies
12
13 # psipred code
14 code=${HOME}/Phd/script_dev/rfpipeline.sh
15
16 # input sequence file
17 data_file="humvarids_${SLURM_ARRAY_TASK_ID }.fasta"
18 # declare the file about to be used
19 echo ${data_file}
20 # run psipred on input file
21 ${code} ${data_file}
Figure 5.5: A SLURM job script run on the HPC Wales Portal that calls the psipred
commandline facility. The script logs a job in a queue containing any other jobs users
submit across HPC clusters, where parameters such as compiler, number of cores and
how long the script should be allowed to run for. It takes 45 hours (time parameter
01-21:00) to process 300 sequences of varying length.
PSIPRED. Each sequence took on average 20 minutes to process on a standard
desktop, therefore this task was completed by running PSIPRED on the HPC Wales
cluster which reduced the time taken to 2-3 minutes. The SLURM script in 5.5 is
the SLURM job schedule script that specifies a variety of parameters needed such as
number of cores, run time and memory required to run psipred. The fair usage limit
on the HPC Wales cluster allowed for a scheduled job to run up to 48 hours, which is
the equivalent of processing 300 sequences, therefore the 21,094 wild type sequences
and 74,393 SNP sequences were split into 318 jobs.
Each PSIPRED output file for a given SNP was compared to it’s corresponding wild
type protein using the bash script in figure 5.6. A sample comparison is given in
Figure 5.7 which shows how the secondary structure prediction changes not only at
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1 # Create index of all faster headers in humvar files
2 for i in *.fasta; do
3 IFS=_ read -ra arr <"$i"
4 mv $i `echo "${arr[0]}_${arr[1]}_$i" | sed -e 's/>//g'`
5 done
6
7
8 # get protein name , snp position and file id number from filename
9 IFS=$'\n' fa=( $(ls *.fasta | awk -F'[_.-]' '{print $1" "$2" "$5}' ) )
10
11 # use file id number to find .ss file (secondary structure file)
12
13 for i in "${fa[@]}" ; do
14 echo "$i" | xargs -n 3 bash -c 'cat *-$2.fasta.ss |sed "s/$/ $0 $1 $2/" | nl -v $2'
15 done > master.ss
16 # Extract SNP line where amino acid positions are equal in both files
17 awk '$2 == $9' master.ss | sed 's/ \{1 ,\}/,/g' | sed 's/^,//' > master.csv
Figure 5.6: A bash script to process output of psipred.
the SNP position, but also in neighbouring SNPs. This is due to the underlying
PSIBLAST alignment used when processing the wild type sequence and the mutated
sequence, where a proportion of candidate protein sequences used in the secondary
structure prediction in both cases will differ, however the largest changes are generally
at the SNP position or next to it.
Figure 5.7: Comparison of two sample PSIPRED output files, where the left shows
predictions for the wild type protein and the right shows the same sequence with
the SNP is inserted. Lines are colour coded by increasing difference in prediction
probabilities between the wild type and SNP sequence, where red depicts the largest
difference and yellow the smallest.
140
5.1.4 Results
After feature extraction the humvar dataset contained 14,266 pathogenic and 29,154
benign SNPs with all feature data. A 5-fold cross validation was performed in which
for each fold 75% of the SNPs were randomly selected to form a training set, and the
remaining 25% were used as an unseen test set on the trained classifiers. 6 classifiers
were built using the training data: Random Forest, Decision Tree, Logistic Regression,
Artificial Neural Network, Naive Bayes and Support Vector Machine (SVM). The R
code in figure 5.8 shows the functions used to train and test each classifier.
Table 5.3 shows the results of each fold for each classifier and figure 5.9 shows a Receiver
Operator Curve (ROC) plotting the sensitivity vs specificity of each classifier for it’s
mean scoring model in terms of accuracy across all scoring thresholds (normalized
between 0 and 1 ) generated by the model. Figure 5.10 shows the importance of each
feature when used in the Random Forest model to discriminate between pathogenic
SNPs and neutral SNPs. The importance is measured by the difference in accuracy
when excluding a feature and re-running the model compared to the model with all
features used.
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1 # Train Random Forest , Logistic Regression , Support Vector Machine
2 # Artificial Neural Network , Decision Tree and Naive Bayes classifiers
3
4
5 # Random Forest
6 # load Random Forest package
7 require(randomForest)
8 # Train the model
9 rf.mdl <- randomForest(label ~.,data=train ,importance=TRUE)
10 # Predict probability belong to each class
11 rf.prob <-predict(rf.mdl , test ,type = "prob")
12 # Give prediction output: Disease or Polymophism
13 rf.pd<-predict(rf.mdl , test)
14
15
16 # Logistic Regression
17 # glm function is in base R
18 # Use glm function with family = "binomial" for logistic regression
19 lr.mdl = glm(label ~ ., data=train , family = binomial("logit"))
20 # Give prediction based on LG response
21 lr.prob <-predict(lr.mdl , test[,2:ncol(test)],type="response")
22
23
24 # C45 Decision Tree
25 # Load the rpart R package
26 library(rpart)
27 # Train decision tree
28 dt.mdl <- rpart(label ~ .,method="class", data=train)
29 # Give prediction
30 dt.prob <-predict(dt.mdl , test[,2:ncol(test)],type="prob")
31
32
33 # Support Vector Machine
34 # Load e1071 R package
35 library(e1071)
36 # Train SVM model
37 svm <- svm(label ~ ., data = train)
38 predict(svm , test[,2:ncol(test)], type = "class")
39
40
41 # Neural Network
42 # load the nnet R package
43 library(nnet)
44 # Train Neural Network
45 nn<-nnet(label ~ ., data = train , size = 3, rang = 0.1,
46 decay = 5e-4, maxit = 200)
47 # Give prediction
48 nn.prob <-predict(nn, test[,2:ncol(test)])
49
50
51 # Naive Bayes
52 # load the e1071 R package
53 library(e1071)
54 # Train Naive Bayes
55 nb <- naiveBayes(label ~ ., data = train)
56 # Give prediction
57 predict(nb, test[,2:ncol(test)], type = "class")
Figure 5.8: R script used to train and test a Random Forest classifier
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Table 5.3: 5 fold cross-validation of the 6 classifiers.
Algorithm Fold Disease Neutral TP FP FN TN TPR FPR Accuracy
Random Forest 1 4137 5426 3778 257 359 5169 93.63 93.51 93.56
2 4045 5518 3687 249 358 5269 93.67 93.64 93.65
3 4127 5436 3813 269 314 5167 93.41 94.27 93.9
4 4125 5438 3791 265 334 5173 93.47 93.93 93.74
5 4155 5408 3806 250 349 5158 93.84 93.66 93.74
Logistic Regression 1 4211 5352 3692 343 519 5009 91.5 90.61 90.99
2 4109 5454 3593 343 516 5111 91.29 90.83 91.02
3 4195 5368 3725 357 470 5011 91.25 91.42 91.35
4 4154 5409 3680 376 474 5033 90.73 91.39 91.11
5 4153 5410 3685 371 468 5039 90.85 91.5 91.23
Neural Network 1 4179 5384 3682 353 497 5031 91.25 91.01 91.11
2 4077 5486 3587 349 490 5137 91.13 91.29 91.23
3 4141 5422 3742 340 399 5082 91.67 92.72 92.27
4 4133 5430 3681 375 452 5055 90.75 91.79 91.35
5 4162 5401 3701 355 461 5046 91.25 91.63 91.47
Na¨ıve Bayes 1 4744 4819 3717 318 1027 4501 92.12 81.42 85.94
2 4652 4911 3614 322 1038 4589 91.82 81.55 85.78
3 4746 4817 3755 327 991 4490 91.99 81.92 86.22
4 4676 4887 3702 354 974 4533 91.27 82.31 86.11
5 4769 4794 3773 283 996 4511 93.02 81.91 86.63
SVM 1 4241 5322 3775 260 466 5062 93.56 91.57 92.41
2 4128 5435 3640 296 488 5139 92.48 91.33 91.8
3 4220 5343 3768 314 452 5029 92.31 91.75 91.99
4 4190 5373 3742 314 448 5059 92.26 91.86 92.03
5 4239 5324 3769 287 470 5037 92.92 91.47 92.08
C45 Decision Tree 1 4333 5230 3685 350 648 4880 91.33 88.28 89.56
2 4165 5398 3590 346 575 5052 91.21 89.78 90.37
3 4370 5193 3715 367 655 4826 91.01 88.05 89.31
4 4308 5255 3689 367 619 4888 90.95 88.76 89.69
5 4353 5210 3706 350 647 4860 91.37 88.25 89.57
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Figure 5.9: Feature importance ranked by the mean decrease in accuracy when each
feature is excluded from the Random Forest model
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Figure 5.10: Feature importance ranked by the mean decrease in accuracy when each
feature is excluded from the Random Forest model
5.1.5 Comparison of Random Forest to other classifiers
Random Forest was the most accurate classifier in every fold (93.56-93.9% accuracy)
and was chosen to be compared against existing classifiers. The model used in the
3rd best fold was used (fold 3 or 4 both had 93.74 % accuracy) as this represented
the mean accuracy in terms of all 5 Random Forest models. The results for the test
set for each of these classifiers was collected as part of the feature extraction pipeline.
The score for each classifier, for each SNP in the test set was compared to the class
probability given by Random Forest and used to generate the ROC curve in Figure
5.11.
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Figure 5.11: ROC curve comparing the classifier from this thesis (black) to scores from
other classifiers when predicting disease/benign status on the humvar test set
Random Forest performed better than any of the other classifiers. Figure 5.12 shows
the specificity of each algorithm when the sensitivity is set to 95% (for algorithms
that could attain 95% sensitivity).
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Figure 5.12: Specificity plot of each algorithm when sensitivity is set to 95%. Only
algorithms that could achieve 95% sensitivity are presented
5.2 Functional Analysis of SNPs associated with
Epilepsy
The Clinvar dataset was queried for all SNPs found in genes that contain mutations
known to cause Epilepsy. Using the Clinvar clinical significance guidelines https://
www.ncbi.nlm.nih.gov/clinvar/docs/clinsig/, query terms ”Benign” were used
to identify non-pathogenic SNPs, and ”Pathogenic” were used to identify pathogenic
SNPs. In total 251 pathogenic and 50 benign SNPs were identified. Table 5.4 shows
which genes were selected when querying Clinvar.
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Table 5.4: Frequency table of genes associated with epilepsy sourced from Clinvar
Gene Count Gene Count Gene Count
SCN1A 153 CPA6 3 STX1B 2
KCNQ3 14 EPM2A 3 CACNA1H 1
EFHC1 13 PLPBP 3 CLN8 1
LGI1 10 POLG 3 DDHD2 1
CHRNB2 9 PRICKLE1 3 GABRA1 1
SCN9A 9 SCN1B 3 GABRB3 1
ALDH7A1 8 SPATA5 3 GAL 1
RELN 7 CHRNA2 2 GLDC 1
SLC2A1 6 CNTNAP2 2 KCNC1 1
CHRNA4 5 GABRG2 2 MRI1 1
MEF2C 5 KCNMA1 2 NACC1 1
SCARB2 5 KCNQ2 2 PRDM8 1
ST3GAL5 5 KCNT1 2
NHLRC1 4 SCN8A 2
Each SNP was used as input to the pipeline to collect they required features for
classification using the Random Forest classifier trained using the humvar dataset.
Each SNP was scored using Random Forest and figure 5.13 shows that Random
Forest achieved higher accuracy (92% accuracy, 93.2% sensitivity, and 86% specificity)
when compared to other commonly used prediction scoring algorithms. Figure 5.14
shows the specificity of each classifier when set to 95% sensitivity (for classifiers that
achieved at least 95% sensitivity), the confusion matrix in table 5.5 shows the overall
predicted results and table 5.6 how many pathogenic SNPs were predicted for each
gene.
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Figure 5.13: ROC curve comparing the classifier from this thesis (black) to rankscores
from other classifiers when predicting disease/benign status for SNPs found in genes
associated with epilepsy
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Figure 5.14: Specificity plot of each algorithm when sensitivity is set to 95%. Only
algorithms that could achieve 95% sensitivity are presented
Table 5.5: Confusion matrix for Random Forest classifier showing the number of
observed vs predicted classifications in 301 SNPs found in genes associated with
epilepsy.
Predicted
Observed Disease Polymorphism
Disease 236 15
Polymorphism 7 43
5.3 Summary of Results
Predicting the effect of SNPs is an essential part of bioinformatics analysis that allows
researchers to prioritize which SNPs should be analyzed using downstream processes in
a laboratory setting. Many existing prediction scoring systems achieve high accuracy,
but few offer both high sensitivity and specificity, as seen when comparing scoring
systems on the humvar dataset. Scoring systems are mostly built from machine
learning processes that use a variety of relevant protein features to train models, and
as such some systems specialize in predicting the effect or certain SNPs, such as
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Table 5.6: Comparison of true pathogenic SNPs and predicted pathogenic SNPs in
each gene
Gene True
Pathogenic
Predicted
Pathogenic
Gene True
Pathogenic
Predicted
Pathogenic
SCN1A 150 149 SCARB2 2 2
LGI1 10 10 SCN1B 2 2
ALDH7A1 8 7 STX1B 2 2
CHRNB2 7 7 CLN8 1 2
RELN 7 6 DDHD2 1 1
SLC2A1 6 6 EFHC1 1 1
MEF2C 5 5 EPM2A 1 1
CHRNA4 4 4 GABRA1 1 1
NHLRC1 4 3 GABRB3 1 1
SCN9A 4 3 GAL 1 1
CPA6 3 3 GLDC 1 1
PLPBP 3 3 KCNC1 1 1
POLG 3 3 KCNQ2 1 1
PRICKLE1 3 2 MRI1 1 1
SPATA5 3 2 NACC1 1 1
ST3GAL5 3 2 PRDM8 1 1
GABRG2 2 2 SCN8A 1 0
KCNMA1 2 2 CACNA1H 0 0
KCNQ3 2 2 CHRNA2 0 0
KCNT1 2 2 CNTNAP2 0 0
ultra-rare SNPs or SNPs found in certain regions such as ion channels.
The approach taken in this chapter incorporates as much knowledge from existing
scoring systems and commonly used features, as well as bespoke features derived with
the use of various bioinformatics software. The aim is to train a classifier to achieve
both high sensitivity and specificity in the capability to predict pathogenic SNPs. An
automated feature extraction pipeline was built to allow ease of use when processing
a large number of SNPs, as demonstrated during the classifier training process of
this chapter. Multiple machine learning techniques were explored and compared to
14 other commonly- used prediction software, in which the Random Forest classifier
trained in this study was able to achieve the highest accuracy amongst all prediction
software.
A comparison of existing prediction software and the Random Forest classifier was
also conducted for epilepsy specific SNPs, where an even larger increase in accuracy
over the existing software was seen. Various other disease specific studies report
reduced accuracy in SNP prediction using existing prediction software, which is
hypothesized to be the use of non-disease specific training sets used to train classifiers.
The results in this chapter show that epilepsy SNPs are also difficult to classify and
show reduced accuracy when compared to the humvar dataset. However, the large
increase in accuracy when compared to other software may be due to the inclusion of
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many different features from prediction software that may specialize in certain areas.
This could also possibly due to the inclusion of structural features in the training
set, where various SNPs that cause epilepsy occur in transmembrane proteins. In
conclusion, the classifier trained in this chapter performs better than commonly used
SNPs prediction software in a large non-disease specific SNP dataset, and performs
even better than prediction software in epilepsy specific SNPs.
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Chapter 6
Discussion
6.1 SAIL studies
The case studies presented in the first results chapter demonstrate the ability to
conduct powerful population level retrospective healthcare studies. Linkage of national
datasets such as those held within the SAIL Databank can be used to facilitate novel
studies in diseases such as epilepsy, where it is possible to measure the burden of
epilepsy in terms of both health and social outcomes. The most important aspect
of these results is the ability to define an accurate epilepsy cohort within the SAIL
databank so that further downstream research can take place. The validation study
to determine people with Epilepsy from GP records shows that data in SAIL can
be compared to gold standard external datasets to achieve higher sensitivity, and
arguably more importantly very high specificity to ensure only people with epilepsy
are used for further studies, and a clear control group can also be defined.
While much research in epilepsy rightly focusses on seizure control, the SAIL databank
can be used effectively to measure the social impact of living with epilepsy. It has
long been thought that people living with epilepsy often suffer in terms of social
deprivation because of factors such as employment and being able to hold a driving
license. These results were able to measure the prevalence and incidence of epilepsy
across all deciles of WIMD scores to which a strong trend of social deprivation and a
diagnosis of epilepsy was found. Importantly, the results were able to address the
question of social deprivation in terms of social drift or social causation by comparing
social deprivation at time of diagnosis to a 10 year follow up period in which it could
not be concluded that there is a strong trend in social drift following a diagnosis of
Epilepsy. It is findings such as these that can be valuable to patients with a new
diagnosis of epilepsy by giving some assurance that their diagnosis will not make
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much difference in terms of social status, while highlighting that extra support is
needed given the existing deprivation profile of people with epilepsy.
It is also possible to link electronic healthcare records held within SAIL to
administrative data sets such as the Department for Children, Education, Lifelong
Learning and Skills in Wales to measure not just the social impact of someone who has
epilepsy, but the educational outcomes of children born to mothers with epilepsy. The
results in this chapter show that mothers being prescribed sodium valproate during
pregnancy are observed to have children that have poorer attainment in national
school tests when compared to a control cohort. This result emphasizes why seizure
control is such a large research focus in epilepsy, but why it must also take into
account situations not limited to effective seizure control. Other UK studies and
audits have found that while sodium valproate prescribing is declining in women
of child bearing age, it still remains high given the already known risks of reduced
IQ and cognition of offspring exposed to sodium valproate inutero. These results
also add the social impact of epilepsy in school results of children born to mothers
with epilepsy, where it is clear these should be an increased focus on limiting sodium
valproate prescriptions for women thinking of having children.
There are however clear limitations in all of these studies, which mainly entail
important information not available form electronic health care records or linked
data, rather than small sample sizes. For example it is not possible to determine
the severity of epilepsy in the SAIL databank as it is often not recorded formal in
GP records, and while it is possible to ascertain what antiepileptic drug has been
prescribed to a patient, the exact daily dose is not recorded. The lack of some of
these variables means it is not possible explore the effects of poor seizure control
during pregnancy on cognitive outcomes of children, or to meausre the variance in
social deprivation of people with epilepsy in terms of their seizure control. Even
the definition of epilepsy found in GP records does accurately describe the type
of epilepsy, such as focal or generalised epilepsy, and so it is not possible to study
outcomes within sub-groups of people with epilepsy. To strengthen the impact of
linked healthcare data in epilepsy research, these data gaps must be addressed in
order to answer more nuanced research questions.
6.1.1 Social deprivation and epilepsy
The aim of this study was to investigate the relationship between social deprivation
of people diagnosed with epilepsy, in particular if high levels of deprivation of chronic
diseases such as epilepsy are due to social drift of social causation.
8,100,232 person years of healthcare records were used to calculated the prevalence
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and incidence of epilepsy in Wales and link them to the Welsh Index of Multiple
Deprivation. The overall epilepsy prevalence using a combination of epilepsy diagnosis
codes and AED prescriptions was 0.77% and incidence of 29.5/100 000 per year,
which is comparable with other studies in developed countries [253], [51], [254], [49].
By comparing the prevalence of epilepsy in each WIMD decile, a strong association
was shown between increased social deprivation as well as higher incidence of epilepsy.
Both prevalence and incidence are doubled in the most deprived population decile
compared to the least deprived decile (see table 3.5.
The increase in epilepsy incidence with increasingly deprived WIMD deciles initially
suggested that the cause of higher epilepsy prevalence in more deprived deciles would
be due to the movement from less deprived areas to more deprived areas following an
epilepsy diagnosis. However, the follow up cohort study supports the hypothesis that
the increased epilepsy prevalence in deprived areas is likely due to social causation
rather than social drift (see table 3.7). While the higher prevalence of parents with
epilepsy in deprived areas will inevitably produce more children with epilepsy, it
is possible that acquired or symptomatic may play a larger role than epilepsy of a
genetic origin in more deprived areas. It is difficult to obtain the cause of epilepsy in
the SAIL Databank (either genetic or acquired), but given that more deprived areas
have increased rates of risk factors for acquired epilepsy, such as perinatal hypoxic
injury, head trauma, and cerebrovascular disease [21, 52, 53] it is possible that living
in more deprived areas leads to an increased risk of developing epilepsy.
Similar results have been reported in both the UK and internationally. A retrospective
study in Wales found more patients with epilepsy living in deprived wards of residence
as measured by the Townsend index [50], and the incidence of epilepsy in a prospective
study across 20 GP practices in London and the South-East of England identified a
strong association between epilepsy incidence and deprivation when comparing the
Carstairs score between deprivation fifths, although the association was weaker inside
London [51]. Another prospective study using adults in Iceland found that poorer
socio-economic status is a risk factor for epilepsy [49].
Area level deprivation measures such as WIMD, Townsend and Carstairs score
have limitations in both geographical granularity, and modelling all possible factors
associated with social deprivation. As seen in the weaker deprivation effects found
in London and the the weaker correlation in the geographical representation of
major cities in Wales, area level deprivation is not entirely suitable to measure social
deprivation, and individual level deprivation scores would benefit these types of
studies. For example, it is possible in this study for two people living in the same
area to have the same deprivation score, but in reality they would have different
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”individual deprivation,” when considering more than geographic location, such as
ease of access to services and employment. Similarly for people developing epilepsy
in densely populated areas such as major cities, we might not expect to see much
movement and therefore the effects of social drift may appear weaker.
These results add further evidence to support the argument that social causation,
rather than social drift, could be responsible for an increase in higher social deprivation
of people with epilepsy. This provides the opportunity to identify risk factors for
epilepsy that could be targeted in areas of higher deprivation, as well as providing
further evidence of the health impact of living in socially deprived areas.
Further work remains however. The WIMD score is based on an LSOA level, and it
would be useful for future studies to study the effects of epilepsy on deprivation at
an individual basis. For example, two people living in the same LSOA will clearly
have different levels of social deprivation. There is potential however to link patient
records to earnings, benefits and tax records using the Administrative Data Research
Center https://adrn.ac.uk, which was set up to help researchers link healthcare
records with administrative data such as those held in the Department of Work and
Pensions. These data could potentially allow researchers to study how deprivation
changes following a diagnosis of epilepsy in more detail.
While it was possible calculate a measure of sensitivity 90.5% for the algorithm used
to determine epilepsy when comparing to patients in the Cardiff epilepsy register,
it was not possible calculate the specificity due to lack of a control group. The
prevalence of 0.77% provides an estimate of specificity, however a further work would
validate this algorithm by using a control group of people that are known to definitely
not have epilepsy. It would also be interesting to study the effects of epilepsy severity
on social deprivation. Epilepsy severity is not well recorded in GP records, and so
there needs to be a focus on enriching datasets routinely collected healthcare records
with more detailed information on disease status.
6.1.2 Validation of epilepsy algorithm using a gold standard
dataset
This study aimed to validate different algorithms for selecting people with epilepsy
using anonymous GP patient records. The previous deprivation study used
an algorithm that took into account epilepsy diagnosis codes and repeat AED
prescriptions which cases identified as epilepsy by the algorithm were compared
to the an epilepsy register with a gold standard diagnosis. This study used epilepsy
patients and patients that definitely did not have a diagnosis of epilepsy sourced from
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Morriston hospital to perform a sensitivity/specificity analysis of three algorithms:
Epilepsy diagnosis codes only, epilepsy diagnosis codes with a repeat AED prescription
and an AED prescription only.
The results showed that by using both epilepsy diagnosis codes with a repeat AED,
anonymised GP records can be used to accurately identify patients with epilepsy.
This algorithm achieved sensitivity and specificity 84%, 87%, 79% and 99%, 98%,
100% for all patients, adults and children respectively. These figures are comparable
with sensitivities and specificities from other epilepsy validation studies in different
healthcare systems e.g. Australian, Italian and American studies achieved sensitivities
of 82-90% and specificities of 94-100% [236], [237], [238]. The results also showed that
using a repeat AED prescription only may be the best approach when identifying
children with epilepsy as it achieved 98% for both sensitivity and specificty. This
algorithm would not be suitable for use on adults as it only achieved a specificity of
61%. This can be explained by the widespread use of AEDs for indications other than
epilepsy in adults (e.g. migraine, mood disorders and neuropathic pain). AEDs are
seldom prescribed for indications other than epilepsy in children in the UK [239].
There was little difference in performance between using just an epilepsy diagnosis
and both an epilepsy diagnosis and a repeat AED other than adding AEDs results
in slightly higher specificity / lower sensitivity. GP diagnosis codes for epilepsy
therefore seem reliable in their own right. Although this is expected, given that
epilepsy diagnosis should be made in secondary care in the UK and later transcribed
into the primary care record by GPs https://www.nice.org.uk/guidance/cg137,
this has not been described in the literature and is an important result for future
research involving GP epilepsy diagnosis codes. It would however be desirable to use
an algorithm that maximizes specificity when selecting patients from anonymized GP
records as it is a priority to be as certain as possible that someone identified with
epilepsy does indeed have epilepsy, especially so if a cohort of epilepsy patients were to
be compared against a control group for further study. Therefore using a repeat AED
in addition to an epilepsy diagnosis is the preferred algorithm for identifying epilepsy
in SAIL. Various reasons might include certain disorders such as non-epileptic attack
disorder that present almost identical symptoms to that of an epileptic seizure which
require detailed EEG examination to tell the difference. For EEGs to be accurate it
requires a seizure to occur during an examination, and so it is difficult to conduct
a thorough analysis, especially if seizures are infrequent, leading to some patients
taking years to have a confirmation of non-epileptic attacks while being treated with
AEDs.
The strengths of this study was that a gold standard dataset of patients with know
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epilepsy diagnosed by an epilepsy specialist was available as well as carefully selected
patient records for patients that definitely did not have epilepsy. These data provided
a robust validation of the three algorithms which could immediately be used to identify
many epilepsy cases from the 2.8 million people with an anonymized GP patient
record in SAIL. Although the reference population was of gold standard, it was a
relatively small population due to the resources needed to manually check medical
records and test results. Also, these results are specific to primary care records in
Wales and are not applicable to other healthcare systems or methods of ascertaining
epilepsy cases (for example hospital discharge summaries). Other parts of the UK
do have similar healthcare systems and although the results may be generalizable
to the remainder of the UK further work needs to be done to prove this. Currently
there is no facility to include EEG and imaging data within SAIL and so we could
not include these in our ascertainment algorithms. Additionally it is impossible to
identify people with epilepsy who do not attend their GP or have not been seen by a
hospital specialist.
The reference epilepsy cohort was obtained from a secondary care epilepsy database
which may have provided a bias towards people with more severe epilepsy, and
thus more likely for an epilepsy diagnosis to be recorded in GP records. Also the
group of people without epilepsy were sourced from patients who had attended
general neurology clinics as a control group. This group therefore does not represent
the ’general’ population without epilepsy. However, this group of patients may
be considered as a ’better test’ of ascertainment algorithms as patients with other
neurological conditions may be more likely to be incorrectly coded as having epilepsy
than the general population. Conversely it is also possible (although unlikely in
our opinion) that neurologists would not record a diagnosis of epilepsy in a general
neurology clinic appointment with a different focus (e.g. headache).
6.1.3 Educational attainment of children born to mother’s
with epilepsy
This study aimed to compare the educational attainment of children born to mothers
with epilepsy to a control group, with a particular focus on which AEDs mothers
took during pregnancy. This study used Key Stage 1 results for mathematics, science
and English/Welsh, a national school assessment for 2,196 children (440 with epilepsy,
1,756 control) at 7 years of age between 2003 and 2008 academic years.
The results showed an association between poorer school attainment and children
exposed to valproate or AEDs in combination inutero. Compared with a matched
control group, fewer children with mothers being prescribed sodium valproate during
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pregnancy achieved the national minimum standard in CSI (-12.7% less than the
control group), mathematics (-12.1%), language (-10.4%) and in science (-12.2%).
Even fewer children with mothers being prescribed multiple AEDs during pregnancy
achieved a national minimum standard: CSI (by -20.7% less than the control group),
mathematics (-21.9%), language (-19.3%) and science (-19.4%)
The results support previous studies that provide consistent evidence that inutero
exposure to sodium valproate and AEDs in combination are linked to adverse
neurodevelopmental outcomes. In contrast there was no difference seen in children
exposed to carbamazepine, lamotrigine or mothers that did not take drugs during
pregnancy, however it is impossible to accurately test for significance in the lamotrigine
group as the sample size is small. While mothers not prescribed any AED during
pregnancy do not appear to give birth to children that have decreased educational
attainment, it is possible that this group of women have less frequent seizures,
thus reducing the risks to the unborn child associated with exposure to seizures
inutero.
Other studies have also studied the effect of intuero exposure to sodium valproate
and the effect on children’s IQ. The NEAD study found a 9-point decrease in IQ in
children at 3 and 6 years old who were born to mothers taking sodium valproate during
pregnancy [27, 243] as well as decreased motor, emotional and behavioural/adaptive
functioning in children at 3 years old [255]. Studies based on the UK Epilepsy and
Pregnancy Register have associated sodium valproate with a decrease in cognitive
development and early cognitive delay that suggests children are at a disadvantage
well before school age [32, 256]. While this study finds a statistically non-significant
trend in language at KS1, other studies have shown decreased language and verbal
skills at early infant stage [257, 258]. Some of the studies mentioned have found
that increased AED dosage plays a part in cognitive impairment, however due to a
lack of dosage information in the SAIL databank this could not be explored. While
some of the mentioned studies associate exposure to carbamazepine with some forms
of cognitive impairment, there are also studies that suggest carbamazepine has no
effect on intelligence; these results supports the latter with no evidence of decreased
educational attainment at school age [259].
The strength of this study is the ability to select a large cohort of 440 children with
national test results without major recruitment bias and compare to a large control
group. Using a standardized national assessment as a measure of performance ensures
that each child has the opportunity to be assessed based on the same curriculum,
and as such these results would closer reflect the learning experience of children at
this age compared to an IQ test. The main limitation of these results are not being
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able to use maternal intelligence quotient (IQ) as a covariate as in [27, 243], which
are not recorded in the SAIL databank.
The SAIL Databank also lacks information on various other potential covariates such
as epilepsy severity and seizure frequency during pregnancy which may effect cognitive
function of unborn child, or if the mother was taking folic acid during pregnancy
as this is available ”over the counter”. The AED data was based on prescriptions,
and so it is impossible to comment on adherence, however there is no reason to
suspect that adherence differs greatly between different AEDs. It is also possible that
mothers with poorly controlled seizures may have an effect on their child’s education
in terms of parental support outside of school settings, but this information is difficult
to ascertain and is not available to any comprehensive standard within the SAIL
databank. Another limitation of this study is that we are unable to report on AED
dosage, although other studies have reported significant cognitive impairment even at
low dosages of sodium valproate.
While these results highlights the risk of cognitive effects in the children of mothers
prescribed sodium valproate or multiple AEDs, it is important to acknowledge that
some epilepsies are difficult to treat without these treatment regimes. Despite this,
these results add to the growing evidence that inutero exposure to certain AEDs can
cause developmental problems in children, to which sodium valproate has recently
been banned for use in women of child bearing age unless a pregnancy prevention
programme is in place https://www.gov.uk/guidance/valproate-use-by-women-
and-girls.
6.2 Natural Language Processing of epilepsy
clinic letters
This study aimed to validate an NLP algorithm developed to extract epilepsy specific
information from unstructured clinic letters. A rules-based system was built using
an open source NLP framework to extract details of epilepsy diagnosis, seizure type,
seizure frequency, status of EEG, MRI and CT investigations. The main purpose of the
NLP algorithm is to enrich routinely collected data sets such as those demonstrated
in the previous chapter using the SAIL databank.
The algorithm was able to extract epilepsy information from a corpus of 200 clinic
letters, written by 6 different clinicians, with an overall precision, recall and F1
score of 91%, 81% and 85% on a per item basis. As expected, the algorithm
performed best in extracting clinic date and date of birth (F1 scores of 98% and
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99%) given that these fields consist of fixed format dates which are relatively easily
to extract. In terms of epilepsy-specific information the algorithm performed best
for medication (F1=95%), confirming a diagnosis of epilepsy (93%), epilepsy type
(84%) and presence of focal seizures (81%). These items are frequently mentioned
and presented in a relatively standard format e.g. medication is usually stated as
drug name-strength-unit-frequency, and diagnosis appears at the top of letters in
structured lists with or in text with clear references to the patient such as ”she has
focal epilepsy” or ”her current medication is” within the main text.
For example, a letter may confirm temporal lobe epilepsy three times but only one
mention of temporal lobe epilepsy is required to correctly classify that person’s
epilepsy. In this context extracting only one mention of temporal lobe epilepsy is just
as useful as extracting all three. In the ”per letter” test we, therefore, aggregated
multiple mentions within a category in each letter to a binary decision based on the
algorithm’s ability to extract at least one true positive mention. In the above example
if the algorithm had only correctly identified one of the three mentions of temporal
lobe epilepsy we would have scored it as having a recall of 100% on a per letter basis
but only 33% (1/3) on a per item basis. For the medication annotation, in the per
letter approach, only a full list of the drugs prescribed with the respective doses was
considered to be a positive outcome.
The algorithm was less accurate in identifying CT (57%), MRI (75%) and EEG
results (78%), seizure frequency (66%) and generalised seizure terms (66%). The two
main reasons for not picking up such terms were due to mapping issues to UMLS, or
the highly varied ways these terms are reported in clinic letters. For example, UMLS
contains terms such as, ”EEG with irregular generalized spike and wave complexes”,
however, it is often the case that when reported in text there are variety of words
between the EEG and the finding e.g. ”EEG was found to show generalized spike
and wave complexes” or ”There was no evidence of generalised spike-wave complexes
when reviewing her EEG”, and so this problem was approached by creating custom
gazetteers that map to smaller terms such as ”spike and wave” or ”EEG”, and writing
JAPE rules to associate the finding with the EEG. Similarly the reporting of seizure
frequency is highly varied e.g. ”she had 5 seizures since March last year” or ”1-2
focal seizures every evening”. Seizure frequency is also often reported with terms
such as ”events” and ”episodes” rather than defined seizure types, hence additional
JAPE rules were built to accommodate such terms as part of seizure frequency in the
presence of an epilepsy diagnosis.
Although every item in a letter was compared to that of a clinician, it is practical to
provide a binary decision for some categories. If epilepsy is confirmed 3 times in a
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letter, the important information is that epilepsy is confirmed. For this reason the
”per letter” score was developed where if 1 true positive for a epilepsy confirmed,
epilepsy type, seizure type or abnormal/normal investigation, then the ”per letter”
score was given a true positive finding by the algorithm. The basis for this decision
boundary is based on the high precision of the ”per item” score, where there is high
confidence a positive identified by the algorithm is a true positive. The ”per letter”
score achieved higher scores for precision, recall, and F1-score (96%, 87%, 91%) on a
per letter basis. The ”per letter” approach for categories containing multiple mentions
could be used with higher confidence than on an individual mention basis, as well as
providing a practical way to summarise information from clinic letters. Additionally
a ”per person” measure (results summarised over several letters) could be used to
determine epilepsy status as there will normally be several letters per person over a
period of time.
Other studies demonstrate that NLP is being increasingly used for clinical information
extraction purposes [260]. Performance of specific phenotype extraction algorithms
developed as part of the i2b2 project using cTAKES (Apache clinical Text Analysis
and Knowledge Extraction System) and HITex (Health Information Text Extraction)
showed that for an NLP approach high PPV (precision) and sensitivity (recall)
was achieved for extracting the following phenotypes; Crohn’s disease (98%,64%),
Ulcerative Colitis (97%,68%) , MS (94%,68%), and Rheumatoid arthritis (89%,56%)
[139]. As we aimed to extract epilepsy specific information other than a confirmed
diagnosis, a recent study on patients with known MS identified from electronic
healthcare records used NLP techniques to extract attributes specific to MS with high
PPV and sensitivity, namely EDSS (Expanded Disability Status Scale) (97%,89%),
T25FW (Timed 25 Foot Walk) (93%,87%), MS subtype (92%,74%) and age of onset
(77%,64%) [140]. This study took into account items attributable only to the patient,
as opposed to family members, which is an important distinction and interesting area
of study in terms of identify potential risk factors for disease development. A study
used clinic letters available at www.mtsamples.com to determine whether sentences
containing disease and procedure information were attributable to a family member
using the BioMedICUS NLP system, which achieved and overall precision, recall and
F1-score of 91%, 94% and 92% [141].
There are however only a few published studies of clinical epilepsy information
extraction systems. Cui et al developed the rule based Epilepsy Data Extraction
and Annotation (EpiDEA) system which extracts epilepsy information from epilepsy
monitoring unit discharge summaries. EpiDEA achieved an overall prevision, recall
and F1 score of 94%, 84% and 89% when extracting EEG pattern, past medications
and current medication from 104 discharge summaries from Cleveland, USA [143].
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Cui et al also developed the rule-based Phenotype Exaction in Epilepsy (PEEP)
pipeline [144]. PEEP extracted epileptogenic zone, seizure semiology, lateralising
sign, interictal and ictal EEG pattern with an overall precision, recall and F1 score
of 93%, 93% and 92% in a validation set of 262 epilepsy monitoring unit discharge
summaries from Cleveland, USA. Sullivan et al used a machine based learning NLP
pipeline to identify a rare epilepsy syndrome from discharge summaries and EEG
reports in Phoenix USA and achieved a precision, recall and F1 score of 77%, 67%
and 71% respectively.
The main strength of this study was the use of a gold standard dataset of de-identified
clinic letters to accurately extract novel data types from free texts that are not well
populated in electronic healthcare records. The algorithm was built using open source
technology so that the algorithm is easily shareable and can be run on potentially
millions of letters as NLP tasks can be parallelism. The algorithm was able to make
use of two open source plugins that have been used for information extraction tasks
previously, as well as widely used medical ontologies that produce easily interpretable
annotations that can be adopted for healthcare research [261] [244]. The algorithm
was developed to extract epilepsy specific information, however this aim was met
by filtering out non-disease specific information. It is possible that the algorithm
could be adapted for other diseases with relative ease and many rules were built to
capture language rules in general, not just medical item tagging. These rules could be
adapted for more nuanced tasks such as finding frequency of events such as depressive
episodes or migraines. Another advantage was that all rules are programmed in a
relatively simple scripting language (JAPE) where other NLP systems rely heavily on
the ability to program in more complicated languages such as Java. For this reason it
is possible that clinicians themselves are more likely to participate in writing their
own rules and embed medical expertise more readily into the algorithm or algorithms
developed in future, for example adding in custom dictionaries for colloquial terms or
coding a particular phrase that is meaningful when reported in clinic letters.
The main limitation of this study was the sample size of letters used to develop and test
the algorithm. This is a limitation across many NLP tasks that focus on information
extraction as it is labour intensive to manually annotate letters in the detail required
to develop information extraction systems. Most information extraction systems
typically use hundreds of letters rather than thousands. However even though this
study only used 200 letters to test the accuracy of the algorithm, 1925 individual
items were compared to those of an epilepsy specialist. Another limitation was the
use of one specialist to annotate the letters used for comparison, where it is possible
that annotations are affected by reviewer fatigue, and it was not possible to produce
an inter-annotation agreement score if multiple clinicians annotated the letters. The
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address this a review of all letters that contained a disagreement between the human
annotations and the algorithm annotations (174 letters out of the 200 letters) was
conducted. The review showed that indeed the human annotator errors tended to be
missing true positive items, which at first lead to a higher number of false positives
produced by the algorithm where the human annotator corrected their annotations.
In future multiple specialists are recommended for information extraction tasks.
While existing medical ontologies were used to tag items in the clinic letters, and
rules were built to arrange which particular order of tagged terms describes a concept,
medical ontologies such as UMLS, SNOMED-CT, READ and ICD were not built
to aid information extraction from clinical free texts. Many descriptions of codes
in these ontologies are too structured to reflect the language used in clinic letters
and thus reduces recall in information extraction tasks. It is however important
to produce annotations that adhere to existing medical ontologies, and so future
work to address this would include developing methods to add some flexibility when
matching terms in clinic letters to ontology descriptions. Much work has been done
in so called ”fuzzy matching” where sequences of words called ”n-grams” are mapped
to each other using word-vectorization and similarity measures [125] [262] [263]. Also
it would be interesting to incorporate machine learning classification tasks where
detailed information extraction is not needed. For example it might be possible to
use machine learning to classify EEG reports as either normal or abnormal, without
worrying about extracting every item that may indicate abnormalities.
6.3 Predicting pathogenicity of SNPs for large
datasets
This study aimed to understand the different approaches for predicting pathogenicity
of SNPs and to build a pipeline that sources a variety of SNP annotation and scoring
data that is used to build an accurate classifier for SNPs. Many existing software have
significantly better sensitivity that specificity, or vice-a-versa, and some specialize in
capturing rare pathogenic variants or variants found within certain protein domains
such as transmembrane regions. Most classifiers are non-disease specific, but some
studies have shown that the accuracy reported on non-disease specific test sets are
not matched in some disease only test sets. As well as building a non-disease specific
SNP classifier, the classifier was also built to accurately classify epilepsy SNPs.
The results in this study showed that by using a mixture of common SNP annotations
such as conservation scores, existing software scoring systems and bespoke features
such as secondary structure prediction, the Random Forest classifier was able to
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score higher than all of the highest performing software currently available on both a
non-disease specific dataset as well as showing a further increase in accuracy when
using an epilepsy dataset. The classifier also achieved both high sensitivity and
specificity, which some classifiers achieved high sensitivity or specificity. Constructing
a ROC curve and using the class probability of predictions allowed the Random
Forest classifier to be compared at different sensitivity thresholds to compare the
corresponding specificity across all other classifiers, in which at a sensitivity threshold
of 95%, the Random Forest classifier achieved 97% specificity which was higher than
the closest classifier, REVEL (92% specificity). Six different classifiers were compared
during the development phase using a 5-fold cross validation coupled with feature
selection techniques to try and improve the accuracy of each algorithm. Internal
parameters of the classifiers were also tuned to achieve higher accuracy, although this
did not have much of an effect. It was interesting that aside from using the Naive
Bayes classifier, many of the algorithms showed higher accuracy than any of the other
existing classifiers used for comparison. This suggests that the samples in the training
set and the features used in the training process many have play more of a role in
classification accuracy than a difference in choosing different classifiers.
Prediction accuracy of new software as presented in their original publications state
high accuracy in non-specific disease datasets such as Humvar, but often vary in
accuracy when used for a particular disease. Given that researching a specific disease
is a common use case of research groups, it is important to know that the accuracy
stated for an algorithm is not expected to be reproduced in other datasets. A study
that compared the prediction accuracy of 17 different classifiers on SNPs in limb-girdle
muscular distrophy (LGMS) showed that the Polyhen Humvar classifier achieved just
70.2% accuracy where in the Polyphen paper an accuracy of 86% is stated, with a
similar trend for the majority of the other classifiers used in the comparison [264]. A
study that selected 23 genes associated with immunity compared PolyPhen2, SIFT,
MutationAssessor, Panther, CADD, and Condel classifiers in which only 20% of
pathogenic SNPs were predicted as such, and over 45% of neutral SNPs were classified
as pathogenic [265]. A larger non-disease specific study using 40,000 variants from
the Phencode and dbSNP databases found that accuracy ranged from 15-65% across
MutPred, nsSNPA-nalyzer, Panther, PhD-SNP, PolyPhen, PolyPhen2, SIFT,SNAP,
and SNPsGO [266].
There have been various studies which have explored creating disease specific classifiers
that have reported higher accuracy than non-disease specific classifiers. A cancer
specific machine learning based classifier was developed using common SNP annotation
for 6326 missense SNPs that are known to be drivers for various subtypes of cancer,
achieving 93% accuracy [267]. Machine learning classifiers that dominate SNP
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prediction require large datasets with many features, in which there are not enough
pathogenic SNPs in the majority of individual disease areas to train a classifier by
using only damaging SNPs in the disease of interest. This is certainly true for epilepsy,
and as such the approach taken was to include many features other than traditional
conservation scores. Some of the prediction scores used in the classifier include
features that specify which protein domain a SNP is found in such as transmembrane
or ion channel regions as well as incorporating the predicted secondary structure of
the SNP location as well as modelling the difference in predicted secondary structures
between sequences containing the wild type and the SNP. Many pathogenic SNPs in
genes associated with epilepsy such as SCN1A are located in ion channels, where any
structural change in these channels can effect cellular excitability and induce seizures
[268]. It is possible that some features used in the RF classifier are able to contribute
towards improving classification accuracy in epilepsy related SNPs.
6.3.1 Use of existing predictors as features
Including the prediction and scores of existing software as a feature for machine
learning purposes is not a novel idea. Earlier attempts to improve classification
accuracy when relatively few prediction software existed involved combining these
scores and weighting them into a single score using a statistical approach. The
Combined Annotation scoRing toOL (CAROL) normalizes polyphen and SIFT scores
by their standard normal deviations to achieve a 1% increase on that of their respective
scores using a test set of 1,959 pathogenic and 9,691 neutral SNPs [269].
6.3.2 Use of physiochemical properties and predicted
secondary structure
Most SNP prediction programs that use secondary structure as features obtain this
information from known protein databases and uses the secondary structure status
where the SNP is located as reported in the wild type protein. Querying secondary
structure in this manner produces many missing data as only a proportion of proteins
have been studied and had their secondary structure profile reported. This study
used secondary structure prediction to obtain a predication of the secondary structure
for every SNP, and modelled the difference in prediction between wild type and SNP
sequences. These differences were reported as the percentage change across three
secondary structure domains, in which they were ranked as the 5th, 9th and 10th
most important features (out of 47 features) used in the Random Forest model.
It is difficult to define ”difference in secondary structure” between a wild type sequence,
and a sequence containing a SNP. The secondary structure of both sequences are
166
predicted, not measured in a laboratory. The only thing that can be measured using
PSIPRED is the likelihood of a single amino acid falling into the three categories of a
beta sheet, alpha coil or helix. While this may be useful, particularly in some strict
complexes of a protein, it is actually not important to this pipeline to determine what
the effect of a SNP may have on a predicted secondary structure category. Firstly
this is because it is not feasible to determine such a change for a SNP via prediction
only, but mainly that the underlying methodology to secondary structure prediction
is similar to sequence homology and evolutionary analysis of proteins - methods that
already play a prominent role in functional prediction programs. Secondary structural
prediction programs are extensions of multiple sequence alignments, where known
secondary structures are incorporated later as a ground truth to assess structure
based on these alignments. It is this inference between multiple sequence alignments
and the disparity in structural prediction between a wild type sequence and a SNP
sequence that is important.
6.4 Future Work
The SAIL case studies in this thesis showed that epilepsy patients can accurately
be determined from GP records. The algorithm developed could be used to create
an epilepsy register within the SAIL databank to facilitate further epilepsy research
and be used in multiple studies. These studies have shown that socio-economic and
national education datasets can be linked to epilepsy patients. One future project
would be to link the educational outcomes of children who have epilepsy compared to
a control group or other neurological conditions. It could be possible to study sub
groups of children by taking into account what prescriptions they were taking during
the school year.
There are limitations, however to the SAIL databank. Rich information found in
clinic letters were largely absent from rountinely collected healthcare records. The
next step would be to use the validated NLP application developed in chapter 4
to link rich epilepsy data from clinic records to the SAIL databank. This would
require producing a version of the NLP application that could run on distributed
systems. The lack of clinic letters available for NLP studies due to patient identifiers
present is a major limitation that is not reflected with the SAIL databank. Forming
a governance model to analyse identifiable patient data would be an important future
project to help facilitate NLP research. Another barrier is not only the lack of clinic
letters, but the lack of letter annotation by a clinician. Every NLP algorithm needs
to be scored against a human annotator, and generating annotated training sets
requires a lot of time. With crowd sourcing becoming popular it may be possible
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to open up annotation tasks to a wider participation group through crowd sourcing
platforms.
Some categories of information from the NLP chapter were difficult to obtain
accurately. Seizure frequency is an important piece of information that provides a
level of severity of epilepsy, and would be an important covariate in an epilepsy study.
The language describing seizures frequency and investigation reports remain to varied
to capture all of the nuances with a rule based approach. Machine learning is one way
to add flexibility into capturing these categories, and one immediate improvement
would be to create methods of matching short phrases and slang terms to UMLS
concept descriptions so that NLP applications aren’t relying on exact phrase matching.
Much work has been done on word embeddings to infer semantic similarity of words,
however some future work in this area could expand this to phrases.
SNP prediction tools are numerous and show effectiveness in different disease areas.
The pipeline developed in chapter 6 successfully incorporated existing SNP prediction
tools as features alongside bespoke protein features to produce higher accuracy than
all common SNP scoring tools in a disease non-specific dataset as well as epilepsy
specific SNPs. With advances in technology powering big data, accurate tools will
become an increasingly important tool in prioritising which SNPs warrant further
research/ Future work would be to set up the pipeline developed as a web service
to be used freely for research. This could help laboratories focus on building assays
for a smaller group of SNPs. The pipeline could also be used to prioritise SNPs
that may be linked to the SAIL databank. The ability to identify patients with
certain conditions and co-morbidities and link them to SNPs may allow researchers
to discover associations between SNPs and disease. Future work will include linking
exomes and genomes from Welsh patients collected as part of the Wales Epilepsy
Research Network to the SAIL databank. These patients have well defined epilepsy
genotypes and it would be interesting to explore any potential trends in co-morbidities
within subgroups of epilepsy syndromes such as exploring if different SNPs for the
same epilepsy syndrome have a a higher propensity form experiencing co-morbidities
such as migraines.
6.5 Conclusions
Epilepsy is a common disease that can have an impact on health and social well
being. Epilepsy can also affect family members such as children born to parents with
epilepsy. Advances in big data have provided the opportunity to explore the impact
of epilepsy on at population levels to uncover trends in healthcare data for people
with epilepsy where insufficient data previously existed.
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The SAIL Databank not only provides national healthcare datasets, but it also
socio-economic and administrative datasets that can all be linked anonymously. Data
linkage is a powerful tool that allows datasets to be aligned to produce novel research,
and the ability to do so anonymously speeds up research in terms of using a governance
model that is exempt from ethical approval. A study using 8.1 million person-years of
data was used to identify a strong trend between increased social deprivation and the
incidence and prevalence of epilepsy. The study found that increased deprivation was
likely to due to social causation rather than social drift. This finding was contrary to
other studies that suggest chronic conditions such as epilepsy cause social drift after
diagnosis.
A study of GP coding habits showed that it is possible to use GP records as a data
source for identifying patients with epilepsy to be used for epidemiology studies. An
algorithm was developed that found a combination of repeat AED prescriptions and a
diagnosis of epilepsy was the most effective way to identify epilepsy from GP records,
which gave 88% sensitivity and 98% specificity. This algorithm was used to select
mother’s with epilepsy who had children with Key Stage 1 education data to compare
attainment between a large control group. This study found that for children exposed
to sodium valproate or a combination of AEDs inutero there was a 12.7% and 19.8%
decrease in attainment when compared to the control group.
Each SAIL study showed that there were various limitations in the data i.e. not having
epilepsy type or AED daily dose. The Natural Language Processing study showed
that there is potential to source rich patient information that is typically missing
from routinely collected data. A validation of 200 epilepsy clinic letters showed that
a rule-based NLP application can accurately identify patients with epilepsy (88.5%),
epilepsy type (84.5%) and prescriptions (95%). Other categories such as seizure
frequency and investigation outcomes were more difficult to capture, however high
specificity is reported across all categories. Aggregating all mentioned per category per
letter achieved even higher accuracy and would be a practical approach to analysing
large volumes of letters.
A SNP prediction pipeline was developed using the Random Forest machine learning
classifier to determine the pathogenicity of SNPs. Validation on a large disease
non-specific SNP dataset showed that the Random Forest classifier produced more
accurate results than all other commonly used SNP prediction software, and was able
to achieve 95% sensitivity with a specificity of 92%. The classifier also achieved the
highest accuracy on a dataset of 301 SNPs reported in epilepsy genes, and confirms
findings in other studies than disease specific SNP datasets can pose a more difficult
challenge in terms of predicting SNP pathogenicity.
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Appendices
Appendix item 1: Read codes used for epilepsy definition
Table 6.1: Read codes used to signify a diagnosis of epilepsy.
Code Description Code Description
F25B. Alcohol-induced epilepsy F25y2 Localisation related epilepsy
F25y4 Benign Rolandic epilepsy F25D. Menstrual epilepsy
F2545 Complex partial epileptic seizure F2511 Neonatal myoclonic epilepsy
F25y3 Complex partial status epilepticus 667B. Nocturnal epilepsy
F25y0 Cursive (running) epilepsy F25y. Other forms of epilepsy
F25C. Drug-induced epilepsy F25yz Other forms of epilepsy NOS
F259. Early infant epileptic encephalopathy
wth suppression bursts
F251y Other specified generalised convulsive
epilepsy
F25.. Epilepsy F250y Other specified generalised
nonconvulsive epilepsy
1O30. Epilepsy confirmed F25y5 Panayiotopoulos syndrome
F25z. Epilepsy NOS F254. Partial epilepsy with impairment of
consciousness
F2544 Epileptic automatism F254z Partial epilepsy with impairment of
consciousness NOS
F2503 Epileptic seizures - akinetic F255. Partial epilepsy without impairment of
consciousness
F2502 Epileptic seizures - atonic F255z Partial epilepsy without impairment of
consciousness NOS
F2512 Epileptic seizures - clonic F255y Partial epilepsy without impairment of
consciousness OS
F2513 Epileptic seizures - myoclonic F2500 Petit mal (minor) epilepsy
F2514 Epileptic seizures - tonic F252. Petit mal status
F25y1 Gelastic epilepsy F25F. Photosensitive epilepsy
F251. Generalised convulsive epilepsy F258. Post-ictal state
F251z Generalised convulsive epilepsy NOS F2541 Psychomotor epilepsy
F250. Generalised nonconvulsive epilepsy F2542 Psychosensory epilepsy
F250z Generalised nonconvulsive epilepsy NOS F2501 Pykno-epilepsy
F2510 Grand mal (major) epilepsy F2561 Salaam attacks
F2516 Grand mal seizure F2551 Sensory induced epilepsy
F253. Grand mal status F2556 Simple partial epileptic seizure
F2560 Hypsarrhythmia F2552 Somatosensory epilepsy
F256z Infantile spasms NOS F25E. Stress-induced epilepsy
F2504 Juvenile absence epilepsy F2515 Tonic-clonic epilepsy
F25A. Juvenile myoclonic epilepsy SC200 Traumatic epilepsy
F257. Kojevnikov’s epilepsy F2555 Unilateral epilepsy
F2505 Lennox-Gastaut syndrome F2553 Visceral reflex epilepsy
F2543 Limbic system epilepsy F2554 Visual reflex epilepsy
Code Description Code Description
dn3e.* ARBIL MR 200mg m/r tablets dnp7. LYRICA 300mg capsules
dn3f. *ARBIL MR 400mg m/r tablets dnp2. LYRICA 50mg capsules
dn2.. *BECLAMIDE dnp3. LYRICA 75mg capsules
dn2z. *BECLAMIDE 500mg tablets dn6.. METHYLPHENOBARBITAL
dnc1. *CLOBAZAM SLS 10mg capsules dn6z. METHYLPHENOBARBITONE 200mg
tablets
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Table 6.2 AED Read codes — Continued . . .
Code Description Code Description
do1z. *DIAZEPAM 20mg/4mL injection dn6x. METHYLPHENOBARBITONE 30mg
tablets
do1B. *DIAZEPAM 20mg/5mL RecTubes dn6y. METHYLPHENOBARBITONE 60mg
tablets
dn53. *EMESIDE 250mg capsules dna1. MYSOLINE 250mg tablets
dn3A. *EPIMAZ 100mg tablets dna2. MYSOLINE 250mg/5mL oral
suspension
dn3B. *EPIMAZ 200mg tablets dna3. MYSOLINE 50mg tablets
dn3C. *EPIMAZ 400mg tablets dnj4. NEURONTIN 100mg capsules
dn51. *ETHOSUXIMIDE 250mg capsules dnj5. NEURONTIN 300mg capsules
dn52. *ETHOSUXIMIDE 250mg/5mL elixir dnj9. NEURONTIN 300mg capsules/600mg
tablets titration pack
dn5y. *ETHOSUXIMIDE 250mg/5mL elixir dnj6. NEURONTIN 400mg capsules
dn79. *GARDENAL 200mg/1mL injection dnj7. NEURONTIN 600mg tablets
dn7a. *LUMINAL 15mg tablets dnj8. NEURONTIN 800mg tablets
dn7b. *LUMINAL 30mg tablets dng2. NOOTROPIL 1.2g tablets
dn7c. *LUMINAL 60mg tablets dng3. NOOTROPIL 33
dn21. *NYDRANE 500mg tablets dng1. NOOTROPIL 800mg tablets
dnba. *ORLEPT 200mg e/c tablets dnbA. ORLEPT 200mg/5mL sugar free liquid
dnbb. *ORLEPT 500mg e/c tablets dnb9. ORLEPT STARTER PACK 200mg e/c
tablets x10
do52. *PARALDEHYDE injection 10mL dnm.. OXCARBAZEPINE
do51. *PARALDEHYDE injection 5mL dnmx. OXCARBAZEPINE 150mg tablets
dn98. *PENTRAN 100mg tablets dnmy. OXCARBAZEPINE 300mg tablets
dn97. *PENTRAN 50mg tablets dnmz. OXCARBAZEPINE 600mg tablets
dn63. *PROMINAL 200mg tablets dnmw. OXCARBAZEPINE 60mg/mL sugar
free oral suspension
dn61. *PROMINAL 30mg tablets do5.. PARALDEHYDE
dn62. *PROMINAL 60mg tablets dn7.. PHENOBARBITAL
do13. *STESOLID 20mg/4mL injection dn74. PHENOBARBITAL 100mg tablets
dn3H. *TERIL CR 200mg m/r tablets dn71. PHENOBARBITAL 15mg tablets
dn3I. *TERIL CR 400mg m/r tablets dn7d. PHENOBARBITAL 15mg/5mL elixir
dn55. *ZARONTIN 250mg capsules dn78. PHENOBARBITAL 200mg/1mL
injection
dn1y. ACETAZOLAMIDE [EP] 250mg tablets dn72. PHENOBARBITAL 30mg tablets
dn1z. ACETAZOLAMIDE [EP] 500mg
injection
dn73. PHENOBARBITAL 60mg tablets
dn1x. ACETAZOLAMIDE [EP] 500mg m/r
capsules
dn77. PHENOBARBITONE 15mg/10mL
elixir
dn1.. ACETAZOLAMIDE [EPILEPSY] dn75. PHENOBARBITONE SODIUM 30mg
tablets
do41. ATIVAN [EP] 4mg/mL injection dn76. PHENOBARBITONE SODIUM 60mg
tablets
dn3J. CARBAGEN SR 200mg m/r tablets dn8.. PHENYTOIN
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Code Description Code Description
dn3K. CARBAGEN SR 400mg m/r tablets dn92. PHENYTOIN 100mg tablets
dn3.. CARBAMAZEPINE dn8y. PHENYTOIN 30mg/5mL suspension
dn3y. CARBAMAZEPINE 100mg chewable
tablets
dn83. PHENYTOIN 50mg chewable tablets
dn31. CARBAMAZEPINE 100mg tablets dn91. PHENYTOIN 50mg tablets
dn3z. CARBAMAZEPINE 100mg/5mL sugar
free liquid
dn8z. PHENYTOIN 90mg/5mL sugar free
suspension
dn3v. CARBAMAZEPINE 125mg
suppositories
dn9.. PHENYTOIN SODIUM
dn3x. CARBAMAZEPINE 200mg chewable
tablets
do6.. PHENYTOIN SODIUM [STATUS
EPILEPSY]
dn3a. CARBAMAZEPINE 200mg m/r tabs dn9z. PHENYTOIN SODIUM 100mg
capsules
dn32. CARBAMAZEPINE 200mg tablets do6z. PHENYTOIN SODIUM 250mg/5mL
injection
dn3w. CARBAMAZEPINE 250mg
suppositories
dn9x. PHENYTOIN SODIUM 25mg caps
dn3b. CARBAMAZEPINE 400mg m/r tabs dn9w. PHENYTOIN SODIUM 300mg
capsules
dn33. CARBAMAZEPINE 400mg tablets dn9y. PHENYTOIN SODIUM 50mg capsules
dnc.. CLOBAZAM [EPILEPSY ONLY] dng.. PIRACETAM
do3.. CLOMETHIAZOLE EDISYLATE
[CENTRAL NERVOUS SYSTEM USE]
dng5. PIRACETAM 1.2g tablets
do3z. CLOMETHIAZOLE EDISYLATE
8mg/mL intravenous infusion
dng6. PIRACETAM 333.3mg/mL oral
solution
dn4.. CLONAZEPAM [EPILEPSY
CONTROL]
dng4. PIRACETAM 800mg tablets
do2.. CLONAZEPAM [STATUS EPILEPSY] dnp.. PREGABALIN
dn4w. CLONAZEPAM 0.5mg/5mL sugar free
oral solution
dnpv. PREGABALIN 100mg capsules
do2z. CLONAZEPAM 1mg/1mL injection dnpw. PREGABALIN 150mg capsules
dn4z. CLONAZEPAM 2mg tablets dnpu. PREGABALIN 200mg capsules
dn4x. CLONAZEPAM 2mg/5mL sugar free
oral solution
dnps. PREGABALIN 225mg capsules
dn4y. CLONAZEPAM 500microgram tablets dnpz. PREGABALIN 25mg capsules
dn... CONTROL OF EPILEPSY dnpt. PREGABALIN 300mg capsules
dnh1. CONVULEX 150mg e/c capsules dnpy. PREGABALIN 50mg capsules
dnh2. CONVULEX 300mg e/c capsules dnpx. PREGABALIN 75mg capsules
dnh3. CONVULEX 500mg e/c capsules dna.. PRIMIDONE
dnh7. DEPAKOTE 250mg e/c tablets dnay. PRIMIDONE 250mg tablets
dnh8. DEPAKOTE 500mg e/c tablets dnaz. PRIMIDONE 250mg/5mL oral
suspension
dns1. DIACOMIT 250mg capsules dnax. PRIMIDONE 50mg tablets
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dns3. DIACOMIT 250mg/sachet powder for
oral suspension
dni2. PRO-EPANUTIN 750mg/10mL
injection concentrate
dns2. DIACOMIT 500mg capsules dnv.. RETIGABINE
dns4. DIACOMIT 500mg/sachet powder for
oral suspension
dnv8. RETIGABINE 100mg tablets
dn12. DIAMOX [EP] 250mg tablets dnv9. RETIGABINE 200mg tablets
dn13. DIAMOX [EP] 500mg injection dnvA. RETIGABINE 300mg tablets
dn11. DIAMOX [EP] 500mg m/r capsules dnvB. RETIGABINE 400mg tablets
do11. DIAZEMULS [EP] 10mg/2mL injection dnv7. RETIGABINE 50mg tablets
do1.. DIAZEPAM [EPILEPSY USE] dnvC. RETIGABINE 50mg+100mg tablets
initiation pack
do1y. DIAZEPAM 10mg/2.5mL rectal
solution
do21. RIVOTRIL 1mg/1mL injection
do19. DIAZEPAM 10mg/2.5mL RecTubes dn42. RIVOTRIL 2mg tablets
do1v. DIAZEPAM 10mg/2mL emulsion
injection
dn41. RIVOTRIL 500micrograms tablets
do1w. DIAZEPAM 10mg/2mL injection dnr.. RUFINAMIDE
do1t. DIAZEPAM 2.5mg/1.25mL rectal
solution
dnrz. RUFINAMIDE 100mg tablets
do1A. DIAZEPAM 2.5mg/1.25mL RecTubes dnry. RUFINAMIDE 200mg tablets
do1u. DIAZEPAM 20mg/5mL rectal solution dnrx. RUFINAMIDE 400mg tablets
do1x. DIAZEPAM 5mg/2.5mL rectal solution dne4. SABRIL 500mg powder sachets
do18. DIAZEPAM 5mg/2.5mL RecTubes dne2. SABRIL 500mg tablets
dn54. EMESIDE 250mg/5mL syrup dnb.. SODIUM VALPROATE
do61. EPANUTIN [EP] 250mg/5mL injection dnbv. SODIUM VALPROATE 100mg
crushable tablets
dn95. EPANUTIN 100mg capsules dnbo. SODIUM VALPROATE 100mg/sachet
m/r granules
dn93. EPANUTIN 25mg capsules dnbJ. SODIUM VALPROATE 150mg m/r
capsules
dn96. EPANUTIN 300mg capsules dnbN. SODIUM VALPROATE 1g/10mL
solution for injection
dn81. EPANUTIN 30mg/5mL suspension dnbM. SODIUM VALPROATE 1g/sachet m/r
granules
dn94. EPANUTIN 50mg capsules dnbw. SODIUM VALPROATE 200mg
crushable tablets
dn82. EPANUTIN 50mg Infatabs dnb7. SODIUM VALPROATE 200mg e/c
tablets
dnb1. EPILIM 100mg crushable tablets dnbr. SODIUM VALPROATE 200mg m/r
tablets
dnb2. EPILIM 200mg e/c tablets dnby. SODIUM VALPROATE 200mg/5mL
sugar free liquid
dnb4. EPILIM 200mg/5mL sugar free liquid dnbz. SODIUM VALPROATE 200mg/5mL
syrup
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dnb5. EPILIM 200mg/5mL syrup dnbp. SODIUM VALPROATE 250mg/sachet
m/r granules
dnb3. EPILIM 500mg e/c tablets dnbK. SODIUM VALPROATE 300mg m/r
capsules
dnbc. EPILIM CHRONO 200 m/r tablets dnbs. SODIUM VALPROATE 300mg m/r
tablets
dnbd. EPILIM CHRONO 300 m/r tablets dnbE. SODIUM VALPROATE 300mg/3mL
solution for injection
dnbe. EPILIM CHRONO 500 m/r tablets dnbu. SODIUM VALPROATE 400mg/4mL
injection
dnbQ. EPILIM CHRONOSPHERE
100mg/sachet m/r granules
dnb8. SODIUM VALPROATE 500mg e/c
tablets
dnbU. EPILIM CHRONOSPHERE 1g/sachet
m/r granules
dnbt. SODIUM VALPROATE 500mg m/r
tablets
dnbR. EPILIM CHRONOSPHERE
250mg/sachet m/r granules
dnbx. SODIUM VALPROATE 500mg tablets
dnbS. EPILIM CHRONOSPHERE
500mg/sachet m/r granules
dnbL. SODIUM VALPROATE 500mg/sachet
m/r granules
dnbP. EPILIM CHRONOSPHERE
50mg/sachet m/r granules
dnbn. SODIUM VALPROATE 50mg/sachet
m/r granules
dnbT. EPILIM CHRONOSPHERE
750mg/sachet m/r granules
dnbq. SODIUM VALPROATE 750mg/sachet
m/r granules
dnb6. EPILIM IV 400mg/4mL injection do... STATUS EPILEPTICUS DRUGS
dnbF. EPISENTA 150mg m/r capsules do12. STESOLID [EP] 10mg/2mL injection
dnbO. EPISENTA 1g/10mL solution for
injection
do15. STESOLID 10mg/2.5mL rectal solution
dnbI. EPISENTA 1g/sachet m/r granules do14. STESOLID 5mg/2.5mL rectal solution
dnbG. EPISENTA 300mg m/r capsules dnsw. STIRIPENDOL 500mg/sachet powder
for oral suspension
dnbD. EPISENTA 300mg/3mL solution for
injection
dns.. STIRIPENTOL
dnbH. EPISENTA 500mg/sachet m/r granules dnsz. STIRIPENTOL 250mg capsules
dnbB. EPIVAL CR 300mg m/r tablets dnsx. STIRIPENTOL 250mg/sachet powder
for oral suspension
dnbC. EPIVAL CR 500mg m/r tablets dnsy. STIRIPENTOL 500mg capsules
dnu.. ESLICARBAZEPINE dn3c. TEGRETOL 100mg chewable tablets
dnu2. ESLICARBAZEPINE ACETATE
800mg tablets
dn34. TEGRETOL 100mg tablets
dn5.. ETHOSUXIMIDE dn37. TEGRETOL 100mg/5mL sugar free
liquid
dn5x. ETHOSUXIMIDE 250mg capsules dn3D. TEGRETOL 125mg suppositories
dn5z. ETHOSUXIMIDE 250mg/5mL syrup dn3d. TEGRETOL 200mg chewable tablets
dni.. FOSPHENYTOIN SODIUM dn35. TEGRETOL 200mg tablets
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dni1. FOSPHENYTOIN SODIUM
750mg/10mL injection concentrate
dn3E. TEGRETOL 250mg suppositories
dnj.. GABAPENTIN dn36. TEGRETOL 400mg tablets
dnj1. GABAPENTIN 100mg capsules dn38. TEGRETOL RETARD 200mg m/r tabs
dnj2. GABAPENTIN 300mg capsules dn39. TEGRETOL RETARD 400mg m/r tabs
dnjx. GABAPENTIN 300mg capsules/600mg
tablets titration pack
dnl.. TIAGABINE
dnj3. GABAPENTIN 400mg capsules dnl2. TIAGABINE 10mg tablets
dnjy. GABAPENTIN 600mg tablets dnl3. TIAGABINE 15mg tablets
dnjz. GABAPENTIN 800mg tablets dnl1. TIAGABINE 5mg tablets
dnl5. GABITRIL 10mg tablets dn3F. TIMONIL RETARD 200mg m/r tablets
dnl6. GABITRIL 15mg tablets dn3G. TIMONIL RETARD 400mg m/r tablets
dnl4. GABITRIL 5mg tablets dnk5. TOPAMAX 100mg tablets
do31. HEMINEVRIN [CNS] 8mg/mL
intravenous infusion
dnk6. TOPAMAX 200mg tablets
dnr1. INOVELON 100mg tablets dnk8. TOPAMAX 25mg tablets
dnr2. INOVELON 200mg tablets dnk4. TOPAMAX 50mg tablets
dnr3. INOVELON 400mg tablets dnkB. TOPAMAX SPRINKLE 15mg capsules
dno5. KEPPRA 100mg/mL s/f oral solution dnkC. TOPAMAX SPRINKLE 25mg capsules
dno3. KEPPRA 1g tablets dnkE. TOPAMAX SPRINKLE 50mg capsules
dno1. KEPPRA 250mg tablets dnk.. TOPIRAMATE
dno2. KEPPRA 500mg tablets dnk2. TOPIRAMATE 100mg tablets
dno6. KEPPRA 500mg/5mL solution for
injection
dnk9. TOPIRAMATE 15mg beads in capsules
dno4. KEPPRA 750mg tablets dnk3. TOPIRAMATE 200mg tablets
dnt.. LACOSAMIDE dnkA. TOPIRAMATE 25mg beads in capsules
dntA. LACOSAMIDE 100mg tablets dnk7. TOPIRAMATE 25mg tablets
dntB. LACOSAMIDE 150mg tablets dnkD. TOPIRAMATE 50mg beads in capsules
dnt8. LACOSAMIDE 15mg/1mL sugar free
liquid
dnk1. TOPIRAMATE 50mg tablets
dntC. LACOSAMIDE 200mg tablets dnm1. TRILEPTAL 150 tablets
dnt7. LACOSAMIDE 200mg/20mL solution
for injection
dnm2. TRILEPTAL 300 tablets
dnt9. LACOSAMIDE 50mg tablets dnm3. TRILEPTAL 600 tablets
dnf9. LAMICTAL 100mg dispersible tablets dnm4. TRILEPTAL 60mg/mL sugar free oral
suspension
dnf4. LAMICTAL 100mg tablets dnv2. TROBALT 100mg tablets
dnfD. LAMICTAL 200mg tablets dnv3. TROBALT 200mg tablets
dnf8. LAMICTAL 25mg dispersible tablets dnv4. TROBALT 300mg tablets
dnf6. LAMICTAL 25mg tablets dnv5. TROBALT 400mg tablets
dnfJ. LAMICTAL 2mg dispersible tablets dnv1. TROBALT 50mg tablets
dnf3. LAMICTAL 50mg tablets dnv6. TROBALT tablets initiation pack
dnf7. LAMICTAL 5mg dispersible tablets do16. VALIUM [EP] 10mg/2mL injection
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dnfF. LAMICTAL MONOTHERAPY 25mg
starter pack
do17. VALIUM [EP] 20mg/4mL injection
dnfH. LAMICTAL NON-VALPROATE
ADD-ON 50mg starter pack
dnh.. VALPROIC ACID
dnfG. LAMICTAL VALPROATE ADD-ON
25mg starter pack
dnh4. VALPROIC ACID 150mg e/c capsules
dnf.. LAMOTRIGINE dnhz. VALPROIC ACID 250mg e/c tablets
dnfC. LAMOTRIGINE 100mg dispersible
tablets
dnh5. VALPROIC ACID 300mg e/c capsules
dnf2. LAMOTRIGINE 100mg tablets dnh6. VALPROIC ACID 500mg e/c capsules
dnfE. LAMOTRIGINE 200mg tablets dnhy. VALPROIC ACID 500mg e/c tablets
dnfB. LAMOTRIGINE 25mg dispersible
tablets
dne.. VIGABATRIN
dnf5. LAMOTRIGINE 25mg tablets dne3. VIGABATRIN 500mg powder sachets
dnfz. LAMOTRIGINE 2mg dispersible
tablets
dne1. VIGABATRIN 500mg tablets
dnf1. LAMOTRIGINE 50mg tablets dnt4. VIMPAT 100mg tablets
dnfA. LAMOTRIGINE 5mg dispersible
tablets
dnt5. VIMPAT 150mg tablets
dno.. LEVETIRACETAM dnt2. VIMPAT 15mg/1mL sugar free liquid
dnov. LEVETIRACETAM 100mg/mL s/f oral
solution
dnt6. VIMPAT 200mg tablets
dnox. LEVETIRACETAM 1g tablets dnt1. VIMPAT 200mg/20mL solution for
injection
dnoz. LEVETIRACETAM 250mg tablets dnt3. VIMPAT 50mg tablets
dnoy. LEVETIRACETAM 500mg tablets dn56. ZARONTIN 250mg/5mL syrup
dnou. LEVETIRACETAM 500mg/5mL
solution for injection
dnu1. ZEBINIX 800mg tablets
dnow. LEVETIRACETAM 750mg tablets dnq6. ZONEGRAN 100mg capsules
do4.. LORAZEPAM [EPILEPSY] dnq4. ZONEGRAN 25mg capsules
dnp4. LYRICA 100mg capsules dnq5. ZONEGRAN 50mg capsules
dnp5. LYRICA 150mg capsules dnq.. ZONISAMIDE
dnp6. LYRICA 200mg capsules dnq3. ZONISAMIDE 100mg capsules
dnp8. LYRICA 225mg capsules dnq1. ZONISAMIDE 25mg capsules
dnp1. LYRICA 25mg capsules dnq2. ZONISAMIDE 50mg capsule
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